STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 193307

TO: Ralph J Gitomer
Location: 3d65 / 3c18
Art Unit: 1655
Thursday, July 06, 2006

Case Serial Number: 09/607602

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 09:57:17 ON 06 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 6 Jul 2006  VOL 145 ISS 2
FILE LAST UPDATED: 5 Jul 2006  (20060705/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all l33 tot

L33  ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:433672  HCAPLUS
DN   140:412026
ED   Entered STN:  28 May 2004
TI   Chewable solid unit dosage forms and methods for delivery of active agents
     such as fluoride into occlusal surfaces of teeth
IN   Scott, Douglas Craig; Eversole, Sandra Lynn; Burgess, Steven Carl; Best,
     John Michael; Faller, Robert Vincent
PA   USA
SO   U.S. Pat. Appl. Publ., 20 pp.
     CODEN: USXXCO
DT   Patent
LA   English
IC   ICM  A61K-0007/16
INCL 424049000
CC   62-7 (Essential Oils and Cosmetics)
     Section cross-reference(s): 63
FAN.CNT 2
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     --------------       ----   --------    --------------------     --------
PI   US2004101493          A1     20040527    2003US-0706103           20031112
     CA---2504488          AA     20040610    2003CA-2504488           20031125
     CA---2504489          AA     20040610    2003CA-2504489           20031125
     WO2004047784          A1     20040610    2003WO-US37879           20031125
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     WO2004047785          A1     20040610    2003WO-US37880           20031125
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
```

```
            NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
            TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
            TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU2003293110          A1    20040618    2003AU-0293110          20031125
    AU2003298723          A1    20040618    2003AU-0298723          20031125
    EP---1565154          A1    20050824    2003EP-0790102          20031125
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    EP---1575543          A1    20050921    2003EP-0796480          20031125
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    CN---1713884          A     20051228    CN 2003-80103898        20031125
    CN---1713886          A     20051228    CN 2003-80103910        20031125
    JP2006509767          T2    20060323    2004JP-0555782          20031125
    JP2006509768          T2    20060323    2004JP-0555783          20031125
PRAI 2002US-429234P       P     20021126
    2003WO-US37879        W     20031125
    2003WO-US37880        W     20031125
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 US 2004101493    ICM    A61K-0007/16
                  INCL   424049000
                  IPCI   A61K0007-16 [ICM,7]
                  IPCR   A61K0009-00 [N,A]; A61K0009-00 [N,C*]
                  NCL    424/049.000
                  ECLA   A61K009/00M18B
 CA---2504488     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]
                  ECLA   A61K009/00M18B
 CA---2504489     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]
                  ECLA   A61K009/00M18B
 WO2004047784     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]
                  ECLA   A61K009/00M18B
 WO2004047785     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]
                  ECLA   A61K009/00M18B
 AU2003293110     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]
 AU2003298723     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]
 EP---1565154     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]
                  ECLA   A61K009/00M18B
 EP---1575543     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]
                  ECLA   A61K009/00M18B
 CN---1713884     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
 CN---1713886     IPCI   A61K0007-16 [ICM,7]; A61K0009-00 [ICS,7]
 JP2006509767     IPCI   A61K0008-00 [I,A]; A61Q0011-00 [I,A]; A61K0008-21
                         [I,A]; A61K0008-19 [I,C*]
                  FTERM  4C083/AB172; 4C083/AB222; 4C083/AB281; 4C083/AB282;
                         4C083/AB292; 4C083/AB312; 4C083/AB322; 4C083/AB332;
                         4C083/AB442; 4C083/AB471; 4C083/AB472; 4C083/AC132;
                         4C083/AC242; 4C083/AC442; 4C083/AC541; 4C083/AC712;
                         4C083/AC742; 4C083/AC782; 4C083/AC812; 4C083/AC852;
                         4C083/AC862; 4C083/AD041; 4C083/AD042; 4C083/AD071;
                         4C083/AD072; 4C083/AD091; 4C083/AD092; 4C083/AD111;
                         4C083/AD112; 4C083/AD131; 4C083/AD211; 4C083/AD212;
                         4C083/AD222; 4C083/AD241; 4C083/AD242; 4C083/AD262;
                         4C083/AD271; 4C083/AD272; 4C083/AD281; 4C083/AD282;
```

4C083/AD301; 4C083/AD302; 4C083/AD351; 4C083/AD352;
4C083/AD412; 4C083/AD611; 4C083/BB21; 4C083/BB41;
4C083/BB48; 4C083/CC41; 4C083/DD21; 4C083/EE32;
4C083/EE35; 4C083/EE36; 4C083/EE37

JP2006509768 IPCI A61K0008-00 [I,A]; A61Q0011-00 [I,A]; A61K0009-20 [I,A]
FTERM 4C076/AA37; 4C076/BB22; 4C076/CC04; 4C076/CC31;
4C076/CC50; 4C076/DD25; 4C076/DD26; 4C076/DD27;
4C076/DD28; 4C076/DD29; 4C076/DD50; 4C076/DD51;
4C076/EE03; 4C076/FF06; 4C076/FF70; 4C083/AB03;
4C083/AB21; 4C083/AB24; 4C083/AB28; 4C083/AB31;
4C083/AB32; 4C083/AB33; 4C083/AB38; 4C083/AB43;
4C083/AB44; 4C083/AB47; 4C083/AC54; 4C083/AC58;
4C083/AD02; 4C083/AD61; 4C083/BB55; 4C083/CC41;
4C083/DD21; 4C083/EE31

AB The present invention relates to methods and an oral care composition for topical, oral administration in a human or other animal comprising (a) from about 1% to about 40%, by weight of the composition, of a retentive agent selected from the group consisting of water soluble hydrophilic gums, water soluble hydrophilic polymers, and mixts. thereof, the retentive agent having the property of hydrating upon exposure to water or saliva resulting in the composition forming an intact hydrated mass to provide a Retention Index of about 1 to about 4; and (b) a safe and effective amount of a topical, oral care carrier; wherein the composition is a non-cariogenic, chewable solid unit dosage form; and the composition comprises less than about 65% by weight of water insol. particulates. The present invention further relates to an oral care dentifrice composition comprising: (a) from about 30% to about 65%, by weight of the composition, of a water insol., particulate retentive agent having a water solubility of less than about 1 g/30 g at 25°; (b) a safe and effective amount of an oral care active; (c) a safe and effective amount of a surfactant; and (d) a safe and effective amount of a buffer; wherein the composition is a chewable dentifrice solid unit dosage form, is non-effervescent, non-cariogenic; and wherein the composition has a Retention Index of from about 1 to about 4. For example, chewable compressed tablets containing stannous fluoride were made by conventional processing techniques.

ST chewable tablet dentifrice active agent delivery tooth

IT **Antihistamines**
(H2; chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT **Dentifrices**
(**anticalculus**; chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT Anesthetics
Anti-inflammatory agents
Antimicrobial agents
Buffers
Dentifrices
Fungicides
Gums and Mucilages
Surfactants
Whitening agents
(chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT Kaolin, biological studies
Mica-group minerals, biological studies
Mineral elements, biological studies
Polymers, biological studies
Vitamins
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT Tooth mineralization
(remineralization, agents for; chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT Drug delivery systems

(tablets, chewable; chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT Mica-group minerals, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(titanium; chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT 123-03-5, Cetylpyridinium chloride 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 1314-13-2, Zinc oxide, biological studies 1327-43-1, Magnesium aluminum silicate 1335-30-4, Aluminum silicate 1343-88-0, Magnesium silicate 3380-34-5, Triclosan 7447-39-4, Copper chloride, biological studies 7646-85-7, Zinc chloride, biological studies 7681-49-4, Sodium fluoride, biological studies 7722-88-5, Tetrasodium pyrophosphate 7757-93-9, Dicalcium phosphate 7758-29-4, Sodium tripolyphosphate 7783-47-3, Stannous fluoride 7787-59-9, Bismuth oxychloride 7790-76-3, Calcium pyrophosphate 10163-15-2, Sodium monofluorophosphate 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 16984-48-8, Fluoride, biological studies 18472-51-0, Chlorhexidine gluconate
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

IT 9002-88-4, Polyethylene 9003-53-6, Polystyrene
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(powder; chewable solid composition for delivery of active agents into occlusal surfaces of teeth)

L33 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
AN **2004:100955** HCAPLUS
DN 140:157441
ED Entered STN: 08 Feb 2004
TI Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
IN Garvey, David S.; Khanapure, Subhash P.; Ranatunge, Ramani R.; Richardson, Stewart K.; Schroeder, Joseph D.
PA Nitromed, Inc., USA
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-7 (**Pharmacology**)
Section cross-reference(s): 7
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004010945	A2	20040205	2003WO-US23605	20030729
	WO2004010945	A3	20040422		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2493156	AA	20040205	2003CA-2493156	20030729
	AU2003261281	A1	20040216	2003AU-0261281	20030729
	US2004072883	A1	20040415	2003US-0628375	20030729
	EP---1542972	A2	20050622	2003EP-0772004	20030729
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

	JP2005538110	T2	20051215	2004JP-0524981	20030729
PRAI	2002US-398829P	P	20020729		
	2003WO-US23605	W	20030729		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004010945	ICM	A61K
	IPCI	A61K [ICM,7]
	IPCR	C07D0213-00 [I,C*]; C07D0213-50 [I,A]; C07D0231-00 [I,C*]; C07D0231-12 [I,A]
	ECLA	C07D213/50; C07D231/12
CA---2493156	IPCI	C07D0401-04 [ICM,7]; C07D0401-00 [ICM,7,C*]; A61P0029-00 [ICS,7]; C07D0231-06 [ICS,7]; C07D0231-00 [ICS,7,C*]; C07D0237-14 [ICS,7]; C07D0237-00 [ICS,7,C*]; C07D0207-325 [ICS,7]; C07D0207-00 [ICS,7,C*]; A61K0031-40 [ICS,7]; A61K0031-415 [ICS,7]; A61K0031-4155 [ICS,7]
	IPCR	C07D0213-00 [I,C*]; C07D0213-50 [I,A]; C07D0231-00 [I,C*]; C07D0231-12 [I,A]
	ECLA	C07D213/50; C07D231/12
AU2003261281	IPCI	C07D0207-325 [ICM,7]; C07D0207-00 [ICM,7,C*]; C07D0231-06 [ICS,7]; C07D0231-00 [ICS,7,C*]; C07D0237-14 [ICS,7]; C07D0237-00 [ICS,7,C*]; C07D0401-04 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0403-04 [ICS,7]; C07D0403-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0413-04 [ICS,7]; C07D0413-00 [ICS,7,C*]; A61K0031-40 [ICS,7]; A61K0031-415 [ICS,7]; A61K0031-4155 [ICS,7]; A61P0029-00 [ICS,7]
	IPCR	C07D0213-00 [I,C*]; C07D0213-50 [I,A]; C07D0231-00 [I,C*]; C07D0231-12 [I,A]
US2004072883	IPCI	A61K0031-427 [ICM,7]; A61K0031-422 [ICS,7]; A61K0031-4015 [ICS,7]; C07D0417-02 [ICS,7]; C07D0417-00 [ICS,7,C*]; C07D0413-02 [ICS,7]; C07D0413-00 [ICS,7,C*]
	IPCR	A61K0031-4015 [I,A]; A61K0031-4015 [I,C*]; A61K0031-422 [I,A]; A61K0031-422 [I,C*]; A61K0031-427 [I,A]; A61K0031-427 [I,C*]; C07D0413-00 [I,C*]; C07D0413-02 [I,A]; C07D0417-00 [I,C*]; C07D0417-02 [I,A]
	NCL	514/365.000
	ECLA	C07D213/50; C07D213/55; C07D231/12B5; C07D231/14
EP---1542972	IPCI	C07D0207-325 [ICM,7]; C07D0207-00 [ICM,7,C*]; C07D0231-06 [ICS,7]; C07D0231-00 [ICS,7,C*]; C07D0237-14 [ICS,7]; C07D0237-00 [ICS,7,C*]; C07D0401-04 [ICS,7]; C07D0401-00 [ICS,7,C*]; C07D0403-04 [ICS,7]; C07D0403-00 [ICS,7,C*]; C07D0405-04 [ICS,7]; C07D0405-00 [ICS,7,C*]; C07D0413-04 [ICS,7]; C07D0413-00 [ICS,7,C*]; A61K0031-40 [ICS,7]; A61K0031-415 [ICS,7]; A61K0031-4155 [ICS,7]; A61P0029-00 [ICS,7]
	IPCR	C07D0213-00 [I,C*]; C07D0213-50 [I,A]; C07D0231-00 [I,C*]; C07D0231-12 [I,A]
	ECLA	C07D213/50; C07D231/12
JP2005538110	IPCI	C07D0213-38 [ICM,7]; A61K0031-167 [ICS,7]; A61K0031-192 [ICS,7]; A61K0031-196 [ICS,7]; A61K0031-198 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0031-223 [ICS,7]; A61K0031-21 [ICS,7,C*]; A61K0031-405 [ICS,7]; A61K0031-403 [ICS,7,C*]; A61K0031-415 [ICS,7]; A61K0031-4402 [ICS,7]; A61K0031-444 [ICS,7]; A61K0031-4427 [ICS,7,C*]; A61K0031-616 [ICS,7]; A61K0031-60 [ICS,7,C*]; A61K0045-00 [ICS,7]; A61P0001-00 [ICS,7]; A61P0001-04 [ICS,7]; A61P0003-00 [ICS,7]; A61P0007-02 [ICS,7]; A61P0007-00 [ICS,7,C*]; A61P0009-00 [ICS,7]; A61P0009-10 [ICS,7]; A61P0011-00 [ICS,7]; A61P0011-02 [ICS,7]; A61P0011-06 [ICS,7]; A61P0013-02 [ICS,7]; A61P0013-12 [ICS,7]; A61P0013-00 [ICS,7,C*]; A61P0015-00 [ICS,7]; A61P0017-00 [ICS,7];

)

A61P0019-02 [ICS,7]; A61P0019-00 [ICS,7,C*];
A61P0025-04 [ICS,7]; A61P0025-28 [ICS,7]; A61P0025-00
[ICS,7,C*]; A61P0027-02 [ICS,7]; A61P0027-00
[ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7];
A61P0031-00 [ICS,7,C*]; A61P0035-00 [ICS,7];
A61P0035-02 [ICS,7]; A61P0037-08 [ICS,7]; A61P0037-00
[ICS,7,C*]; A61P0043-00 [ICS,7]; C07D0213-50 [ICS,7];
C07D0213-00 [ICS,7,C*]; C07D0231-12 [ICS,7];
C07D0231-14 [ICS,7]; C07D0231-00 [ICS,7,C*]

FTERM 4C055/AA01; 4C055/BA02; 4C055/BA06; 4C055/BA08;
4C055/BA18; 4C055/CA03; 4C055/CA06; 4C055/CA08;
4C055/CA21; 4C055/CB15; 4C055/DA01; 4C055/EA01;
4C084/AA19; 4C084/MA02; 4C084/NA14; 4C084/ZA02;
4C084/ZA07; 4C084/ZA08; 4C084/ZA16; 4C084/ZA33;
4C084/ZA39; 4C084/ZA45; 4C084/ZA54; 4C084/ZA59;
4C084/ZA66; 4C084/ZA68; 4C084/ZA81; 4C084/ZA89;
4C084/ZA96; 4C084/ZB11; 4C084/ZB13; 4C084/ZB26;
4C084/ZB27; 4C084/ZB35; 4C084/ZC20; 4C084/ZC21;
4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/BC14;
4C086/BC17; 4C086/BC36; 4C086/DA17; 4C086/MA01;
4C086/MA02; 4C086/MA05; 4C086/MA09; 4C086/MA10;
4C086/NA14; 4C086/ZA02; 4C086/ZA07; 4C086/ZA08;
4C086/ZA16; 4C086/ZA33; 4C086/ZA39; 4C086/ZA45;
4C086/ZA54; 4C086/ZA59; 4C086/ZA66; 4C086/ZA68;
4C086/ZA81; 4C086/ZA89; 4C086/ZA96; 4C086/ZB11;
4C086/ZB13; 4C086/ZB26; 4C086/ZB27; 4C086/ZB35;
4C086/ZC20; 4C086/ZC21; 4C206/AA01; 4C206/AA02;
4C206/AA03; 4C206/DA22; 4C206/DA24; 4C206/DA25;
4C206/FA31; 4C206/FA44; 4C206/GA02; 4C206/GA31;
4C206/JA76; 4C206/MA01; 4C206/MA02; 4C206/MA04;
4C206/MA12; 4C206/NA14; 4C206/ZA02; 4C206/ZA07;
4C206/ZA08; 4C206/ZA16; 4C206/ZA33; 4C206/ZA39;
4C206/ZA45; 4C206/ZA54; 4C206/ZA59; 4C206/ZA66;
4C206/ZA68; 4C206/ZA81; 4C206/ZA89; 4C206/ZA96;
4C206/ZB11; 4C206/ZB13; 4C206/ZB26; 4C206/ZB27;
4C206/ZB35; 4C206/ZC20; 4C206/ZC21

OS MARPAT 140:157441

AB The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compns. comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

ST antiinflammatory analgesic antiplatelet COX2 inhibitor cancer therapy

IT Inflammation
(Crohn's disease; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Intestine, disease
(Crohn's; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT **Antihistamines**
(**H2**; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Thiols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(S-nitroso; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT Pancreas, neoplasm
(Zollinger-Ellison syndrome; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Neutrophil
(activation; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Carcinoma
(adenocarcinoma; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Neutrophil
(adhesion; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Allergy
Inflammation
Nose, disease
(allergic rhinitis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Intestine
(anastomosis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Thromboxanes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT 5-HT agonists
Alzheimer's disease
Analgesics
Angiogenesis
Anti-inflammatory agents
Antipyretics
Antitumor agents
Arthritis
Asthma
Atherosclerosis
Bladder, neoplasm
Bone, neoplasm
Brain, neoplasm
Carcinoma
Cardiovascular system, disease
Central nervous system, disease
Decongestants
Digestive tract, disease
Digestive tract, neoplasm
Diuretics
Drug delivery systems
Dyspepsia
Esophagus, neoplasm
Eye, disease
Fever and Hyperthermia
Human
Inflammation
Kidney
Liver, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Mouth, neoplasm
Nephrotoxicity
Ovary, neoplasm
Pain
Pancreas, neoplasm
Platelet aggregation inhibitors
Prostate gland, neoplasm
Respiratory distress syndrome
Skin, neoplasm
Stomach, neoplasm
Ulcer
Urogenital system, disease
Wound healing
(antiinflammatory cyclooxygenase-2 selective **inhibitors**)

noble jarrell 06/07/2006

IT Opioids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Infection
(bacterial; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Skin, neoplasm
(basal cell carcinoma; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Carcinoma
Skin
(basal cell; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Acute myeloid leukemia
(basophilic leukemia; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Bronchi, disease
Inflammation
(bronchitis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Disease, animal
(bursitis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Injury
(central nervous system; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Ischemia
(cerebral; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Uterus, neoplasm
(cervix; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Intestine, neoplasm
(colon; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Mental and behavioral disorders
(dementia, cortical, alc.; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Mental and behavioral disorders
(dementia, multi-infarct; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Mental and behavioral disorders
(dementia, vascular; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Animal tissue
Organ, animal
(deterioration; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Tendon
(disease, tendinitis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Blood vessel, disease
(endothelium; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Intestine, neoplasm
(familial polyposis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Ulcer
(gastric, stress, bleeding; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Inflammation
Stomach, disease
(gastritis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Digestive tract, disease
(gastroesophageal reflux; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Stomach, disease
(gastroparesis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Neutrophil
(infiltration; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Intestine, disease
(inflammatory; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Helicobacter pylori
(inhibitors; antiinflammatory cyclooxygenase-2 selective inhibitors)

noble jarrell 06/07/2006

IT Central nervous system, disease
(injury; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Intestine, disease
(irritable bowel syndrome; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Brain, disease
(ischemia; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Prostanoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(isoprostane, inhibitors; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Leukotriene receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(leukotriene B4, antagonists; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Neoplasm
(lips; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Infection
(microbial; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Cell migration
(neutrophil infiltration; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Adhesion, biological
Cell activation
(neutrophil; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Anti-inflammatory agents
(nonsteroidal; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Ulcer
(peptic; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Medical goods
(pharmaceutical kits; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Inflammation
Lung, disease
(pneumonitis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Intestine, neoplasm
(polyp; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Parturition
(premature; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Transport proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proton pump, inhibitors; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Kidney, neoplasm
(renal cell carcinoma; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Carcinoma
(renal cell; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Fibrosis
(resulting from radiation therapy; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Antihistamines
(sedating or nonsedating; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Shock (circulatory collapse)
(septic; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Intestine, disease
(short bowel syndrome; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Intestine, neoplasm
(small; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Muscle, disease
(spasm, menstrual; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Carcinoma

(squamous cell; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Brain, disease
(stroke; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Mastocytoma
(systemic mastocytosis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Inflammation
(tendinitis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Respiratory system, disease
(toxicity; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Brain, disease
(trauma; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Digestive tract, disease
(ulcer, peptic; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Stomach, disease
(ulcer, stress, bleeding; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Inflammation
Intestine, disease
(ulcerative colitis; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT Endothelium
(vascular, disease; antiinflammatory cyclooxygenase-2 selective inhibitors)
IT 363-24-6, PGE-2 10102-43-9, Nitric oxide, biological studies 90880-94-7, Endothelium derived relaxing factor 329900-75-6, Cyclooxygenase 2 329967-85-3, Cyclooxygenase-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antiinflammatory cyclooxygenase-2 selective inhibitors)
IT 654058-48-7P 654058-50-1P 654058-51-2P 654058-52-3P 654058-53-4P 654058-67-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antiinflammatory cyclooxygenase-2 selective inhibitors)
IT 654058-54-5P 654058-56-7P 654058-58-9P 654058-60-3P 654058-62-5P 654058-64-7P 654058-68-1P 654058-70-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiinflammatory cyclooxygenase-2 selective inhibitors)
IT 50-78-2, Aspirin 53-86-1, Indomethacin 56-85-9, L-Glutamine, biological studies 56-87-1, L-Lysine, biological studies 70-26-8, L-Ornithine 74-79-3, L-Arginine, biological studies 74-79-3D, L-Arginine, nitrosated and/or nitrosylated derivs. 103-90-2, Acetaminophen 156-86-5, L-Homoarginine 156-86-5D, L-Homoarginine, nitrosated and/or nitrosylated derivs. 372-75-8, L-Citrulline 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 51209-75-7, S-Nitrosocysteine 53054-07-2 56577-02-7, S-Nitroso-N-acetylcysteine 57564-91-7, S-Nitrosoglutathione 79032-48-7, S-Nitroso-N-acetylpenicillamine 122130-63-6, S-Nitrosocaptopril 139427-42-2, S-Nitroso-homocysteine 162758-33-0, S-Nitroso-cysteinylglycine 273752-78-6D, nitrosated and/or nitrosylated derivs. 654058-66-9 654058-72-7 654058-74-9 654058-76-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory cyclooxygenase-2 selective inhibitors)
IT 76-05-1, Trifluoroacetic acid, reactions 79-37-8, Oxalyl chloride 553-90-2, Dimethyl oxalate 622-08-2, 2-Benzyloxyethanol 870-46-2, tert-Butyl carbazate 1073-06-9, 1-Bromo-3-fluorobenzene 1073-62-7, Benzylhydrazine hydrochloride 1778-09-2, 4'-(Methylthio)acetophenone 2043-61-0, Cyclohexanecarboxaldehyde 10297-73-1 49609-84-9 98546-51-1, 4-(Methylthio)benzeneboronic acid 191220-44-7 213994-27-5 654059-12-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(antiinflammatory cyclooxygenase-2 selective inhibitors)

noble jarrell 06/07/2006

IT 149267-56-1P 346684-15-9P, Methyl (2Z)-2-hydroxy-4-(4-methylthiophenyl)-4-oxobut-2-enoate 640727-90-8P, Methyl(2Z)-2-hydroxy-4-[4-(methylsulfonyl)phenyl]-4-oxobut-2-enoate 654058-77-2P 654058-80-7P 654058-81-8P 654058-83-0P 654058-86-3P 654058-88-5P 654058-90-9P 654058-92-1P 654058-94-3P 654058-95-4P 654058-96-5P 654058-98-7P 654058-99-8P 654059-02-6P 654059-05-9P 654059-07-1P 654059-10-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(antiinflammatory cyclooxygenase-2 selective inhibitors)

IT 51-45-6, Histamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperhistaminemia; antiinflammatory cyclooxygenase-2 selective inhibitors)

IT 1553-55-5, 3-Hydroxy-3-methylglutaryl coenzyme A 9000-96-8, Arginase 9002-04-4, Thrombin 80619-02-9, 5-Lipoxygenase 90119-07-6, Leukotriene A4 hydrolase 501433-35-8, Inducible nitric oxide synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; antiinflammatory cyclooxygenase-2 selective inhibitors)

L33 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
AN **2003:511412** HCAPLUS
DN 139:84365
ED Entered STN: 04 Jul 2003
TI Cereal beta glucan compositions, methods of preparation and uses thereof
IN Redmond, Mark J.; Fielder, David A.
PA Ceapro Inc., Can.
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C08L-0005/00
ICS C08J-0005/18; C09D-0105/00; A61K-0009/70; A61K-0009/36
CC 17-6 (Food and Feed Chemistry)
Section cross-reference(s): 43, 44, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003054077	A1	20030703	2002WO-CA01896	20021211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2467378	AA	20030703	2002CA-2467378	20021211
	AU2002347165	A1	20030709	2002AU-0347165	20021211
	EP---1453909	A1	20040908	2002EP-0782583	20021211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP2005513140	T2	20050512	2003JP-0554788	20021211
	US2005031674	A1	20050210	2004US-0498568	20040721
PRAI	2001US-338649P	P	20011211		
	2002WO-CA01896	W	20021211		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003054077	ICM	C08L-0005/00
	ICS	C08J-0005/18; C09D-0105/00; A61K-0009/70; A61K-0009/36
	IPCI	C08L0005-00 [ICM,7]; C08J0005-18 [ICS,7]; C09D0105-00 [ICS,7]; A61K0009-70 [ICS,7]; A61K0009-36 [ICS,7]; A61K0009-30 [ICS,7,C*]
	IPCR	A23L0001-00 [I,A]; A23L0001-00 [I,C*]; A23L0001-05

		[I,C*]; A23L0001-054 [I,A]; A23L0001-10 [I,A]; A23L0001-10 [I,C*]; A23L0001-22 [I,A]; A23L0001-22 [I,C*]; A23L0001-236 [I,A]; A23L0001-236 [I,C*]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0009-28 [I,A]; A61K0009-28 [I,C*]; A61K0009-70 [I,A]; A61K0009-70 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C*]; A61Q0019-00 [I,A]; A61Q0019-00 [I,C*]; C08J0005-18 [I,A]; C08J0005-18 [I,C*]; C08L0005-00 [I,A]; C08L0005-00 [I,C*]; C09D0105-00 [I,A]; C09D0105-00 [I,C*]
	ECLA	A23L001/00P8B6; A23L001/054C; A23L001/10E; A23L001/22B10; A23L001/236; A61K008/73; A61K009/28H6F; A61K009/70B; A61Q011/00; A61Q013/00; A61Q019/00; C08J005/18+L5/00; C08L005/00; C09D105/00
CA---2467378	IPCI	C08L0005-00 [ICM,7]; C09D0105-00 [ICS,7]; C08J0005-18 [ICS,7]; A61K0009-36 [ICS,7]; A61K0009-30 [ICS,7,C*]; A61K0009-70 [ICS,7]
	IPCR	A23L0001-00 [I,A]; A23L0001-00 [I,C*]; A23L0001-05 [I,C*]; A23L0001-054 [I,A]; A23L0001-10 [I,A]; A23L0001-10 [I,C*]; A23L0001-22 [I,A]; A23L0001-22 [I,C*]; A23L0001-236 [I,A]; A23L0001-236 [I,C*]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0009-28 [I,A]; A61K0009-28 [I,C*]; A61K0009-70 [I,A]; A61K0009-70 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C*]; A61Q0019-00 [I,A]; A61Q0019-00 [I,C*]; C08J0005-18 [I,A]; C08J0005-18 [I,C*]; C08L0005-00 [I,A]; C08L0005-00 [I,C*]; C09D0105-00 [I,A]; C09D0105-00 [I,C*]
AU2002347165	IPCI	C08L0005-00 [ICM,7]; C08J0005-18 [ICS,7]; C09D0105-00 [ICS,7]; A61K0009-70 [ICS,7]; A61K0009-36 [ICS,7]; A61K0009-30 [ICS,7,C*]
	IPCR	A23L0001-00 [I,A]; A23L0001-00 [I,C*]; A23L0001-05 [I,C*]; A23L0001-054 [I,A]; A23L0001-10 [I,A]; A23L0001-10 [I,C*]; A23L0001-22 [I,A]; A23L0001-22 [I,C*]; A23L0001-236 [I,A]; A23L0001-236 [I,C*]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0009-28 [I,A]; A61K0009-28 [I,C*]; A61K0009-70 [I,A]; A61K0009-70 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C*]; A61Q0019-00 [I,A]; A61Q0019-00 [I,C*]; C08J0005-18 [I,A]; C08J0005-18 [I,C*]; C08L0005-00 [I,A]; C08L0005-00 [I,C*]; C09D0105-00 [I,A]; C09D0105-00 [I,C*]
EP---1453909	IPCI	C08L0005-00 [ICM,7]; C08J0005-18 [ICS,7]; C09D0105-00 [ICS,7]; A61K0009-70 [ICS,7]; A61K0009-36 [ICS,7]; A61K0009-30 [ICS,7,C*]
	IPCR	A23L0001-00 [I,A]; A23L0001-00 [I,C*]; A23L0001-05 [I,C*]; A23L0001-054 [I,A]; A23L0001-10 [I,A]; A23L0001-10 [I,C*]; A23L0001-22 [I,A]; A23L0001-22 [I,C*]; A23L0001-236 [I,A]; A23L0001-236 [I,C*]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0009-28 [I,A]; A61K0009-28 [I,C*]; A61K0009-70 [I,A]; A61K0009-70 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C*]; A61Q0019-00 [I,A]; A61Q0019-00 [I,C*]; C08J0005-18 [I,A]; C08J0005-18 [I,C*]; C08L0005-00 [I,A]; C08L0005-00 [I,C*]; C09D0105-00 [I,A]; C09D0105-00 [I,C*]
JP2005513140	IPCI	A61K0047-36 [ICM,7]; A23L0001-22 [ICS,7]; A61J0003-06 [ICS,7]; A61J0003-07 [ICS,7]; A61K0009-08 [ICS,7]; A61K0009-107 [ICS,7]; A61K0009-36 [ICS,7]; A61K0009-30 [ICS,7,C*]; A61K0009-48 [ICS,7]; A61K0009-70 [ICS,7]; A61K0047-46 [ICS,7]; A61M0029-02 [ICS,7]; A61P0001-12 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0009-10 [ICS,7];

A61P0009-00 [ICS,7,C*]; A61P0011-00 [ICS,7]; A61P0011-10 [ICS,7]; A61P0025-00 [ICS,7]; A61P0025-04 [ICS,7]; A61P0025-16 [ICS,7]; A61P0025-26 [ICS,7]; A61P0025-28 [ICS,7]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0043-00 [ICS,7]

IPCR A23L0001-00 [I,A]; A23L0001-00 [I,C*]; A23L0001-05 [I,C*]; A23L0001-054 [I,A]; A23L0001-10 [I,A]; A23L0001-10 [I,C*]; A23L0001-22 [I,A]; A23L0001-22 [I,C*]; A23L0001-236 [I,A]; A23L0001-236 [I,C*]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0009-28 [I,A]; A61K0009-28 [I,C*]; A61K0009-70 [I,A]; A61K0009-70 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0013-00 [I,A]; A61Q0013-00 [I,C*]; A61Q0019-00 [I,A]; A61Q0019-00 [I,C*]; C08J0005-18 [I,A]; C08J0005-18 [I,C*]; C08L0005-00 [I,A]; C08L0005-00 [I,C*]; C09D0105-00 [I,A]; C09D0105-00 [I,C*]

FTERM 4B047/LB02; 4B047/LE10; 4B047/LG05; 4B047/LP09; 4C076/AA12; 4C076/AA17; 4C076/AA44; 4C076/AA45; 4C076/AA60; 4C076/AA74; 4C076/AA94; 4C076/AA95; 4C076/BB01; 4C076/BB31; 4C076/CC01; 4C076/CC05; 4C076/CC11; 4C076/CC29; 4C076/CC32; 4C076/CC40; 4C076/DD01; 4C076/DD37; 4C076/DD43; 4C076/DD67; 4C076/EE30; 4C076/EE32; 4C076/EE53; 4C076/EE58; 4C076/FF25; 4C076/FF27; 4C076/FF31; 4C167/AA50; 4C167/BB06; 4C167/CC09; 4C167/DD01; 4C167/GG50

US2005031674 IPCI A61K0009-70 [ICM,7]; A61K0035-78 [ICS,7]

IPCR A61K0009-70 [I,A]; A61K0009-70 [I,C*]

NCL 424/443.000

ECLA A23L001/00P8E; A23L001/10E; A23L001/22B10; A23L001/236D; A23L001/30; A61K008/73; A61K009/28H6F; A61L031/10+C08L5/00; A61Q011/00; A61Q013/00; A61Q019/00

AB Cereal β(1→3) β (1→4) glucan is used as a film or coating agent to produce clear, edible, biodegradable, delivery, lubricating, and protecting agents. Cereal β(1→-3) β (1→4) glucans are distinctive polymers of glucose differentiated from other polymers by not only their source but also their physicochem. properties. The β(1→3) β (1→4) forms a matrix to sequester other materials, such as pharmaceutical, medical and therapeutic agents, flavors, fragrances. The technol. has applications to essential oils and non-aqueous materials that are rendered deliverable by the β(1→3) β (1→4) glucan. The β(1→3) β (1→4) glucan films described may be consumed whereby they dissolve in the mouth in a controlled manner and may be used for the delivery of pharmaceutical, medical or confectionery products.

ST cereal beta glucan film pharmaceutical medical goods confectionery

IT **Antihistamines**
(**H2**; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT Quaternary ammonium compounds, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT Drug delivery systems
(capsules; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT **Dentifrices**
(**dental floss**; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT Food
(films; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT Anti-inflammatory agents
Antidiarrheals

Antihistamines
Antimicrobial agents
Antiparkinsonian agents
Antipyretics
Antitussives
Avena sativa
Cereal (grain)
Confectionery
Decongestants
Drugs
Expectorants
Flavor
Flavoring materials
Food emulsions
Hordeum vulgare
Narcotics
Nervous system agents
Nervous system depressants
Nervous system stimulants
Odor and Odorous substances
Panicum
Secale cereale
Sorghum bicolor
Sweetening agents
Triticum aestivum
Zea mays
(preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT Essential oils
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT Medical goods
(stents; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT Drug delivery systems
(tablets; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT Paper
(tissue; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT 60-00-4, EDTA, biological studies 89-78-1, Menthol 89-83-8, Thymol 119-36-8, Methyl salicylate 123-03-5, Cetyl pyridinium chloride 470-82-6, Eucalyptol 538-71-6, Domiphen bromide 2447-54-3, Sanguinarine 3380-34-5, Triclosan 7440-66-6D, Zinc, compds. 7761-88-8, Silver nitrate, biological studies 16984-48-8, Fluoride, biological studies 22573-93-9, Alexidine 71251-02-0, Octenidine
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial; preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT 9041-22-9P, β Glucan
RL: FFD (Food or feed use); IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); PYP (Physical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

IT 55589-62-3, Acesulfame potassium
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and uses of cereal beta glucan compns. for delivery of pharmaceutical, medical or confectionery products)

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Anon; PATENT ABSTRACTS OF JAPAN 1996, V1996(11)
(2) Brennen Medical Inc; WO--02076358 A 2002
(3) Fuji Capsule Kk; JP--08169817 A 1996 HCAPLUS
(4) Fuji Capsule Kk; JP--08169817 A 1996 HCAPLUS
(5) Granate Seed Limited; WO---0157092 A 2001 HCAPLUS
(6) Industrial Research Limited; WO---9813056 A 1998
(7) Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo; FR---2537496 A 1984 HCAPLUS
(8) Marine Bioproducts International; WO--02072687 A 2002
(9) New Zealand Institute For Crop And Food Research Limited; WO---0056268 A 2000 HCAPLUS
(10) Potter; US---6323338 B1 2001 HCAPLUS
(11) Provonchee; US---4774093 A 1998 HCAPLUS
(12) Takeda Chemical Industries Ltd; EP---0328317 A 1989 HCAPLUS
(13) Warner-Lambert Company; WO---0018365 A 2000 HCAPLUS
(14) Williams; US---5676967 A 1997 HCAPLUS

L33 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
AN **1997:397376** HCAPLUS
DN 127:23599
ED Entered STN: 27 Jun 1997
TI Enhanced anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils
IN Pan, Pauline; Sturdivant, Linda D.; Rubin, Michael
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/16
ICS A61K-0007/26; A61K-0035/78
CC 62-7 (Essential Oils and Cosmetics)
Section cross-reference(s): **63**

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO---9716159	A1	19970509	1996WO-US16948	19961023 <--
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR, LK, LR, LS, LT, LV, MG, MK, MN, MW, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU---9674680	A1	19970522	1996AU-0074680	19961023 <--
PRAI 1995US-0550045	A	19951030 <--		
1996WO-US16948	W	19961023 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9716159	ICM	A61K-0007/16
	ICS	A61K-0007/26; A61K-0035/78
	IPCI	A61K0007-16 [ICM,6]; A61K0007-26 [ICS,6]; A61K0035-78 [ICS,6]
	IPCR	A61K0008-30 [I,C*]; A61K0008-49 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K008/49H; A61K008/92C; A61K035/78+M; A61Q011/00
AU---9674680	IPCI	A61K0007-16 [ICM,6]; A61K0007-26 [ICS,6]; A61K0035-78 [ICS,6]
	IPCR	A61K0008-30 [I,C*]; A61K0008-49 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]

AB An anti-inflammatory oral composition that is effective in preventing and treating gingivitis and periodontitis contains an H2 receptor antagonist and antimicrobial oils. A method of preventing or treating inflammations in the oral cavity by applying an effective amount of the anti-inflammatory oral composition to the oral cavity is also provided. The H2 receptor antagonists include ranitidine, cimetidine, nizatidine, and famotidine and

the antimicrobial oils are selected from the group consisting of thymol, Me salicylate, menthol, eucalyptol, spearmint oil, cinnamon oil, clove oil, rosemary oil, and peppermint oil. The oral compns. are preferably in the forms of toothpastes, mouthwashes, and the like.

ST dentifrice antiinflammatory H2 receptor antagonist bactericide

IT **Antihistamines**
(**H2**; anti-inflammatory oral composition containing **H2**-receptor antagonist and antimicrobial oils and F compds.)

IT Anti-inflammatory agents
Antimicrobial agents
Dentifrices
(anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT Alkali metal fluorides
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT Essential oils
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cinnamon; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT Essential oils
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(clove; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT Gingiva
(gingivitis; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT Drug delivery systems
(oral; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT Essential oils
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT Periodontium
(periodontitis; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT Essential oils
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rosemary; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT Essential oils
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spearmint; anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

IT 89-78-1, Menthol 89-83-8, Thymol 119-36-8, Methyl salicylate 470-82-6, Eucalyptol 7783-47-3, Stannous fluoride 13537-32-1, Phosphorofluoridic acid 51481-61-9, Cimetidine 59481-66-2 66357-35-5, Ranitidine 74847-31-7 76824-35-6, Famotidine 76963-41-2, Nizatidine
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory oral composition containing H2-receptor antagonist and antimicrobial oils and F compds.)

=> d all,l34 tot

L34 ANSWER 1 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:162193 HCAPLUS
DN 140:204860
ED Entered STN: 29 Feb 2004
TI Method of applying oral composition
IN Moneuze, Gaelle; Strand, Ross; White, Christopher David; Williams, Michael Kevin
PA The **Procter & Gamble** Company, USA
SO U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K-0007/16
ICS A61K-0007/18
INCL 424049000; X42-4 5.2
CC 62-7 (Essential Oils and Cosmetics)
Section cross-reference(s): **63**
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US2004037789	A1	20040226	2003US-0641430	20030815
EP---1393710	A1	20040303	2002EP-0255842	20020821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA---2492790	AA	20040304	2003CA-2492790	20030820
WO2004017933	A1	20040304	2003WO-US26269	20030820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU2003262777	A1	20040311	2003AU-0262777	20030820
EP---1542651	A1	20050622	2003EP-0793258	20030820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN---1674860	A	20050928	2003CN-0818903	20030820
JP2005537310	T2	20051208	2004JP-0529819	20030820
PRAI 2002EP-0255842	A	20020821		
2003WO-US26269	W	20030820		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004037789	ICM	A61K-0007/16
	ICS	A61K-0007/18
	INCL	424049000; X42-4 5.2
	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000
	ECLA	A61K008/34F; A61K008/49C4; A61K008/73C; A61K008/81M; A61Q011/00
EP---1393710	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K008/34F; A61K008/49C4; A61K008/73C; A61K008/81M; A61Q011/00
CA---2492790	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-49

		[I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
WO2004017933	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K008/34F; A61K008/49C4; A61K008/73C; A61K008/81M; A61Q011/00
AU2003262777	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
EP---1542651	IPCI	A61K0007-16 [ICM,7]
CN---1674860	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-49 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2005537310	IPCI	A61K0007-16 [ICM,7]
	FTERM	4C083/AC121; 4C083/AC122; 4C083/AC131; 4C083/AC132; 4C083/AC691; 4C083/AC692; 4C083/AC811; 4C083/AC812; 4C083/AC862; 4C083/AD111; 4C083/AD112; 4C083/AD281; 4C083/AD282; 4C083/BB55; 4C083/CC41; 4C083/DD41; 4C083/EE32; 4C083/EE33; 4C083/EE34; 4C083/EE36

AB The present invention relates to a method of applying oral care benefit agent to the oral tissues. More specifically, a method for treating an oral cavity is provided comprising the application of an aqueous composition comprising oral care benefit agents to a large proportion of the oral cavity, application occurring as part of the daily oral care routine shortly before retiring, and the composition remaining in contact with the oral tissues while sleeping. The method and aqueous compns. of the invention provide overnight application and delivery of oral care benefit agents with improved ease of use and consumer aesthetics. Thus, a formulation contained water 66.90, HPMC 3.30, sodium saccharin 0.20, cetylpyridinium chloride 1.00, propylene glycol 22.00, xylitol 6.00, and flavor 0.80%.

ST oral thickener alc polymer

IT Alcohols, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(C1-6; method of applying oral composition)

IT **Antihistamines**
(**H2**; method of applying oral composition)

IT Tooth, disease
(calculus; method of applying oral composition)

IT Calculi
(dental; method of applying oral composition)

IT **Dentifrices**
(**gels**; method of applying oral composition)

IT Abrasives
Antimicrobial agents
Antioxidants
Humectants
Nutrients
Shear
Thickening agents
Viscosity
(method of applying oral composition)

IT Alditols
Clays, biological studies
Glycols, biological studies
Polyoxyalkylenes, biological studies
Polysaccharides, biological studies
Polysiloxanes, biological studies
Proteins

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(method of applying oral composition)
IT Tooth, disease
(plaque; method of applying oral composition)
IT Alcohols, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(polyhydric; method of applying oral composition)
IT 9011-16-9, Gantrez AN 69
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(Gantrez AN 69; method of applying oral composition)
IT 79-10-7D, Acrylic acid, esters, polymers
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(crosslinked; method of applying oral composition)
IT 87-99-0, Xylitol 123-03-5, Cetylpyridinium chloride 3380-34-5, Triclosan 9004-62-0, Natrosol 250 9004-65-3, Hydroxypropyl methyl cellulose 16984-48-8, Fluoride, biological studies 25322-68-3, Polyethylene glycol
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(method of applying oral composition)

L34 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:892231 HCAPLUS
DN 139:369392
ED Entered STN: 14 Nov 2003
TI Compositions comprising anionic functionalized polyorganosiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents to surfaces treated therewith
IN Majeti, Satyanarayana; Reno, Elizabeth Ann Brown; Kovacs, Stephen Andras
PA The **Procter** & **Gamble** Company, USA
SO U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K-0007/16
ICS A61K-0007/20
INCL 424049000; 424053000
CC 62-7 (Essential Oils and Cosmetics)
Section cross-reference(s): 46, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2003211050	A1	20031113	2003US-0430520	20030506
	AU2003233532	A1	20031111	2003AU-0233532	20030509
	CA---2483928	AA	20031120	2003CA-2483928	20030509
	WO2003095559	A1	20031120	2003WO-US14696	20030509
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP---1501895	A1	20050202	2003EP-0728810	20030509
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN---1653136	A	20050810	2003CN-0810360	20030509
	JP2005524750	T2	20050818	2004JP-0503560	20030509
	RU---2271376	C2	20060310	2004RU-0135919	20030509
	ZA2004008527	A	20050622	2004ZA-0008527	20041021
PRAI	2002US-378997P	P	20020509		
	2003WO-US14696	W	20030509		

CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

US 2003211050	ICM	A61K-0007/16
	ICS	A61K-0007/20
	INCL	424049000; 424053000
	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]
	NCL	424/049.000
AU2003233532	IPCI	C08L0083-04 [ICM,7]; C08L0083-10 [ICS,7]; C08L0083-00 [ICS,7,C*]; A61K0007-16 [ICS,7]
	IPCR	A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A]; C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10 [I,A]
CA---2483928	IPCI	C08L0083-04 [ICM,7]; C08L0083-10 [ICS,7]; C08L0083-00 [ICS,7,C*]; A61K0007-16 [ICS,7]
	IPCR	A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A]; C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10 [I,A]
WO2003095559	IPCI	C08L0083-04 [ICM,7]; C08L0083-10 [ICS,7]; C08L0083-00 [ICS,7,C*]; A61K0007-16 [ICS,7]
	IPCR	A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A]; C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10 [I,A]
EP---1501895	IPCI	C08L0083-04 [ICM,7]; C08L0083-10 [ICS,7]; C08L0083-00 [ICS,7,C*]; A61K0007-16 [ICS,7]
	IPCR	A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A]; C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10 [I,A]
CN---1653136	IPCI	C08L0083-04 [ICM,7]; A61K0007-16 [ICS,7]; C08L0083-10 [ICS,7]; C08L0083-00 [ICS,7,C*]
	IPCR	A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A]; C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10 [I,A]
JP2005524750	IPCI	C08L0083-04 [ICM,7]; C08L0083-00 [ICM,7,C*]; A61K0007-00 [ICS,7]; A61K0007-16 [ICS,7]; A61K0007-24 [ICS,7]; C08G0077-04 [ICS,7]; C08G0077-00 [ICS,7,C*]; C08K0003-00 [ICS,7]
	IPCR	A61K [I,S]; C08G0077-00 [I,C*]; C08G0077-04 [I,A]; C08K0003-00 [I,A]; C08K0003-00 [I,C*]; C08L [I,S]; C08L0083-00 [I,C*]; C08L0083-04 [I,A]; C08L0083-10 [I,A]
	FTERM	4C083/AB172; 4C083/AB212; 4C083/AB282; 4C083/AB412; 4C083/AB472; 4C083/AC032; 4C083/AC072; 4C083/AC122; 4C083/AC132; 4C083/AC392; 4C083/AC482; 4C083/AC532; 4C083/AC562; 4C083/AC782; 4C083/AC852; 4C083/AC862; 4C083/AD022; 4C083/AD042; 4C083/AD092; 4C083/AD161; 4C083/AD162; 4C083/AD242; 4C083/AD352; 4C083/AD662; 4C083/CC41; 4C083/EE31; 4C083/EE35; 4J002/CP051; 4J002/DE046; 4J002/DE196; 4J002/DE206; 4J002/DE226; 4J002/DG056; 4J002/DK006; 4J002/FD206; 4J002/GB01; 4J246/AA03; 4J246/AB01; 4J246/BA02X; 4J246/BA020; 4J246/BB02X; 4J246/BB020; 4J246/BB022; 4J246/CA01U; 4J246/CA010; 4J246/CA26M; 4J246/CA260; 4J246/CA27M; 4J246/CA27X; 4J246/CA270; 4J246/CA52M; 4J246/CA520; 4J246/CA53M; 4J246/CA53X; 4J246/CA530; 4J246/CA58M; 4J246/CA58U; 4J246/CA580; 4J246/CA63M; 4J246/CA630; 4J246/CA64M; 4J246/CA640; 4J246/CA76M; 4J246/CA760; 4J246/CB03; 4J246/FA222; 4J246/FC162; 4J246/GC30; 4J246/GC49; 4J246/HA36; 4J246/HA52; 4J246/HA53
RU---2271376	IPCI	C08L0083-04 [I,A]; C08L0083-10 [I,A]; C08L0083-00 [I,C*]; A61K0006-093 [I,A]; A61K0006-02 [I,C*]
ZA2004008527	IPCI	A61K [ICM,7]; C08L [ICS,7]

AB Disclosed are compns. and methods for treating and modifying surfaces and

for enhancing delivery of active agents to surfaces treated therewith, wherein the compns. comprise siloxane polymers functionalized with pendant moieties comprising two or more anionic groups, at least one anionic group being a carboxy group. When applied to a suitable surface, the present composition forms a substantially hydrophobic coating of the anionic functionalized siloxane polymer on the treated surface. These polymers effectively deposit on surfaces that have cationic sites, which are capable of forming bonds or linkages with the anionic groups of the polymer. The treated surface becomes hydrophobic due to the deposition of the anionic functionalized siloxane polymer, which then imparts a variety of end use benefits to that surface such as ease of cleaning, soil release, stain removal and prevention, conditioning, etc. The anionic functionalized siloxane polymer further acts as a carrier to deposit active agents onto the surface and to improve retention and efficacy of the active agents on the treated surface. The present compns. are useful in a variety of applications including oral care, hair and skin care, personal care, cosmetics, and fabric and hard surface cleaning and conditioning. For example, a denture adhesive cream can be made by blending together white mineral oil 23.93, white petrolatum 21.77, CM-cellulose sodium 20.00, colloidal silica 1.14, colorant 0.06, functionalized siloxane polymer (polysiloxane functionalized with malic acid or phthalic anhydride) 0.10, and alkyl vinyl ether-maleic acid (AVE/MA) copolymer salt 33.00 parts.

ST anionic functionalized polysiloxane hydrophobic coating surface treatment; cosmetic dentifrice anionic functionalized polysiloxane

IT **Antihistamines**
(**H2**; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Polysiloxanes, biological studies
RL: COS (Cosmetic use); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)
(anionic group-containing; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT **Dentifrices**
(**chewing gums**; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Textiles
(cleaning and conditioning; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Cosmetics
Wipes
(cleansing; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Analgesics
Anti-inflammatory agents
Antimicrobial agents
Antiviral agents
Bleaching agents
Cosmetics
Dentifrices
Hair preparations
Mouthwashes
Shampoos
Softening agents
Whitening agents
(compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Chlorites
Peroxides, biological studies
Peroxy acids

Peroxysulfates
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Chewing gum
(dentifrices; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Dental materials and appliances
(denture adhesives; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Drug delivery systems
(gels, topical; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Detergents
(liquid; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT Cosmetics
(lotions; compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

IT 88-99-3D, Phthalic acid, reaction products with polysiloxanes 123-03-5, Cetylpyridinium chloride 124-43-6 563-69-9D, Carbonoperoxoic acid, salts 1305-79-9, Calcium peroxide 3380-34-5, Triclosan 6915-15-7D, Malic acid, reaction products with polysiloxanes 7722-84-1, Hydrogen peroxide, biological studies 7758-19-2, Sodium chlorite 12674-33-8D, Perboric acid, salts 14314-27-3, Potassium chlorite 15630-89-4, Sodium percarbonate
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(compns. comprising anionic functionalized polysiloxanes for hydrophobically modifying surfaces and enhancing delivery of active agents)

L34 ANSWER 3 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:874766 HCAPLUS
DN 139:354473
ED Entered STN: 07 Nov 2003
TI Promoting whole body health with topical oral compositions containing antimicrobials
IN **Doyle, Matthew Joseph**; **Hunter-Rinderle, Stephen Joseph**; Glandorf, William Michael; White, Donald James
PA The **Procter & Gamble** Company, USA
SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 39,620.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K-0007/16
ICS A61K-0007/28
INCL 424049000; 424050000
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): 62
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2003206874	A1	20031106	2003US-0454843	20030605
	US---5939052	A	19990817	1996US-0754577	19961121
	US---6350436	B1	20020226	1999US-0451420	19991130
	US---6555094	B1	20030429	2000US-0710440	20001110
	US2002106336	A1	20020808	2001US-0039620	20011024
	US---6667027	B2	20031223		
	US2003152527	A1	20030814	2003US-0351205	20030124
	US---6821507	B2	20041123		

	US2005112070	A1	20050526	2004US-0975963	20041028
PRAI	1996US-0754577	A2	19961121		
	1998US-0203216	B2	19981130		
	1999US-0451420	A3	19991130		
	2000US-0607240	A2	20000630		
	2000US-0710440	A2	20001110		
	2001US-0039620	A2	20011024		
	1999US-165350P	P	19991112		
	2003US-0351205	A3	20030124		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003206874	ICM	A61K-0007/16
	ICS	A61K-0007/28
	INCL	424049000; 424050000
	IPCI	A61K0007-16 [ICM,7]; A61K0007-28 [ICS,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-41 [I,A]; A61K0008-43 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A]; A61K0031-14 [I,A]; A61K0031-14 [I,C*]; A61K0031-155 [I,A]; A61K0031-155 [I,C*]; A61K0033-24 [I,A]; A61K0033-24 [I,C*]; A61K0033-30 [I,A]; A61K0033-30 [I,C*]; A61K0033-34 [I,A]; A61K0033-34 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000
	ECLA	A61Q011/00; A61K008/19; A61K008/21; A61K008/24; A61K008/34F; A61K008/41L; A61K008/43; A61K008/49; A61K008/49C4; A61K031/05; A61K031/14; A61K031/155; A61K033/24; A61K033/30; A61K033/34; A61K045/06
US---5939052	IPCI	A61K0007-16 [ICM,6]; A61K0007-18 [ICS,6]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61K0008-72 [I,C*]; A61K0008-90 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/052.000; 424/049.000; 424/057.000
	ECLA	A61Q011/00; A61K008/19; A61K008/21; A61K008/24; A61K008/90
US---6350436	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]
	IPCR	A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/052.000; 424/049.000; 424/059.000
	ECLA	A61K007/16B; A61K007/16D8; A61K007/16P; A61K008/21; A61K008/24; A61Q011/00
US---6555094	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-90 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/052.000; 424/049.000; 424/057.000
	ECLA	A61K008/19; A61K008/21; A61K008/24; A61Q011/00
US2002106336	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/057.000
	ECLA	A61K007/16B; A61K008/24; A61Q011/00; A61K007/16D8; A61K007/16P; A61K008/21
US2003152527	IPCI	A61K0007-18 [ICM,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-90 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/052.000

	ECLA	A61K008/19; A61K008/21; A61K008/24; A61K008/365; A61K008/73; A61K008/73C; A61K008/81; A61K008/81K2; A61K008/90; A61Q011/00
US2005112070	IPCI	A61K0007-18 [ICM,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-21 [I,A]; A61K0008-24 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-90 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/052.000
	ECLA	A61K008/19; A61K008/21; A61K008/24; A61K008/365; A61K008/73; A61K008/73C; A61K008/81; A61K008/81K2; A61K008/90; A61Q011/00

AB The present invention relates to promoting whole body health by using topical oral compns. comprising an antimicrobial agent, in particular stannous salts, such as stannous fluoride and stannous chloride in combination with a polymeric mineral surface active agent such as condensed polyphosphates or polyphosphonates. In addition to providing a spectrum of intraoral benefits, topical administration of the present compns. to the oral cavity surprisingly provides benefits to systemic health. In particular, the present invention relates to methods of using the present topical oral compns. to reduce the risk in development of cardiovascular disease, stroke, atherosclerosis, diabetes, severe respiratory infections, premature births and low birth weight, post-partum dysfunction in neurol. and developmental functions, and associated increased risk of mortality. For example, a mouthwash composition contained flavor 0.05, FD&C Blue number 1 0.02, Na saccharin 0.06, glycerin 7.5, stannous chloride 0.2, cetylpyridinium chloride 0.045, polyphosphonate 0.5, Na gluconate, ethanol 14.46, and water balance to 100 %.

ST dentifrice stannous compd polyphosphate systemic therapeutic effect

IT **Antihistamines**
(**H2**; topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT Cytokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT Redox reaction
(biochem., modifiers; topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT Drug delivery systems
(buccal, sprays; topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT Lipopolysaccharides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(complexing agents; topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT Drug delivery systems
(lozenges; topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT Analgesics
Anti-inflammatory agents
Antimicrobial agents
Chewing gum
Dentifrices
Human
Immunostimulants
Mouthwashes

(topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT Bacteriocins
Essential oils
Growth factors, animal
Hormones, animal, biological studies
Minerals, biological studies
Polyphosphates
Polyphosphoric acids
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

IT 55-56-1, Chlorhexidine 87-17-2, Salicylanilide 123-03-5, Cetylpyridinium chloride 141-94-6, Hexetidine 538-71-6, Domiphen bromide 638-39-1, Stannous acetate 814-94-8, Stannous oxalate 815-85-0, Stannous tartrate 1414-45-5, Nisin 2447-54-3, Sanguinarine 2785-54-8, Tetradecylpyridinium chloride 3380-34-5, Triclosan 7440-50-8D, Copper, compds. 7440-66-6D, Zinc, compds. 7488-55-3, Stannous sulfate 7772-99-8, Stannous chloride, biological studies 7783-47-3, Stannous fluoride 22573-93-9, Alexidine 34509-48-3, Stannous lactate 35014-84-7, N-Tetradecyl-4-ethylpyridinium chloride 35984-19-1, Stannous gluconate 67651-57-4, Triclosan monophosphate 71138-71-1, Octapinol 71251-02-0, Octenidine 79874-76-3, Delmopinol 145266-99-5, Metalloproteinase inhibitor
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. for oral cavity containing stannous compds. and polyphosphates and addnl. drugs for promoting whole body health)

L34 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:888450 HCAPLUS
DN 137:369112
ED Entered STN: 22 Nov 2002
TI Crunchy and non-cariogenic confectionery compositions for oral care
IN Day, Trevor Neil; Greenwood, Mark; Strand, Ross
PA The **Procter** & **Gamble** Company, USA
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A23G-0003/00
ICS A61K-0007/16
CC 17-6 (Food and Feed Chemistry)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002091847	A1	20021121	2002WO-US15264	20020514
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---2442771	AA	20021121	2002CA-2442771	20020514
EP---1392125	A1	20040303	2002EP-0769738	20020514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US2003008062	A1	20030109	2002US-0146698	20020515
US---6719962	B2	20040413		
PRAI 2001US-291167P	P	20010515		
2002WO-US15264	W	20020514		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002091847	ICM	A23G-0003/00
	ICS	A61K-0007/16
	IPCI	A23G0003-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23G0003-00 [I,A]; A23G0003-00 [I,C*]; A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-24 [I,A]; A61K0008-27 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A23G003/00+D; A23G003/00+D4; A23G003/00+F; A23G003/00+H; A23G003/00+H6; A23G003/30+D; A23G003/30+D4; A23G003/30+F; A23G003/30+H6; A61K008/02; A61K008/19; A61K008/24; A61K008/27; A61K008/365; A61Q011/00
CA---2442771	IPCI	A23G0003-00 [ICM,7]; A61K0007-16 [ICS,7]
EP---1392125	IPCI	A23G0003-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23G0003-00 [I,A]; A23G0003-00 [I,C*]; A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-24 [I,A]; A61K0008-27 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
US2003008062	IPCI	A23G0003-00 [ICM,7]
	IPCR	A23G0003-00 [I,A]; A23G0003-00 [I,C*]; A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-24 [I,A]; A61K0008-27 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	426/660.000
	ECLA	A23G003/00+D; A23G003/00+F; A23G003/00+H; A23G003/30+D; A23G003/30+F; A23G003/30+H; A61K008/02; A61K008/19; A61K008/24; A61K008/27; A61K008/365; A61Q011/00

AB A crunchy, non-cariogenic oral care confectionery composition comprises: (i) from about 0.1 % to about 50 %, by weight of the composition, of an oral care active selected from the group consisting of anti-calculus agents; anti-plaque agents; desensitizing agents; oral malodor control agents; H2 antagonists; and mixts. thereof; (ii) from about 0.1 % to about 50 %, by weight of the composition, of a solid particulate wherein the solid particulate has a particle size such that passes through a 2000μm mesh and is retained by a 100μm mesh and has an aqueous solubility of at least 1 g per 100mL at 25°; (iii) greater than about 10 %, by weight of the composition, of a confectionery carrier material; and wherein compns. comprising polyphosphate with an average anion chain length of greater than or equal to 4 and having the solid particulate properties of (ii) are excluded. The present invention relates to stable, portable, oral care confectionery wherein the confectionery composition has a crunchy texture which acts to reinforce for the consumer the oral care benefit of the product. Thus, an chewing gum comprises gumbase 32.0, sorbitol 58.0, glycerin 5.0, water 1.0, zinc acetate 0.45, sodium tripolyphosphate 1.0, flavor 2.5, acesulfam K 0.05%.

ST anticariogenic confectionery oral care odor texture

IT **Antihistamines**
(**H2**; crunchy and non-cariogenic confectionery compns. for oral care)

IT Polyphosphoric acids
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(alkali metal salts; crunchy and non-cariogenic confectionery compns. for oral care)

IT Chewing gum
(anticariogenic dentifrices; crunchy and non-cariogenic confectionery compns. for oral care)

IT Tooth, disease
(calculus, anti-; crunchy and non-cariogenic confectionery compns. for

oral care)
IT Candy
Chewing gum
(carrier; crunchy and non-cariogenic confectionery compns. for oral care)
IT Carbohydrates, biological studies
Gelatins, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(carrier; crunchy and non-cariogenic confectionery compns. for oral care)
IT **Dentifrices**
(**chewing gums**, **anticariogenic**; crunchy and non-cariogenic confectionery compns. for oral care)
IT Confectionery
Flavoring materials
Food solubility
Food texture
Particle size
(crunchy and non-cariogenic confectionery compns. for oral care)
IT Diphosphates
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(crunchy and non-cariogenic confectionery compns. for oral care)
IT Calculi
(dental, anti-; crunchy and non-cariogenic confectionery compns. for oral care)
IT Sweetening agents
(noncariogenic; crunchy and non-cariogenic confectionery compns. for oral care)
IT Odor and Odorous substances
(off-odor; crunchy and non-cariogenic confectionery compns. for oral care)
IT Tooth, disease
(plaque, anti-; crunchy and non-cariogenic confectionery compns. for oral care)
IT Polyphosphoric acids
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(potassium salts; crunchy and non-cariogenic confectionery compns. for oral care)
IT Polyphosphoric acids
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(sodium salts; crunchy and non-cariogenic confectionery compns. for oral care)
IT 50-70-4, Sorbitol, biological studies 56-81-5, Glycerin, biological studies 557-34-6, Zinc acetate 7440-31-5D, Tin, salts 7440-66-6D, Zinc, salts 7440-70-2D, Calcium, salts 7732-18-5, Water, biological studies 7758-29-4, Sodium tripolyphosphate 15477-76-6, Phosphonate 55589-62-3
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(crunchy and non-cariogenic confectionery compns. for oral care)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Chow, L; US---5833954 A 1998 HCAPLUS
(2) Gen Foods Corp; GB---1372932 A 1974 HCAPLUS
(3) Reed, M; US---4792453 A 1988 HCAPLUS
(4) Warner Lambert Pharmaceutical; GB---1102024 A 1968
(5) Winston, A; US---5958380 A 1999 HCAPLUS

L34 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:736084 HCAPLUS
DN 137:268220
ED Entered STN: 27 Sep 2002
TI Denture care compositions and kits containing polybutene
IN Rajaiah, Jayanth; Ernst, Lisa Catron; Case, Anna Maria; Glandorf, William Michael; Ha, Thinh Nguyen; Mayer, Christopher Robert
PA The **Procter & Gamble** Company, USA
SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/30
CC 62-7 (Essential Oils and Cosmetics)
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002074276	A2	20020926	2002WO-US08137	20020315
	WO2002074276	A3	20030912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US---6500406	B1	20021231	2002US-0085383	20020228
	US2003082113	A1	20030501	2002US-0242012	20020912
	US---6905673	B2	20050614		
	US2003086878	A1	20030508	2002US-0241961	20020912
	US2003099603	A1	20030529	2002US-0242645	20020912
PRAI	2001US-276976P	P	20010319		
	2001US-276978P	P	20010319		
	2001US-276979P	P	20010319		
	2002US-0084870	A1	20020228		
	2002US-0084898	A1	20020228		
	2002US-0085383	A1	20020228		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002074276	ICM	A61K-0007/30
	IPCI	A61K0007-30 [ICM,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02 [I,A]; A23G0004-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	ECLA	A23G003/30+D; A23G003/30+D4; A23G003/30+H6; A23G003/30P; A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02
US---6500406	IPCI	C11D0001-02 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02 [I,A]; A23G0004-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	NCL	424/049.000; 134/002.000; 134/042.000; 510/117.000;

noble jarrell 06/07/2006

		523/120.000
	ECLA	A23G003/30+D; A23G003/30+D4; A23G003/30+H6; A23G003/30P; A23G004/08; A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/25; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02
US2003082113	IPCI	A61K0007-16 [ICM,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02 [I,A]; A23G0004-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	NCL	424/049.000
	ECLA	A23G003/30+D; A23G003/30+D4; A23G003/30+H6; A23G003/30P; A61K008/19; A61K008/22; A61K008/37; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02
US2003086878	IPCI	A61K0007-16 [ICM,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02 [I,A]; A23G0004-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	NCL	424/049.000
	ECLA	A23G003/30+D; A23G003/30+D4; A23G003/30+H6; A23G003/30P; A23G004/08; A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/25; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02
US2003099603	IPCI	A61K0007-20 [ICM,7]
	IPCR	A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	NCL	424/053.000
	ECLA	A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/02

AB A non-self-supporting denture care composition comprises polybutene with a mol. weight of about 300 to about 3000 and a denture care active. The denture care composition may further comprise a denture care carrier. Kits comprising polybutene, a container and instructions for use or an applicator for applying the composition directly to the denture surface are also disclosed. The polybutene composition of the kits can further comprise a denture care active such as triclosan.

ST denture care compn polybutene

IT **Antihistamines**
(**H2**; denture care compns. and kits containing polybutene)

IT Analgesics
Anesthetics
Anti-inflammatory agents
Antioxidants
Antiviral agents
Dentifrices
Fungicides
(denture care compns. and kits containing polybutene)
IT Fats and Glyceridic oils, biological studies
Paraffin oils
Petrolatum
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(denture care compns. and kits containing polybutene)
IT Dental materials and appliances
(dentures; denture care compns. and kits containing polybutene)
IT Citrus paradisi
(seed extract; denture care compns. and kits containing polybutene)
IT Polyphosphoric acids
RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium salts; denture care compns. and kits containing polybutene)
IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(vegetable; denture care compns. and kits containing polybutene)
IT 13473-26-2
RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Opatint D&C Red 27; denture care compns. and kits containing polybutene)
IT 123-03-5, Cetylpyridinium chloride 144-55-8, Sodium bicarbonate, biological studies 1400-61-9, Nystatin 3380-34-5, Triclosan 7631-99-4, Sodium nitrate, biological studies 7681-49-4, Sodium fluoride, biological studies 7722-88-5, Tetrasodium pyrophosphate 7757-79-1, Potassium nitrate, biological studies 7783-47-3, Stannous fluoride 13537-32-1, Phosphorofluoridic acid 16984-48-8, Fluoride, biological studies
RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(denture care compns. and kits containing polybutene)
IT 9003-29-6, Polybutene 9044-17-1, Indopol H 300
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(denture care compns. and kits containing polybutene)

L34 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:736083 HCAPLUS
DN 137:268219
ED Entered STN: 27 Sep 2002
TI Systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier
IN Rajaiah, Jayanth; Ernst, Lisa Catron; Case, Anna Maria; Glandorf, William Michael; Ha, Thinh Nguyen; Mayer, Christopher Robert
PA The **Procter & Gamble** Company, USA
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/16
ICS A61C-0019/00
CC 62-7 (Essential Oils and Cosmetics)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002074275	A2	20020926	2002WO-US08139	20020315
	WO2002074275	A3	20030605		

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
            GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
            GN, GQ, GW, ML, MR, NE, SN, TD, TG
    US2002176827          A1    20021128    2002US-0084896          20020228
    US---6514484          B2    20030204
    CA---2441860          AA    20020926    2002CA-2441860          20020315
    EP---1370228          A2    20031217    2002EP-0715139          20020315
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    CN---1503658          A     20040609    2002CN-0806529          20020315
    JP2004535372          T2    20041125    2002JP-0572983          20020315
    RU---2257888          C2    20050810    2003RU-0130734          20020315
    US2003113276          A1    20030619    2002US-0241990          20021218
    US---6719995          B2    20040413
PRAI 2001US-276977P       P     20010319
    2002US-0084896        A1    20020228
    2002WO-US08139        W     20020315
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 2002074275    ICM    A61K-0007/16
                  ICS    A61C-0019/00
                  IPCI   A61K0007-16 [ICM,7]; A61C0019-00 [ICS,7]
                  IPCR   A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72
                         [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  ECLA   A61C019/06B; A61K008/81C2; A61Q011/00
 US2002176827     IPCI   A61K0007-16 [ICM,7]; A61C0015-00 [ICS,7]
                  IPCR   A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72
                         [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  NCL    424/049.000
                  ECLA   A61C019/06B; A61K008/81C2; A61Q011/00
 CA---2441860     IPCI   A61K0007-16 [ICM,7]; A61C0019-00 [ICS,7]
                  IPCR   A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72
                         [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
 EP---1370228     IPCI   A61K0007-16 [ICM,7]; A61C0019-00 [ICS,7]
                  IPCR   A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72
                         [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
 CN---1503658     IPCI   A61K0007-16 [ICM,7]; A61C0019-00 [ICS,7]
                  IPCR   A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72
                         [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  ECLA   A61C019/06B; A61K008/81C2; A61Q011/00
 JP2004535372     IPCI   A61K0007-16 [ICM,7]; A61K0009-70 [ICS,7]; A61K0031-085
                         [ICS,7]; A61K0031-075 [ICS,7,C*]; A61K0031-17 [ICS,7];
                         A61K0033-40 [ICS,7]; A61K0047-32 [ICS,7]; A61P0001-02
                         [ICS,7]; A61P0001-00 [ICS,7,C*]
                  IPCR   A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72
                         [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  FTERM  4C076/AA74; 4C076/BB22; 4C076/CC03; 4C076/CC16;
                         4C076/DD45; 4C076/DD60; 4C076/EE03; 4C076/FF70;
                         4C083/AA111; 4C083/AB081; 4C083/AB172; 4C083/AB272;
                         4C083/AB281; 4C083/AB311; 4C083/AB372; 4C083/AB411;
                         4C083/AB471; 4C083/AB472; 4C083/AC012; 4C083/AC312;
                         4C083/AC342; 4C083/AC442; 4C083/AC681; 4C083/AC812;
```

4C083/AC852; 4C083/AD021; 4C083/AD022; 4C083/AD072; 4C083/AD412; 4C083/AD532; 4C083/BB47; 4C083/BB48; 4C083/BB55; 4C083/CC41; 4C083/CC42; 4C083/DD12; 4C083/EE03; 4C083/EE05; 4C083/EE32; 4C083/EE35; 4C083/EE36; 4C086/AA10; 4C086/HA22; 4C086/MA03; 4C086/MA05; 4C086/MA32; 4C086/MA57; 4C086/NA10; 4C086/ZA67; 4C206/AA10; 4C206/HA27; 4C206/MA03; 4C206/MA05; 4C206/MA52; 4C206/MA77; 4C206/NA20; 4C206/ZA67

RU---2257888	IPCI	A61K0007-16 [ICM,7]
	ECLA	A61C019/06B; A61K008/81C2; A61Q011/00
US2003113276	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-20 [ICS,7]
	IPCR	A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000
	ECLA	A61C019/06B; A61K008/81C2; A61Q011/00

AB Systems for delivering cosmetic and therapeutic actives to the oral cavity employ a strip comprising a first layer of material, a second layer comprising polybutene with a mol. weight of about 300 to about 3000, and a cosmetic or therapeutic active included within the second layer. Therapeutic and cosmetic actives in compns. comprising polybutene inhibit or prevent gingivitis, caries, staining, fungi, bacteria and plaque build-up in the oral cavity by means of the delivery system. A composition contains Indopol H-300, Glass H, and triclosan.

ST polybutene cosmetic drug delivery oral

IT **Antihistamines**
(**H2**; systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier)

IT Drug delivery systems
(oral; systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier)

IT Tooth, disease
(plaque; systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier)

IT Analgesics
Anesthetics
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antiviral agents
Dentifrices
Fungicides
Nutrients
Pigments, nonbiological
(systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier)

IT 13473-26-2
RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Opatint D&C Red 27; systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier)

IT 123-03-5, Cetylpyridinium chloride 124-43-6, Carbamide peroxide 144-55-8, Sodium bicarbonate, biological studies 1400-61-9, Nystatin 3380-34-5, Triclosan 7631-99-4, Sodium nitrate, biological studies 7681-49-4, Sodium fluoride, biological studies 7722-88-5, Tetrasodium pyrophosphate 7757-79-1, Potassium nitrate, biological studies 7783-47-3, Stannous fluoride 13537-32-1, Phosphorofluoridic acid 16984-48-8, Fluoride, biological studies
RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier)

IT 9003-29-6, Polybutene 9044-17-1, Indopol H 300
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);

USES (Uses)
(systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier)

L34 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:736082 HCAPLUS
DN 137:268218
ED Entered STN: 27 Sep 2002
TI Dentifrice compositions containing polybutene
IN Rajaiah, Jayanth; Ernst, Lisa Catron; Case, Anna Maria; Glandorf, William Michael; Ha, Thinh Nguyen; Mayer, Christopher Robert
PA The **Procter** & **Gamble** Company, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/16
CC 62-7 (Essential Oils and Cosmetics)
Section cross-reference(s): **63**

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002074274	A2	20020926	2002WO-US08136	20020315
	WO2002074274	A3	20030925		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US2002187108	A1	20021212	2002US-0084898	20020228
	US---6509007	B2	20030121		
	CA---2441865	AA	20020926	2002CA-2441865	20020315
	EP---1370227	A2	20031217	2002EP-0707983	20020315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP2004524334	T2	20040812	2002JP-0572982	20020315
	CN---1635866	A	20050706	2002CN-0806545	20020315
	US2003082113	A1	20030501	2002US-0242012	20020912
	US---6905673	B2	20050614		
	US2003086878	A1	20030508	2002US-0241961	20020912
PRAI	2001US-276978P	P	20010319		
	2001US-276979P	P	20010319		
	2001US-276976P	P	20010319		
	2002US-0084898	A1	20020228		
	2002US-0085383	A1	20020228		
	2002WO-US08136	W	20020315		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002074274	ICM	A61K-0007/16
	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	ECLA	A61K008/19; A61K008/22; A61K008/37; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02
US2002187108	IPCI	A61K0007-16 [ICM,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02

		[I,A]; A23G0004-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	NCL	424/049.000
	ECLA	A61K008/19; A61K008/22; A61K008/37; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02
CA---2441865	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
EP---1370227	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
JP2004524334	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	FTERM	4C083/AA112; 4C083/AB102; 4C083/AB172; 4C083/AB242; 4C083/AB282; 4C083/AB312; 4C083/AB412; 4C083/AB472; 4C083/AB502; 4C083/AC122; 4C083/AC132; 4C083/AC472; 4C083/AC682; 4C083/AC782; 4C083/AC812; 4C083/AC852; 4C083/AC862; 4C083/AD021; 4C083/AD022; 4C083/AD042; 4C083/AD072; 4C083/AD272; 4C083/AD352; 4C083/AD532; 4C083/BB41; 4C083/CC41; 4C083/DD06; 4C083/EE37
CN---1635866	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
US2003082113	IPCI	A61K0007-16 [ICM,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02 [I,A]; A23G0004-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-30 [I,C*]; A61K0008-37 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	NCL	424/049.000
	ECLA	A23G003/30+D; A23G003/30+D4; A23G003/30+H6; A23G003/30P; A61K008/19; A61K008/22; A61K008/37; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02
US2003086878	IPCI	A61K0007-16 [ICM,7]
	IPCR	A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02 [I,A]; A23G0004-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A];

A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
NCL 424/049.000
ECLA A23G003/30+D; A23G003/30+D4; A23G003/30+H6; A23G003/30P; A23G004/08; A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/25; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02

AB An oral care composition (a dentifrice) comprises polybutene with a mol. weight of about 300 to about 3000 and an oral care active. The oral care composition may further comprise an oral care carrier. Kits comprising polybutene, a container and instructions for use or an applicator for applying the composition directly to the tooth surfaces are also disclosed. The polybutene component of the kits can further comprise an oral care active or an oral care carrier. Thus, a formulation contained polybutene 99.757, and NaF 0.243%.

ST dentifrice polybutene fluoride

IT **Antihistamines**
(H2; dentifrice compns. containing polybutene)

IT Tooth, disease
(calculus; dentifrice compns. containing polybutene)

IT Calculi
(dental; dentifrice compns. containing polybutene)

IT Abrasives
Analgesics
Anesthetics
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antiviral agents
Buffers
Dentifrices
Flavoring materials
Fungicides
Humectants
Mouthwashes
Nutrients
Opacifiers
Surfactants
Sweetening agents
Thickening agents
Whitening agents
(dentifrice compns. containing polybutene)

IT **Dentifrices**
(**gels**; dentifrice compns. containing polybutene)

IT Viscosity
(modifiers; dentifrice compns. containing polybutene)

IT Tooth, disease
(plaque; dentifrice compns. containing polybutene)

IT Vitis vinifera
(seed exts.; dentifrice compns. containing polybutene)

IT Polyphosphoric acids
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium salts; dentifrice compns. containing polybutene)

IT 13473-26-2
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Opatint D&C Red 27; dentifrice compns. containing polybutene)

IT 87-99-0, Xylitol 123-03-5, Cetylpyridinium chloride 144-55-8, Baking soda, biological studies 1400-61-9, Nystatin 3380-34-5, Triclosan

7440-31-5, Tin, biological studies 7631-99-4, Nitric acid sodium salt, biological studies 7681-49-4, Sodium fluoride, biological studies 7722-88-5, Tetrasodium pyrophosphate 7757-79-1, Nitric acid potassium salt, biological studies 7783-47-3, Tin fluoride (SnF2) 9003-27-4, Indopol H 1900 9003-28-5, Polybutene 9044-17-1, Indopol H 300 13537-32-1, Phosphorofluoridic acid 16984-48-8, Fluoride, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dentifrice compns. containing polybutene)

L34 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:736071 HCAPLUS
DN 137:252754
ED Entered STN: 27 Sep 2002
TI Polybutene-containing denture cleanser compositions
IN Rajaiah, Jayanth; Ernst, Lisa Catron; Case, Anna Maria; Glandorf, William Michael; Ha, Thinh Nguyen; Mayer, Christopher Robert
PA The **Procter** & **Gamble** Company, USA
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/00
CC 62-7 (Essential Oils and Cosmetics)
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002074263	A2	20020926	2002WO-US08140	20020315
	WO2002074263	A3	20030904		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US---6491896	B1	20021210	2002US-0084870	20020228
	US2003086878	A1	20030508	2002US-0241961	20020912
	US2003099603	A1	20030529	2002US-0242645	20020912
PRAI	2001US-276976P	P	20010319		
	2001US-276978P	P	20010319		
	2002US-0084870	A1	20020228		
	2002US-0085383	A1	20020228		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002074263	ICM	A61K-0007/00
	IPCI	A61K0007-00 [ICM,7]
	IPCR	A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
	ECLA	A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/02
US---6491896	IPCI	A61K0009-46 [ICM,7]; C11D0007-18 [ICS,7]; C11D0007-02

[ICS,7,C*]; C11D0007-54 [ICS,7]; C11Q0017-00 [ICS,7]
IPCR A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
NCL 424/044.000; 510/117.000
ECLA A61K008/02; A61K008/19; A61K008/22; A61K008/23; A61K008/365; A61K008/37; A61K008/38; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/02

US2003086878 IPCI A61K0007-16 [ICM,7]
IPCR A23G0004-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-02 [I,A]; A23G0004-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-25 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
NCL 424/049.000
ECLA A23G003/30+D; A23G003/30+D4; A23G003/30+H6; A23G003/30P; A23G004/08; A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/25; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/00; A61Q011/02

US2003099603 IPCI A61K0007-20 [ICM,7]
IPCR A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-04 [I,A]; A61K0008-04 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-23 [I,A]; A61K0008-30 [I,C*]; A61K0008-365 [I,A]; A61K0008-37 [I,A]; A61K0008-38 [I,A]; A61K0008-41 [I,A]; A61K0008-42 [I,A]; A61K0008-72 [I,C*]; A61K0008-81 [I,A]; A61K0008-898 [I,A]; A61K0008-92 [I,A]; A61K0008-92 [I,C*]; A61Q0011-02 [I,A]; A61Q0011-02 [I,C*]
NCL 424/053.000
ECLA A61K008/02; A61K008/04F; A61K008/19; A61K008/22; A61K008/23; A61K008/365; A61K008/37; A61K008/38; A61K008/41; A61K008/42; A61K008/81C2; A61K008/898; A61K008/92C; A61Q011/02

AB A denture cleanser composition comprises polybutene, with a mol. weight of about 300 to about 3000, an effervescence generator and a bleaching agent. Optionally, denture cleanser compns. may further comprise tablet binders, organic peroxyacid bleach precursors, surfactants including a dimethicone copolyol, lipophilic compds. such as flavorants and coolants, chelating agents, and other therapeutic and cosmetic active agents.

ST denture cleanser polybutene

IT **Antihistamines**
(H2; polybutene-containing denture cleanser compns.)

IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(anise; polybutene-containing denture cleanser compns.)

IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(bay; polybutene-containing denture cleanser compns.)

IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(bitter almond; polybutene-containing denture cleanser compns.)
IT Polyphosphoric acids
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(calcium salts; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cedar leaf; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cinnamon; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(citronella; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(clove; polybutene-containing denture cleanser compns.)
IT **Dentifrices**
(**denture cleansers**; polybutene-containing denture cleanser compns.)
IT Polysiloxanes, biological studies
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(di-Me, 3-hydroxypropyl Me, ethoxylated propoxylated; polybutene-containing denture cleanser compns.)
IT Polyoxyalkylenes, biological studies
Polyoxyalkylenes, biological studies
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(di-Me, Me hydrogen polysiloxane-; polybutene-containing denture cleanser compns.)
IT Polysiloxanes, biological studies
Polysiloxanes, biological studies
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(di-Me, Me hydrogen, polyoxyalkylene-; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(lavender; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(lemon; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(margoram; polybutene-containing denture cleanser compns.)
IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(mustard; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(orange, sweet; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(oregano; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(peppermint; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(pine leaf; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(pine; polybutene-containing denture cleanser compns.)
IT Tooth, disease
(plaque; polybutene-containing denture cleanser compns.)

IT Analgesics
Anesthetics
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antiviral agents
Bleaching agents
Flavoring materials
Fungicides
Nutrients
(polybutene-containing denture cleanser compns.)
IT Aluminosilicates, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(rosemary; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(sage, Salvia officinalis; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(sassafras; polybutene-containing denture cleanser compns.)
IT Polyphosphoric acids
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(sodium salts; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(spearmint; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(thyme, Thymus vulgaris; polybutene-containing denture cleanser compns.)
IT Essential oils
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(wintergreen; polybutene-containing denture cleanser compns.)
IT 9003-29-6, Polybutene 9044-17-1, Indopol H-300
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(polybutene-containing denture cleanser compns.)
IT 65-85-0, Benzoic acid, biological studies 76-22-2, Camphor 89-78-1, Menthol 89-83-8, Thymol 94-13-3, Propylparaben 94-26-8, Butylparaben 94-36-0, Benzoyl peroxide, biological studies 99-76-3, Methylparaben 100-52-7, Benzaldehyde, biological studies 108-95-2, Phenol, biological studies 136-77-6, 4-Hexylresorcinol 470-82-6, Eucalyptol 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 1343-88-0, Magnesium silicate 1344-28-1, Alumina, biological studies 3380-34-5, Triclosan 5329-14-6, Sulfamic acid 7631-86-9, Silica, biological studies 7758-87-4, Calcium orthophosphate 10086-45-0, Calcium pyrophosphate 10101-52-7, Zirconium silicate 13477-39-9, Calcium metaphosphate 16984-48-8, Fluoride, biological studies
RL: COS (Cosmetic use); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(polybutene-containing denture cleanser compns.)

L34 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:331997 HCAPLUS
DN 136:345525
ED Entered STN: 03 May 2002
TI Dental care compositions containing polysiloxanes
IN Lawlor, Thomas Mark
PA The **Procter & Gamble** Company, USA
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/16

```
     ICS  A61K-0007/48; C08L-0083/04
CC   62-7 (Essential Oils and Cosmetics)
     Section cross-reference(s): 63
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     --------------       ----   --------    --------------------     --------
PI   WO2002034221          A1    20020502    2000WO-US29384           20001025
         W:  AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI,
             GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
             KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
             MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM,
             TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
             MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA---2424566           AA    20020502    2000CA-2424566           20001025
     AU2001016543           A5    20020506    2001AU-0016543           20001025
     EP---1328245           A1    20030723    2000EP-0979130           20001025
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     BR2000017362           A     20031028    2000BR-0017362           20001025
     JP2004517820           T2    20040617    2002JP-0537275           20001025
     RU---2248787           C2    20050327    2003RU-0115439           20001025
     US2003198604           A1    20031023    2003US-0424640           20030425
     US---6685921           B2    20040203
PRAI 2000WO-US29384         W     20001025
CLASS
 PATENT NO.        CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------    -----  ----------------------------------------------
 WO 2002034221     ICM    A61K-0007/16
                   ICS    A61K-0007/48; C08L-0083/04
                   IPCI   A61K0007-16 [ICM,7]; A61K0007-48 [ICS,7]; C08L0083-04
                          [ICS,7]; C08L0083-00 [ICS,7,C*]
                   IPCR   A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0006-093
                          [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A];
                          A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81
                          [I,A]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];
                          A61Q0011-00 [I,C*]
                   ECLA   A61K006/02; A61K006/093; A61K007/16D14; A61K007/48N16
 CA---2424566      IPCI   A61K0007-16 [ICM,7]; C08L0083-04 [ICS,7]; C08L0083-00
                          [ICS,7,C*]; A61K0007-48 [ICS,7]
 AU2001016543      IPCI   A61K0007-16 [ICM,7]; A61K0007-48 [ICS,7]; C08L0083-04
                          [ICS,7]; C08L0083-00 [ICS,7,C*]
 EP---1328245      IPCI   A61K0007-16 [ICM,7]; A61K0007-48 [ICS,7]; C08L0083-04
                          [ICS,7]; C08L0083-00 [ICS,7,C*]
                   IPCR   A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0006-093
                          [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A];
                          A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81
                          [I,A]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];
                          A61Q0011-00 [I,C*]
 BR2000017362      IPCI   A61K0007-16 [ICM,7]; A61K0007-48 [ICS,7]; C08L0083-04
                          [ICS,7]; C08L0083-00 [ICS,7,C*]
                   IPCR   A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0006-093
                          [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A];
                          A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81
                          [I,A]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];
                          A61Q0011-00 [I,C*]
 JP2004517820      IPCI   A61K0006-00 [ICM,7]; A61K0006-093 [ICS,7]; A61K0006-02
                          [ICS,7,C*]; A61K0047-02 [ICS,7]; A61K0047-04 [ICS,7];
                          A61K0047-10 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-32
                          [ICS,7]; A61K0047-34 [ICS,7]; A61K0047-36 [ICS,7];
                          A61K0047-38 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00
                          [ICS,7,C*]; A61P0003-02 [ICS,7]; A61P0003-00
                          [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7];
```

A61P0031-12 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0043-00 [ICS,7]
IPCR A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0006-093 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-72 [I,C*]; A61K0008-73 [I,A]; A61K0008-81 [I,A]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
FTERM 4C076/AA09; 4C076/BB22; 4C076/BB23; 4C076/CC01; 4C076/CC07; 4C076/CC09; 4C076/CC21; 4C076/CC31; 4C076/CC35; 4C076/DD22; 4C076/DD23; 4C076/DD26; 4C076/DD28F; 4C076/DD29; 4C076/DD37; 4C076/DD38; 4C076/EE08F; 4C076/EE23F; 4C076/EE27F; 4C076/EE30F; 4C076/EE31F; 4C076/FF21; 4C076/FF22; 4C076/FF51; 4C076/FF53; 4C089/AA20; 4C089/BA07; 4C089/BA09; 4C089/BA11; 4C089/BA13; 4C089/BA16; 4C089/BA20; 4C089/BC03; 4C089/BC06; 4C089/BE01; 4C089/BE11; 4C089/BE15; 4C089/CA03
RU---2248787 IPCI A61K0007-16 [ICM,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]
US2003198604 IPCI A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-06 [ICS,7]; A61K0007-11 [ICS,7]
IPCR A61K0006-02 [I,C*]; A61K0006-093 [I,A]; A61K0008-30 [I,C*]; A61K0008-34 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0008-892 [I,A]; A61K0008-893 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
NCL 424/049.000
ECLA A61K006/093; A61K008/34D; A61K008/891; A61K008/892; A61K008/893; A61Q011/00

AB The present invention relates to non volatile compns. that comprises: i) from about 0.5 % to about 60 % by weight, of a silicone resin; ii) from about 0.1 % to about 30 %, by weight, of a silicon gum; iii) from about 0.1 % to about 95 %, by weight, of a non volatile polysiloxane fluid which has a viscosity from about 1cStk to about 1000cStk; and from about 0.01 % to about 50 %, by weight, of an oral care active selected from teeth color modifying substances, antitartar agents, antiplaque agents, fluoride ion sources, antimicrobial agents, nutrients, antioxidants, H-2 antagonists, analgesics, antiviral agents, mucosally absorbed pharmacol. agents and mixts. thereof. A second aspect of the present invention relates to the user of non volatile oral care silicone compns. in the oral cavity to treat the hard and soft tissue surfaces wherein the composition comprises: (i) from about 0.5 % to about 60 %, by weight, of a silicone resin; (ii) from about 0.1 % to about 30 %, by weight of a silicone gum; (iii) from about 1cStk to about 1000cStk. Compns. of the present invention are useful for providing a substantive composition on the surfaces of the oral cavity which can provide prophylactic, therapeutic or cosmetic benefits. A composition contained silicone reson (SR1000) 30.00, silicone gum (SE30) 10.00, silicone fluid (SC200) 60.00 % weight/weight

ST oral dental compn silicone; polysiloxane dental compn

IT **Antihistamines**
(**H2**; dental care compns. containing polysiloxanes)

IT Analgesics
Antimicrobial agents
Antioxidants
Antiviral agents
Dentifrices
Nutrients
(dental care compns. containing polysiloxanes)

IT Clays, biological studies
Polyphosphates
RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dental care compns. containing polysiloxanes)

IT Polysiloxanes, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dental care compns. containing polysiloxanes)

IT Silicone rubber, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-Me, SE 30; dental care compns. containing polysiloxanes)
IT Drug delivery systems
(oral; dental care compns. containing polysiloxanes)
IT 87-99-0, Xylitol 3380-34-5, Triclosan 7440-66-6D, Zinc, salts 7631-86-9, Silica, biological studies 7732-18-5, Water, biological studies 7757-79-1, Potassium nitrate, biological studies 7783-47-3, Stannous fluoride 9004-34-6D, Cellulose, polymers 11138-66-2, Xanthan gum 14915-07-2, Peroxide 16984-48-8, Fluoride, biological studies 106392-12-5, Oxirane, polymer with methyloxirane, block
RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dental care compns. containing polysiloxanes)
IT 9016-00-6, Polydimethylsiloxane 31900-57-9, Polydimethylsiloxane 56275-01-5, SR 1000
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dental care compns. containing polysiloxanes)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Dow Corning France; WO---0122923 A 2001 HCAPLUS
(2) Kanebo; JP--11222420 A CAPLUS 1999:518667 1999 HCAPLUS
(3) Procter & Gamble; WO---9210161 A 1992 HCAPLUS
(4) Procter & Gamble; WO---9717059 A 1997 HCAPLUS
(5) Procter & Gamble; WO---0101942 A 2001 HCAPLUS

L34 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:151471 HCAPLUS
DN 136:189127
ED Entered STN: 27 Feb 2002
TI Oral care compositions comprising chlorite
IN Witt, Jonathan James; Wimalasena, Rohan Lalith; Wong, Andrew Lee; Goulbourne, Eric Altman, Jr.; **Doyle, Matthew Joseph**
PA The **Procter & Gamble** Company, USA
SO U.S., 15 pp., Cont.-in-part of U.S. 6,251,372.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K-0007/16
ICS A61K-0007/20
INCL 424053000
CC 62-7 (Essential Oils and Cosmetics)
Section cross-reference(s): **1, 63**
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---6350438	B1	20020226	2000US-0607242	20000630
	US---6077502	A	20000620	1998US-0032238	19980227
	US---6132702	A	20001017	1998US-0032234	19980227
	US---6251372	B1	20010626	1998US-0032237	19980227
	CA---2414573	AA	20020110	2001CA-2414573	20010628
	WO2002002061	A2	20020110	2001WO-US20614	20010628
	WO2002002061	A3	20020627		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	EP---1294347	A2	20030326	2001EP-0946731	20010628

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

```
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    JP2004501942          T2    20040122    2002JP-0506684          20010628
PRAI 1998US-0032234       A2    19980227
     1998US-0032237       A2    19980227
     1998US-0032238       A2    19980227
     2000US-0607242       A     20000630
     2001WO-US20614       W     20010628
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 US 6350438       ICM    A61K-0007/16
                  ICS    A61K-0007/20
                  INCL   424053000
                  IPCI   A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61K0033-20 [I,A];
                         A61K0033-20 [I,C*]
                  NCL    424/053.000; 424/049.000
                  ECLA   A61K033/20; A23K001/18N; A61K008/20; A61Q011/00
 US---6077502     IPCI   A61K0007-20 [ICM,7]; A61K0033-20 [ICS,7]; A61K0009-20
                         [ICS,7]
                  IPCR   A61K0033-20 [I,A]; A61K0033-20 [I,C*]
                  NCL    424/053.000; 424/049.000; 424/464.000; 424/613.000;
                         424/661.000
                  ECLA   A61K033/20; A61K008/20; A61Q011/00
 US---6132702     IPCI   A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]; A61K0033-20
                         [ICS,7]
                  IPCR   A61K0033-20 [I,A]; A61K0033-20 [I,C*]
                  NCL    424/053.000; 424/661.000
                  ECLA   A61K008/20; A61Q011/00
 US---6251372     IPCI   A61K0007-20 [ICM,7]
                  NCL    424/053.000
                  ECLA   A61Q011/00; A61K008/20
 CA---2414573     IPCI   A61K0007-20 [ICM,7]; A61K0007-16 [ICS,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
 WO2002002061     IPCI   A61K0007-00 [ICM,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  ECLA   A23K001/18N; A61K008/20; A61Q011/00
 EP---1294347     IPCI   A61K0007-20 [ICM,7]; A61K0007-16 [ICS,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
 JP2004501942     IPCI   A61K0007-20 [ICM,7]; A61C0017-00 [ICS,7]; A61K0007-22
                         [ICS,7]; A61K0007-24 [ICS,7]; A61L0002-18 [ICS,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  FTERM  4C058/AA13; 4C058/AA28; 4C058/BB07; 4C058/JJ07;
                         4C083/AB032; 4C083/AB101; 4C083/AB102; 4C083/AB172;
                         4C083/AB211; 4C083/AB242; 4C083/AB312; 4C083/AB331;
                         4C083/AB332; 4C083/AB472; 4C083/AC102; 4C083/AC122;
                         4C083/AC132; 4C083/AC242; 4C083/AC442; 4C083/AC471;
                         4C083/AC482; 4C083/AC641; 4C083/AC691; 4C083/AC741;
                         4C083/AC782; 4C083/AC791; 4C083/AC811; 4C083/AC842;
                         4C083/AC851; 4C083/AC862; 4C083/AD092; 4C083/AD211;
                         4C083/AD272; 4C083/AD352; 4C083/AD412; 4C083/AD591;
                         4C083/AD611; 4C083/BB41; 4C083/BB43; 4C083/BB48;
                         4C083/BB55; 4C083/CC41; 4C083/DD05; 4C083/DD08;
                         4C083/DD15; 4C083/DD22; 4C083/DD23; 4C083/DD27;
                         4C083/DD41; 4C083/EE03; 4C083/EE31; 4C083/EE33;
                         4C083/EE36; 4C083/FF05
AB   The present invention relates to topical oral compns., including
```

therapeutic rinses, especially mouth rinses, as well as toothpastes, gels, tooth powders, chewing gums, mouth sprays, lozenges (including breath mints), dental implements (such as dental floss and tape), and pet care products comprising at least a minimally effective amount of chlorite ion, wherein the pH of the final composition is > 7 and the composition is essentially free of chlorine dioxide or chlorous acid. This invention further relates to a method for treating or preventing diseases and conditions of the oral cavity such as gingivitis, plaque, periodontal disease, herpetic lesions, and infections that may develop following dental procedures such as osseous surgery, tooth extraction, periodontal flap surgery, dental implantation, and scaling and root planing, in humans and other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity. For example, an oral spray contained sodium chlorite (80%) 1.25%, sodium bicarbonate 0.192%, sodium carbonate 0.289%, and water up to 100%. Chlorite-containing pet rawhide chips and toy ropes were prepared by spraying with the oral spray (10-20 mL per item). The impregnated items are given to dogs immediately or stored in sealed plastic bags to remain moist.

ST chlorite dentifrice topical oral care

IT **Antihistamines**
(**H2**; chlorite-containing oral care compns.)

IT Bone resorption
(alveolar, prevention of; chlorite-containing oral care compns.)

IT Cytokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; chlorite-containing oral care compns.)

IT **Dentifrices**
(**antiplaque**; chlorite-containing oral care compns.)

IT Deodorants (personal)
(breath fresheners; chlorite-containing oral care compns.)

IT **Dentifrices**
(**chewing gums**; chlorite-containing oral care compns.)

IT Syringes
(chlorite delivery to periodontal pockets with; chlorite-containing oral care compns.)

IT Gingiva
Tongue
(chlorite delivery to; chlorite-containing oral care compns.)

IT Analgesics
Anti-inflammatory agents
Antimicrobial agents
Human
Immunostimulants
Mouthwashes
Periodontium, disease
Redox agents
(chlorite-containing oral care compns.)

IT Chlorites
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorite-containing oral care compns.)

IT Growth factors, animal
Hormones, animal, biological studies
Mineral elements, biological studies
Vitamins
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorite-containing oral care compns.)

IT Lipopolysaccharides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(complexing agents; chlorite-containing oral care compns.)

IT **Dentifrices**
(**dental floss**, and tapes; chlorite-containing oral care compns.)

IT Chewing gum
(dentifrices; chlorite-containing oral care compns.)

noble jarrell 06/07/2006

IT **Dentifrices**
(**gels**; chlorite-containing oral care compns.)
IT Gingiva, disease
Inflammation
(gingivitis; chlorite-containing oral care compns.)
IT Mouth, disease
(lesions, herpetic; chlorite-containing oral care compns.)
IT Herpesviridae
Human herpesvirus
(lesions; chlorite-containing oral care compns.)
IT Tooth
(loose; chlorite-containing oral care compns.)
IT Drug delivery systems
(lozenges; chlorite-containing oral care compns.)
IT Mouth
(mucosa, chlorite delivery to; chlorite-containing oral care compns. for)
IT Pet animal
(oral care products; chlorite-containing oral care compns.)
IT Periodontium
(pockets; chlorite-containing oral care compns.)
IT **Dentifrices**
(**powders**; chlorite-containing oral care compns.)
IT Mouth, disease
(prevention and treatment of; chlorite-containing oral care compns.)
IT Drug delivery systems
(sprays, oral; chlorite-containing oral care compns.)
IT Drug delivery systems
(topical, oral; chlorite-containing oral care compns.)
IT 123-03-5, Cetylpyridinium chloride 7758-19-2, Sodium Chlorite
14998-27-7, Chlorite
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorite-containing oral care compns.)
IT 10049-04-4, Chlorine dioxide
RL: MSC (Miscellaneous)
(chlorite-containing oral care compns. free of chlorine dioxide)
IT 13898-47-0, Chlorous acid
RL: MSC (Miscellaneous)
(chlorite-containing oral care compns. free of chlorous acid)
IT 14380-61-1, Hypochlorite
RL: MSC (Miscellaneous)
(chlorite-containing oral care compns. free of hypochlorite)
IT 7790-92-3D, Hypochlorous acid, salts
RL: MSC (Miscellaneous)
(chlorite-containing oral care compns. free of hypochlorous acid)
IT 81669-70-7, Metalloproteinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; chlorite-containing oral care compns.)
RE.CNT 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Agricola; US---4902498 A 1990 HCAPLUS
(2) Alliger; US---4084747 A 1978 HCAPLUS
(3) Alliger; US---4330531 A 1982 HCAPLUS
(4) Alliger; US---6039934 A 2000 HCAPLUS
(5) Anon; DE---2329753 1973 HCAPLUS
(6) Anon; JP--60054311 1985
(7) Anon; JP--60105610 1985 HCAPLUS
(8) Anon; EP---0287074 1988 HCAPLUS
(9) Anon; WO---8903179 1989 HCAPLUS
(10) Anon; JP---2104509 A 1990
(11) Anon; EP---0565134 A1 1993 HCAPLUS
(12) Anon; WO---9318781 1993 HCAPLUS
(13) Anon; GB---2289841 A 1995 HCAPLUS
(14) Anon; GB---2290233 A 1995 HCAPLUS
(15) Anon; WO---9527472 1995 HCAPLUS
(16) Anon; WO---9625916 1996 HCAPLUS

(17) Anon; JP--09183706 1997
(18) Anon; WO---9804235 1998 HCAPLUS
(19) Berger; US---4574084 A 1986 HCAPLUS
(20) Davidson; US---4986990 A 1991 HCAPLUS
(21) Davidson; US---5185161 A 1993 HCAPLUS
(22) Davidson; US---RE36064 E 1999
(23) Gaffar; US---4273759 A 1981 HCAPLUS
(24) Gordon; US---4880638 A 1989 HCAPLUS
(25) Haefele; US---3954002 A 1976 HCAPLUS
(26) Hutchings; US---4861514 A 1989 HCAPLUS
(27) Hutchings; US---5091107 A 1992 HCAPLUS
(28) Kelley; US---4829912 A 1989
(29) Kross; US---4891216 A 1990 HCAPLUS
(30) Kross; US---5019402 A 1991 HCAPLUS
(31) Kross; US---5100652 A 1992 HCAPLUS
(32) Kross; US---5772986 A 1998 HCAPLUS
(33) Kross; US---5820822 A 1998 HCAPLUS
(34) Lukacovic; US---5281412 A 1994 HCAPLUS
(35) Lynch; Free Rad Res 1996, V26, P209
(36) McNicholas; US---3271242 A 1966 HCAPLUS
(37) McNicholas; US---3278447 A 1966 HCAPLUS
(38) Montgomery; US---5944528 A 1999 HCAPLUS
(39) Ratcliff; US---4689215 A 1987 HCAPLUS
(40) Ratcliff; US---4696811 A 1987 HCAPLUS
(41) Ratcliff; US---4786492 A 1988 HCAPLUS
(42) Ratcliff; US---4788053 A 1988 HCAPLUS
(43) Ratcliff; US---4792442 A 1988 HCAPLUS
(44) Ratcliff; US---4793989 A 1988 HCAPLUS
(45) Ratcliff; US---4808389 A 1989 HCAPLUS
(46) Ratcliff; US---4818519 A 1989 HCAPLUS
(47) Ratcliff; US---4837009 A 1989 HCAPLUS
(48) Ratcliff; US---4851213 A 1989 HCAPLUS
(49) Ratcliff; US---4855135 A 1989 HCAPLUS
(50) Ratcliff; US---4886657 A 1989 HCAPLUS
(51) Ratcliff; US---4889714 A 1989 HCAPLUS
(52) Ratcliff; US---4925656 A 1990 HCAPLUS
(53) Ratcliff; US---4975285 A 1990 HCAPLUS
(54) Ratcliff; US---4978535 A 1990 HCAPLUS
(55) Ratcliff; US---5052590 A 1991
(56) Ratcliff; US---5200171 A 1993 HCAPLUS
(57) Ratcliff; US---5348734 A 1994 HCAPLUS
(58) Ratcliff; US---5489435 A 1996 HCAPLUS
(59) Ratcliff; US---5618550 A 1997 HCAPLUS
(60) Richter; US---5738840 A 1998 HCAPLUS
(61) Richter; Compendium 1996, V17(4), P370 MEDLINE
(62) Sagel; US---5891453 A 1999 HCAPLUS
(63) Sagel; US---6096328 A 2000 HCAPLUS
(64) Sagel; US---6136297 A 2000 HCAPLUS
(65) Sasson; US---6280775 B1 2001 HCAPLUS
(66) Simon; US---4592487 A 1986 HCAPLUS
(67) Tell; US---4690772 A 1987 HCAPLUS
(68) Tice; US---4585482 A 1986 HCAPLUS
(69) Vit; US---4060600 A 1977
(70) Wellinghoff; US---5631300 A 1997 HCAPLUS
(71) Wellinghoff; US---5650446 A 1997 HCAPLUS
(72) White; Industrial and Engineering Chemistry 1942, V34(7), P782
(73) Witt; US--09032234 1998
(74) Witt; US--09032237 1998
(75) Witt; US--09032238 1998
(76) Witt; US--09481624 2000
(77) Witt; US--09487692 2000
(78) Witt; US---6077502 A 2000 HCAPLUS
(79) Witt; US---6132702 A 2000 HCAPLUS
(80) Witt; US---6235269 B1 2001 HCAPLUS
(81) Witt; US---6251372 B1 2001 HCAPLUS
(82) Witt; US---6264924 B1 2001 HCAPLUS

(83) Yates; J Clin Periodontol 1997, V24, P603 HCAPLUS

L34 ANSWER 11 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:31268 HCAPLUS
DN 136:90976
ED Entered STN: 11 Jan 2002
TI Topical oral compositions containing antimicrobial agents for promoting whole body health
IN **Doyle, Matthew Joseph; Hunter-Rinderle, Stephen Joseph ; Singer, Robert Ernest, Jr.**
PA **Procter & Gamble** Company, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0033/00
ICS A61K-0031/05; A61K-0031/155; A61K-0031/14; A61K-0033/30; A61K-0033/34; A61K-0045/06; A61P-0001/02; A61K-0007/16; A61K-0007/22
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): 62
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002002128	A2	20020110	2001WO-US20516	20010628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA---2415068	AA	20020110	2001CA-2415068	20010628
EP---1294383	A2	20030326	2001EP-0950570	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP2004517038	T2	20040610	2002JP-0506749	20010628
CN---1522149	A	20040818	2001CN-0812035	20010628
US2005163727	A1	20050728	2004US-0854065	20040525
PRAI 2000US-0607240	A	20000630		
2001WO-US20516	W	20010628		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002002128	ICM	A61K-0033/00
	ICS	A61K-0031/05; A61K-0031/155; A61K-0031/14; A61K-0033/30; A61K-0033/34; A61K-0045/06; A61P-0001/02; A61K-0007/16; A61K-0007/22
	IPCI	A61K0033-00 [ICM,7]; A61K0031-05 [ICS,7]; A61K0031-045 [ICS,7,C*]; A61K0031-155 [ICS,7]; A61K0031-14 [ICS,7]; A61K0033-30 [ICS,7]; A61K0033-34 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0007-16 [ICS,7]; A61K0007-22 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-41 [I,A]; A61K0008-43 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A]; A61K0031-14 [I,A]; A61K0031-14 [I,C*]; A61K0031-155 [I,A]; A61K0031-155 [I,C*]; A61K0033-24 [I,A]; A61K0033-24 [I,C*]; A61K0033-30 [I,A]; A61K0033-30 [I,C*]; A61K0033-34 [I,A]; A61K0033-34 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43; A61K008/49; A61K008/49C4; A61K031/05; A61K031/14; A61K031/155; A61K033/24; A61K033/30; A61K033/34;

		A61K045/06
CA---2415068	IPCI	A61K0033-00 [ICM,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0031-05 [ICS,7]; A61K0031-045 [ICS,7,C*]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61K0031-14 [ICS,7]; A61K0031-155 [ICS,7]; A61K0007-16 [ICS,7]; A61K0007-22 [ICS,7]; A61K0033-30 [ICS,7]; A61K0033-34 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-41 [I,A]; A61K0008-43 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A]; A61K0031-14 [I,A]; A61K0031-14 [I,C*]; A61K0031-155 [I,A]; A61K0031-155 [I,C*]; A61K0033-24 [I,A]; A61K0033-24 [I,C*]; A61K0033-30 [I,A]; A61K0033-30 [I,C*]; A61K0033-34 [I,A]; A61K0033-34 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43; A61K008/49; A61K008/49C4; A61K031/05; A61K031/14; A61K031/155; A61K033/24; A61K033/30; A61K033/34; A61K045/06
EP---1294383	IPCI	A61K0033-00 [ICM,7]; A61K0031-05 [ICS,7]; A61K0031-045 [ICS,7,C*]; A61K0031-155 [ICS,7]; A61K0031-14 [ICS,7]; A61K0033-30 [ICS,7]; A61K0033-34 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0007-16 [ICS,7]; A61K0007-22 [ICS,7]
	IPCR	A61K0008-30 [I,C*]; A61K0008-41 [I,A]; A61K0008-43 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A]; A61K0031-14 [I,A]; A61K0031-14 [I,C*]; A61K0031-155 [I,A]; A61K0031-155 [I,C*]; A61K0033-24 [I,A]; A61K0033-24 [I,C*]; A61K0033-30 [I,A]; A61K0033-30 [I,C*]; A61K0033-34 [I,A]; A61K0033-34 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43; A61K008/49; A61K008/49C4; A61K031/05; A61K031/14; A61K031/155; A61K033/24; A61K033/30; A61K033/34; A61K045/06
JP2004517038	IPCI	A61K0031-14 [ICM,7]; A61K0007-16 [ICS,7]; A61K0031-085 [ICS,7]; A61K0031-075 [ICS,7,C*]; A61K0031-155 [ICS,7]; A61K0031-4425 [ICS,7]; A61K0033-24 [ICS,7]; A61K0045-00 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0003-10 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0009-00 [ICS,7]; A61P0009-10 [ICS,7]; A61P0011-00 [ICS,7]; A61P0015-00 [ICS,7]; A61P0031-02 [ICS,7]; A61P0031-00 [ICS,7,C*]
	IPCR	A61K0008-30 [I,C*]; A61K0008-41 [I,A]; A61K0008-43 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A]; A61K0031-14 [I,A]; A61K0031-14 [I,C*]; A61K0031-155 [I,A]; A61K0031-155 [I,C*]; A61K0033-24 [I,A]; A61K0033-24 [I,C*]; A61K0033-30 [I,A]; A61K0033-30 [I,C*]; A61K0033-34 [I,A]; A61K0033-34 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	FTERM	4C083/AB032; 4C083/AB172; 4C083/AB242; 4C083/AB271; 4C083/AB272; 4C083/AB282; 4C083/AB312; 4C083/AB331; 4C083/AB472; 4C083/AC102; 4C083/AC122; 4C083/AC132; 4C083/AC302; 4C083/AC312; 4C083/AC442; 4C083/AC471; 4C083/AC482; 4C083/AC691; 4C083/AC692; 4C083/AC782; 4C083/AC841; 4C083/AC851; 4C083/AC852; 4C083/AD042; 4C083/AD092; 4C083/AD272; 4C083/AD352; 4C083/AD411; 4C083/CC41; 4C083/DD08; 4C083/DD22; 4C083/DD27; 4C083/EE32; 4C083/EE33; 4C084/AA19; 4C084/MA13; 4C084/MA17; 4C084/MA28; 4C084/MA35; 4C084/MA52; 4C084/MA57; 4C084/NA14; 4C084/ZA082; 4C084/ZA361; 4C084/ZA451; 4C084/ZA671; 4C084/ZB022; 4C084/ZB092; 4C084/ZB112; 4C084/ZB352; 4C084/ZC032; 4C084/ZC202;

4C084/ZC212; 4C084/ZC222; 4C084/ZC351; 4C084/ZC372; 4C084/ZC442; 4C086/AA01; 4C086/AA02; 4C086/BC17; 4C086/MA02; 4C086/MA04; 4C086/MA10; 4C086/MA13; 4C086/MA17; 4C086/MA28; 4C086/MA35; 4C086/MA52; 4C086/MA57; 4C086/NA14; 4C086/ZA36; 4C086/ZA45; 4C086/ZA59; 4C086/ZA67; 4C086/ZA81; 4C086/ZC35; 4C206/AA01; 4C206/AA02; 4C206/CA28; 4C206/HA31; 4C206/MA02; 4C206/MA04; 4C206/MA14; 4C206/MA33; 4C206/MA37; 4C206/MA48; 4C206/MA72; 4C206/MA77; 4C206/NA14; 4C206/ZA36; 4C206/ZA45; 4C206/ZA59; 4C206/ZA67; 4C206/ZA81; 4C206/ZC35

CN---1522149 IPCI A61K0033-00 [ICM,7]; A61K0031-05 [ICS,7]; A61K0031-045 [ICS,7,C*]; A61K0031-155 [ICS,7]; A61K0031-14 [ICS,7]; A61K0033-30 [ICS,7]; A61K0033-34 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0007-16 [ICS,7]

IPCR A61K0008-30 [I,C*]; A61K0008-41 [I,A]; A61K0008-43 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A]; A61K0031-14 [I,A]; A61K0031-14 [I,C*]; A61K0031-155 [I,A]; A61K0031-155 [I,C*]; A61K0033-24 [I,A]; A61K0033-24 [I,C*]; A61K0033-30 [I,A]; A61K0033-30 [I,C*]; A61K0033-34 [I,A]; A61K0033-34 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]

ECLA A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43; A61K008/49; A61K008/49C4; A61K031/05; A61K031/14; A61K031/155; A61K033/24; A61K033/30; A61K033/34; A61K045/06

US2005163727 IPCI A61K0009-68 [ICM,7]; A61K0007-16 [ICS,7]; A61K0007-20 [ICS,7]; A61K0031-44 [ICS,7]; A01N0033-12 [ICS,7]; A01N0033-00 [ICS,7,C*]

IPCR A61K0008-30 [I,C*]; A61K0008-41 [I,A]; A61K0008-43 [I,A]; A61K0031-045 [I,C*]; A61K0031-05 [I,A]; A61K0031-14 [I,A]; A61K0031-14 [I,C*]; A61K0031-155 [I,A]; A61K0031-155 [I,C*]; A61K0033-24 [I,A]; A61K0033-24 [I,C*]; A61K0033-30 [I,A]; A61K0033-30 [I,C*]; A61K0033-34 [I,A]; A61K0033-34 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]

NCL 424/048.000

ECLA A61Q011/00; A61K008/34F; A61K008/41L; A61K008/43; A61K008/49; A61K008/49C4; A61K031/05; A61K031/14; A61K031/155; A61K033/24; A61K033/30; A61K033/34; A61K045/06

AB The present invention relates to promoting whole body health in humans and animals by using topical oral compns. comprising a safe and effective amount of an antimicrobial agent in admixt. with a pharmaceutically acceptable carrier, said compns. being effective in controlling bacterial-mediated diseases and conditions present in the oral cavity and in inhibiting the spread into the bloodstream of pathogenic oral bacteria, associated bacterial toxins and endotoxins, and resultant inflammatory cytokines and mediators. The present invention also encompasses methods of use of these compns. by topically applying to the oral cavity, a safe and effective amount of an antimicrobial agent to promote and/or enhance whole body health in humans and other animals. A dual phase stannous fluoride dentifrice was prepared

ST antimicrobial oral compn; dentifrice compn

IT **Antihistamines**
(**H2**; topical oral compns. containing antimicrobial agents for promoting whole body health)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; topical oral compns. containing antimicrobial agents for promoting whole body health)

IT Cytokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; topical oral compns. containing antimicrobial agents for

promoting whole body health)
IT Lipopolysaccharides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(complexing agents; topical oral compns. containing antimicrobial agents for promoting whole body health)
IT Anti-inflammatory agents
(nonsteroidal; topical oral compns. containing antimicrobial agents for promoting whole body health)
IT Drug delivery systems
(oral; topical oral compns. containing antimicrobial agents for promoting whole body health)
IT Essential oils
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint; topical oral compns. containing antimicrobial agents for promoting whole body health)
IT Analgesics
Anti-inflammatory agents
Antimicrobial agents
Dentifrices
Immunostimulants
(topical oral compns. containing antimicrobial agents for promoting whole body health)
IT Amino acids, biological studies
Antibodies and Immunoglobulins
Antigens
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical oral compns. containing antimicrobial agents for promoting whole body health)
IT Bacteriocins
Chlorophylls, biological studies
Essential oils
Fats and Glyceridic oils, biological studies
Hormones, animal, biological studies
Minerals, biological studies
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical oral compns. containing antimicrobial agents for promoting whole body health)
IT Drug delivery systems
(topical; topical oral compns. containing antimicrobial agents for promoting whole body health)
IT 81669-70-7, Metalloproteinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; topical oral compns. containing antimicrobial agents for promoting whole body health)
IT 50-23-7, Hydrocortisone 50-78-2, Aspirin 50-81-7, Vitamin c, biological studies 53-86-1, Indomethacin 55-56-1, Chlorhexidine 56-95-1, Chlorhexidine diacetate 59-02-9, α-Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 60-54-8, Tetracycline 87-17-2, Salicylanilide 94-09-7, Benzocaine 97-53-0, Eugenol 108-95-2D, Phenol, derivs. 123-03-5, Cetylpyridinium chloride 124-43-6 128-37-0, Bht, biological studies 137-58-6, Lidocaine 141-94-6, Hexetidine 149-91-7, Gallic acid, biological studies 303-98-0, Coenzyme q10 443-48-1, Metronidazole 538-71-6, Domiphen bromide 564-25-0, Doxycycline 616-91-1, N-Acetylcysteine 644-62-2, Meclofenamic acid 1404-04-2, Neomycin 1406-11-7, Polymyxin 1414-45-5, Nisin 2447-54-3, Sanguinarine 2785-54-8, Tetradecylpyridinium chloride 3380-34-5, Triclosan 5104-49-4, Flurbiprofen 7439-97-6D, Mercury, derivs. 7553-56-2, Iodine, biological studies 7681-49-4, Sodium fluoride, biological studies 7757-79-1, Potassium nitrate, biological studies 8063-07-8, Kanamycin 10118-90-8, Minocycline 10476-85-4, Strontium chloride 11103-57-4, Vitamin a 14769-73-4, Levamisole 15158-11-9D, derivs., biological studies 15687-27-1, Ibuprofen 18323-44-9, Clindamycin 22071-15-4,

Ketoprofen 22204-53-1, Naproxen 22573-93-9, Alexidine 23713-49-7D, Zinc ion, derivs., biological studies 26787-78-0, Amoxicillin 35014-84-7, N-Tetradecyl-4-ethylpyridinium chloride 36322-90-4, Piroxicam 51481-61-9, Cimetidine 66357-35-5, Ranitidine 67651-57-4, Triclosan monophosphate 71138-71-1, Octapinol 71251-02-0, Octenidine 72909-34-3, Pqq 74103-06-3, Ketorolac 74469-00-4, Augmentin 76824-35-6, Famotidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine 79874-76-3, Delmopinol 83184-43-4, Mifentidine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical oral compns. containing antimicrobial agents for promoting whole body health)

L34 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:31237 HCAPLUS
DN 136:107507
ED Entered STN: 11 Jan 2002
TI Topical oral compositions for periodontal disease and promoting whole body health
IN **Doyle, Matthew Joseph**; **Hunter-Rinderle, Stephen Joseph**; **Singer, Robert Ernest, Jr.**
PA **Procter & Gamble** Company, USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0031/00
ICS A61K-0031/4164; A61K-0031/426; A61K-0031/662; A61K-0031/407; A61K-0045/06; A61P-0001/02; A61K-0007/16
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): 62
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002002096	A2	20020110	2001WO-US20515	20010628 <--
WO2002002096	A3	20020912		
WO2002002096	C1	20031106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA---2415065	AA	20020110	2001CA-2415065	20010628 <--
EP---1294367	A2	20030326	2001EP-0950569	20010628 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP2004501966	T2	20040122	2002JP-0506718	20010628 <--
CN---1536989	A	20041013	2001CN-0811860	20010628 <--
PRAI 2000US-0607602	A	20000630 <--		
2001WO-US20515	W	20010628		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002002096	ICM	A61K-0031/00
	ICS	A61K-0031/4164; A61K-0031/426; A61K-0031/662; A61K-0031/407; A61K-0045/06; A61P-0001/02; A61K-0007/16
	IPCI	A61K0031-00 [ICM,7]; A61K0031-4164 [ICS,7]; A61K0031-426 [ICS,7]; A61K0031-662 [ICS,7]; A61K0031-407 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0007-16 [ICS,7]
	IPCR	A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-407

		[I,A]; A61K0031-407 [I,C*]; A61K0031-4164 [I,A]; A61K0031-4164 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]; A61K0031-662 [I,A]; A61K0031-662 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
	ECLA	A61K007/16; A61K007/22; A61K031/00; A61K031/407; A61K031/4164; A61K031/426; A61K031/662; A61K045/06
CA---2415065	IPCI	A61K0031-00 [ICM,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61K0007-16 [ICS,7]; A61K0031-407 [ICS,7]; A61K0031-4164 [ICS,7]; A61K0031-426 [ICS,7]; A61K0031-662 [ICS,7]
	IPCR	A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-407 [I,A]; A61K0031-407 [I,C*]; A61K0031-4164 [I,A]; A61K0031-4164 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]; A61K0031-662 [I,A]; A61K0031-662 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
	ECLA	A61K007/16; A61K007/22; A61K031/00; A61K031/407; A61K031/4164; A61K031/426; A61K031/662; A61K045/06
EP---1294367	IPCI	A61K0031-00 [ICM,7]; A61K0031-4164 [ICS,7]; A61K0031-426 [ICS,7]; A61K0031-662 [ICS,7]; A61K0031-407 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0007-16 [ICS,7]
	IPCR	A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-407 [I,A]; A61K0031-407 [I,C*]; A61K0031-4164 [I,A]; A61K0031-4164 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]; A61K0031-662 [I,A]; A61K0031-662 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
JP2004501966	IPCI	A61K0045-00 [ICM,7]; A61K0009-06 [ICS,7]; A61K0009-08 [ICS,7]; A61K0009-12 [ICS,7]; A61K0009-20 [ICS,7]; A61K0009-68 [ICS,7]; A61K0031-341 [ICS,7]; A61K0031-407 [ICS,7]; A61K0031-4164 [ICS,7]; A61K0031-426 [ICS,7]; A61K0045-06 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0003-02 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0043-00 [ICS,7]
	IPCR	A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-407 [I,A]; A61K0031-407 [I,C*]; A61K0031-4164 [I,A]; A61K0031-4164 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]; A61K0031-662 [I,A]; A61K0031-662 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
	FTERM	4C076/AA09; 4C076/AA12; 4C076/AA24; 4C076/AA29; 4C076/AA36; 4C076/AA69; 4C076/BB22; 4C076/BB23; 4C076/CC01; 4C076/CC04; 4C076/CC09; 4C076/CC22; 4C076/CC26; 4C076/CC29; 4C076/CC32; 4C076/CC34; 4C076/FF01; 4C076/FF11; 4C076/FF52; 4C076/FF68; 4C084/AA02; 4C084/AA03; 4C084/AA17; 4C084/BA44; 4C084/CA59; 4C084/MA02; 4C084/MA17; 4C084/MA27; 4C084/MA28; 4C084/MA35; 4C084/MA43; 4C084/MA47; 4C084/MA57; 4C084/NA09; 4C084/NA10; 4C084/NA14; 4C084/ZA022; 4C084/ZA082; 4C084/ZA672; 4C084/ZB112; 4C084/ZB212; 4C084/ZB352; 4C086/AA01; 4C086/AA02; 4C086/BC38; 4C086/BC82; 4C086/CB03; 4C086/MA01; 4C086/MA02; 4C086/MA17; 4C086/MA27; 4C086/MA28; 4C086/MA35; 4C086/MA43; 4C086/MA47; 4C086/MA57; 4C086/NA09; 4C086/NA10; 4C086/NA14; 4C086/ZA02; 4C086/ZA08; 4C086/ZA67; 4C086/ZB11; 4C086/ZB21; 4C086/ZB35
CN---1536989	IPCI	A61K0031-00 [ICM,7]; A61K0031-4164 [ICS,7]; A61K0031-426 [ICS,7]; A61K0031-662 [ICS,7]; A61K0031-407 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61K0007-16 [ICS,7]
	IPCR	A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0031-407 [I,A]; A61K0031-407 [I,C*]; A61K0031-4164 [I,A]; A61K0031-4164 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]; A61K0031-662 [I,A]; A61K0031-662 [I,C*];

A61K0045-00 [I,C*]; A61K0045-06 [I,A]
ECLA A61K007/16; A61K007/22; A61K031/00; A61K031/407; A61K031/4164; A61K031/426; A61K031/662; A61K045/06

AB The present invention relates to promoting whole body health in humans and animals by using topical oral compns. comprising a safe and effective amount of a host-response modulating agent in admixt. with a pharmaceutically acceptable carrier, said compns. being effective in mediating host reaction to the presence of periodontal pathogens in the oral cavity as well as the toxins and endotoxins released by these pathogens and the inflammatory cytokines and mediators prompted by these oral pathogens. Dentifrices were prepared as well as an oral composition containing ketorolac tromethamine 0.10, ethanol 12.00, glycerin 10.00, disodium phosphate heptahydrate 0.07, saccharin sodium 0.08, monosodium phosphate monohydrate 2.03, Polysorbate 80 0.33, FD&C Blue (1% solution) 0.02, and flavor 0.15 and water q.s.

ST oral topical compn periodontal disease

IT **Antihistamines**
(**H2**; topical oral compns. for periodontal disease and promoting whole body health)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NF-κB (nuclear factor of κ light chain gene enhancer in B-cells), activation of, inhibitors; topical oral compns. for periodontal disease and promoting whole body health)

IT Biofilms (microbial)
(inhibitors; topical oral compns. for periodontal disease and promoting whole body health)

IT Anesthetics
(local; topical oral compns. for periodontal disease and promoting whole body health)

IT Anti-inflammatory agents
(nonsteroidal; topical oral compns. for periodontal disease and promoting whole body health)

IT Drug delivery systems
(oral; topical oral compns. for periodontal disease and promoting whole body health)

IT **Tooth, disease**
(**plaque, inhibitors**; topical oral compns. for periodontal **disease** and promoting whole body health)

IT Anti-inflammatory agents
Antimicrobial agents
Chewing gum
Dental materials and appliances
Dentifrices
Periodontium, disease
Pet animal
(topical oral compns. for periodontal disease and promoting whole body health)

IT 81669-70-7, Metalloproteinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; topical oral compns. for periodontal disease and promoting whole body health)

IT 50-78-2, Aspirin 50-81-7, Vitamin c, biological studies 53-86-1, Indomethacine 303-98-0, Coenzyme q10 500-38-9, Nordihydroguaiaretic acid 532-11-6, Anethole dithiolthione 644-62-2, Meclofenamic acid 989-51-5, Epigallocatechin gallate 1406-18-4, Vitamin e 3380-34-5, Triclosan 5104-49-4, Flurbiprofen 11103-57-4, Vitamin a 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 36322-90-4, Piroxicam 51481-61-9, Cimetidine 55273-05-7, Impromidine 66357-35-5, Ranitidine 69014-14-8, Tiotidine 69014-64-8, ICIA-5165 69539-53-3, Etintidine 72909-34-3, PQQ 73278-54-3, Lamtidine 74103-06-3, Ketorolac 74103-07-4, Ketorolac tromethamine 75438-42-5, ORF-17578 76824-35-6, Famotidine 76956-02-0, Loxtidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine 78441-82-4, BMY-25271 78441-84-6, BL-6341A 78628-28-1, Pifatidine 80343-63-1, Sufotidine 83184-43-4, Mifentidine 83903-06-4, Lupitidine 84071-15-8, Ramixotidine 84545-30-2, ICI-162846

85195-15-9, L-643728 85604-00-8, Zaltidine 86134-80-7, BMY-25368
87107-94-6, BL-6548 89077-71-4, BMY-25405 89250-13-5, DA-4634
90287-93-7, SR 58042 93064-63-2, D-16637 94662-53-0, Wy-45727
96153-56-9, Bisfentidine 99248-32-5, Donetidine 100981-43-9,
Ebrotidine 104428-51-5, HB-408 105805-28-5, HE-30256 108498-50-6,
FRG-8701 118288-08-7, FRG-8813
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical oral compns. for periodontal disease and promoting whole body health)

L34 ANSWER 13 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:31206 HCAPLUS
DN 136:90959
ED Entered STN: 11 Jan 2002
TI Promoting whole body health using chlorite-containing compositions
IN **Doyle, Matthew Joseph; Hunter-Rinderle, Stephen Joseph** ; **Singer, Robert Ernest, Jr.**; Wimalasena, Rohan Lalith
PA **Procter & Gamble** Company, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/16
ICS A61K-0007/20
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): **1**, 62
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002002063	A2	20020110	2001WO-US20517	20010628
	WO2002002063	A3	20020725		
	WO2002002063	C1	20031106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US---6846478	B1	20050125	2000US-0607729	20000630
	CA---2414576	AA	20020110	2001CA-2414576	20010628
	EP---1294345	A2	20030326	2001EP-0948785	20010628
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP2004501944	T2	20040122	2002JP-0506686	20010628
PRAI	2000US-0607729	A	20000630		
	1998US-0032234	A3	19980227		
	1998US-0032237	A3	19980227		
	1998US-0032238	A3	19980227		
	2000US-0481624	A2	20000112		
	2001WO-US20517	W	20010628		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002002063	ICM	A61K-0007/16
	ICS	A61K-0007/20
	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]
	ECLA	A61K007/16P; A61K007/20
US---6846478	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0033-20 [I,A]; A61K0033-20 [I,C*]
	NCL	424/049.000
	ECLA	A61K033/20; A61K008/20; A61Q011/00
CA---2414576	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]

EP---1294345 IPCI A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]
JP2004501944 IPCI A61K0007-16 [ICM,7]
FTERM 4C083/AB011; 4C083/AB012; 4C083/AB102; 4C083/AB172; 4C083/AB211; 4C083/AB242; 4C083/AB282; 4C083/AB312; 4C083/AC102; 4C083/AC112; 4C083/AC122; 4C083/AC132; 4C083/AC241; 4C083/AC482; 4C083/AC531; 4C083/AC581; 4C083/AC641; 4C083/AC691; 4C083/AC782; 4C083/AC811; 4C083/AC841; 4C083/AC851; 4C083/AC862; 4C083/AD042; 4C083/AD112; 4C083/AD272; 4C083/AD352; 4C083/AD411; 4C083/AD471; 4C083/AD531; 4C083/AD641; 4C083/AD661; 4C083/CC41; 4C083/DD08; 4C083/DD15; 4C083/DD17; 4C083/DD22; 4C083/DD23; 4C083/EE33

AB The present invention relates to promoting whole body health in humans and animals by using topical oral compns. comprising a safe and effective amount of chlorite ion in admixt. with a pharmaceutically acceptable carrier, said compns. being effective in controlling bacterial-mediated diseases and conditions present in the oral cavity and inhibiting the spread into the bloodstream of oral pathogenic bacteria and associated bacterial toxins and resultant inflammatory cytokines and mediators. The present invention also encompasses methods of use of these compns. by topically applying to the oral cavity, a safe and effective amount of chlorite ion to promote and/or enhance whole body health in humans and other animals. For example, an oral spray was prepared containing sodium chlorite (80%) 1.25%, sodium bicarbonate 0.192%, sodium carbonate 0.289%, and water up to 100%. The formulation has a pH of approx. 10. In an animal clin. study conducted among Beagle dogs, 30 mL of the spray solution according was applied evenly throughout the dog's mouth twice daily (n = 10). After 9 mo, significant redns. in attachment loss were observed in the treated animals compared to those receiving placebo (n = 30), i.e., a spray solution containing the same ingredients but without sodium chlorite.

ST chlorite topical oral pharmaceutical dentifrice mouthrinse health; antibacterial antiinflammatory chlorite topical oral

IT **Antihistamines**
(H2; chlorite-containing topical oral compns. for promoting whole body health)

IT Mouth
(administration to; chlorite-containing topical oral compns. for promoting whole body health)

IT Quaternary ammonium compounds, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; chlorite-containing topical oral compns. for promoting whole body health)

IT Cytokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; chlorite-containing topical oral compns. for promoting whole body health)

IT Redox reaction
(biochem., cellular, modifiers; chlorite-containing topical oral compns. for promoting whole body health)

IT **Dentifrices**
(**chewing gums**; chlorite-containing topical oral compns. for promoting whole body health)

IT Analgesics
Anti-inflammatory agents
Antibacterial agents
Antimicrobial agents
Dentifrices
Immunostimulants
Mouthwashes
(chlorite-containing topical oral compns. for promoting whole body health)

IT Chlorites
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorite-containing topical oral compns. for promoting whole body health)

IT Amino acids, biological studies

Antibodies and Immunoglobulins
Antigens
Bacteriocins
Chlorophylls, biological studies
Essential oils
Growth factors, animal
Hormones, animal, biological studies
Hydroxamic acids
Mineral elements, biological studies
Phenols, biological studies
Sulfonamides
Vitamins
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(chlorite-containing topical oral compns. for promoting whole body health)

IT Health
Human
Pet animal
(chlorite-containing topical oral compns. for promoting whole body health in humans and pets)

IT Hypochlorites
RL: MSC (Miscellaneous)
(chlorite-containing topical oral compns. free of chlorine dioxide, chlorous acid, and hypochlorite)

IT Lipopolysaccharides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(complexing agents; chlorite-containing topical oral compns. for promoting whole body health)

IT Chewing gum
(dentifrices; chlorite-containing topical oral compns. for promoting whole body health)

IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(essential; chlorite-containing topical oral compns. for promoting whole body health)

IT **Dentifrices**
Drug delivery systems
(**gels**; chlorite-containing topical oral compns. for promoting whole body health)

IT Drug delivery systems
(lozenges; chlorite-containing topical oral compns. for promoting whole body health)

IT Essential oils
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(peppermint; chlorite-containing topical oral compns. for promoting whole body health)

IT **Dentifrices**
(**powders**; chlorite-containing topical oral compns. for promoting whole body health)

IT Drug delivery systems
(sprays, mouth; chlorite-containing topical oral compns. for promoting whole body health)

IT Drug delivery systems
(topical, oral; chlorite-containing topical oral compns. for promoting whole body health)

IT 56-03-1D, Biguanide, derivs.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(bisguanidines; chlorite-containing topical oral compns. for promoting whole body health)

IT 7758-19-2, Sodium chlorite 14998-27-7, Chlorite
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorite-containing topical oral compns. for promoting whole body health)

IT 50-23-7, Hydrocortisone 50-78-2, Aspirin 50-81-7, Vitamin C, biological studies 53-86-1, Indomethacin 55-56-1, Chlorhexidine 59-02-9, α-Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 60-54-8, Tetracycline 87-17-2, Salicylanilide 94-09-7, Benzocaine 97-53-0, Eugenol 123-03-5, Cetylpyridinium chloride 124-43-6 128-37-0, Butylated hydroxytoluene, biological studies 137-58-6, Lidocaine 141-94-6, Hexetidine 149-91-7, Gallic acid, biological studies 303-98-0, Coenzyme Q10 443-48-1, Metronidazole 538-71-6, Domiphen bromide 564-25-0, Doxycycline 616-91-1, N-Acetylcysteine 644-62-2, Meclofenamic acid 1404-04-2, Neomycin 1406-11-7, Polymyxin 1414-45-5, Nisin 2447-54-3, Sanguinarine 2785-54-8, Tetradecylpyridinium chloride 3380-34-5, Triclosan 5104-49-4, Flurbiprofen 6303-21-5D, Phosphinic acid, amides 7440-31-5D, Tin, compds. 7440-66-6D, Zinc, compds. 7553-56-2, Iodine, biological studies 7681-49-4, Sodium fluoride, biological studies 7757-79-1, Potassium nitrate, biological studies 8063-07-8, Kanamycin 9001-63-2, Lysozyme 9025-70-1, Dextranase 9075-84-7, Mutanase 10118-90-8, Minocycline 10476-85-4, Strontium chloride 11103-57-4, Vitamin A 14769-73-4, Levamisole 15687-27-1, Ibuprofen 18323-44-9, Clindamycin 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22573-93-9, Alexidine 26787-78-0, Amoxicillin 35014-84-7, N-Tetradecyl-4-ethylpyridinium chloride 36322-90-4, Piroxicam 51481-61-9, Cimetidine 66357-35-5, Ranitidine 71138-71-1, Octapinol 71251-02-0, Octenidine 72909-34-3, Pyrroloquinoline quinone 74103-06-3, Ketorolac 74469-00-4, Augmentin antibiotic 76824-35-6, Famotidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine 79874-76-3, Delmopinol 83184-43-4, Mifentidine 85554-61-6D, Furanone, derivs.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorite-containing topical oral compns. for promoting whole body health)

IT 10049-04-4, Chlorine dioxide 13898-47-0, Chlorous acid 14380-61-1, Hypochlorite
RL: MSC (Miscellaneous)
(chlorite-containing topical oral compns. free of chlorine dioxide, chlorous acid, and hypochlorite)

IT 81669-70-7, Metalloproteinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; chlorite-containing topical oral compns. for promoting whole body health)

IT 7439-97-6D, Mercury, compds.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mercurials; chlorite-containing topical oral compns. for promoting whole body health)

L34 ANSWER 14 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:31204 HCAPLUS
DN 136:90958
ED Entered STN: 11 Jan 2002
TI Oral care compositions comprising chlorite, and methods
IN Witt, Jonathan James; Wimalasena, Rohan Lalith; Wong, Andrew Lee; Goulbourne, Eric Altman, Jr.; **Doyle, Matthew Joseph**
PA **Procter & Gamble** Company, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/00
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): 1, 62
FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2002002061	A2	20020110	2001WO-US20614	20010628
WO2002002061	A3	20020627		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
            HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
            LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
            RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
            YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    US---6350438          B1    20020226    2000US-0607242          20000630
    CA---2414573          AA    20020110    2001CA-2414573          20010628
    EP---1294347          A2    20030326    2001EP-0946731          20010628
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    JP2004501942          T2    20040122    2002JP-0506684          20010628
PRAI 2000US-0607242       A     20000630
    1998US-0032234        A2    19980227
    1998US-0032237        A2    19980227
    1998US-0032238        A2    19980227
    2001WO-US20614        W     20010628
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 2002002061    ICM    A61K-0007/00
                  IPCI   A61K0007-00 [ICM,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  ECLA   A23K001/18N; A61K008/20; A61Q011/00
 US---6350438     IPCI   A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61K0033-20 [I,A];
                         A61K0033-20 [I,C*]
                  NCL    424/053.000; 424/049.000
                  ECLA   A61K033/20; A23K001/18N; A61K008/20; A61Q011/00
 CA---2414573     IPCI   A61K0007-20 [ICM,7]; A61K0007-16 [ICS,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
 EP---1294347     IPCI   A61K0007-20 [ICM,7]; A61K0007-16 [ICS,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
 JP2004501942     IPCI   A61K0007-20 [ICM,7]; A61C0017-00 [ICS,7]; A61K0007-22
                         [ICS,7]; A61K0007-24 [ICS,7]; A61L0002-18 [ICS,7]
                  IPCR   A23K0001-18 [I,A]; A23K0001-18 [I,C*]; A61K0008-19
                         [I,C*]; A61K0008-20 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  FTERM  4C058/AA13; 4C058/AA28; 4C058/BB07; 4C058/JJ07;
                         4C083/AB032; 4C083/AB101; 4C083/AB102; 4C083/AB172;
                         4C083/AB211; 4C083/AB242; 4C083/AB312; 4C083/AB331;
                         4C083/AB332; 4C083/AB472; 4C083/AC102; 4C083/AC122;
                         4C083/AC132; 4C083/AC242; 4C083/AC442; 4C083/AC471;
                         4C083/AC482; 4C083/AC641; 4C083/AC691; 4C083/AC741;
                         4C083/AC782; 4C083/AC791; 4C083/AC811; 4C083/AC842;
                         4C083/AC851; 4C083/AC862; 4C083/AD092; 4C083/AD211;
                         4C083/AD272; 4C083/AD352; 4C083/AD412; 4C083/AD591;
                         4C083/AD611; 4C083/BB41; 4C083/BB43; 4C083/BB48;
                         4C083/BB55; 4C083/CC41; 4C083/DD05; 4C083/DD08;
                         4C083/DD15; 4C083/DD22; 4C083/DD23; 4C083/DD27;
                         4C083/DD41; 4C083/EE03; 4C083/EE31; 4C083/EE33;
                         4C083/EE36; 4C083/FF05
```

AB The present invention relates to topical oral compns., including therapeutic rinses, especially mouth rinses, as well as toothpastes, gels, tooth powders, chewing gums, mouth sprays, lozenges (including breath mints), dental implements (such as dental floss and tape), and pet care products comprising at least a minimally effective amount of chlorite ion

(0.02-6.0%), wherein the pH of the final composition is greater than 7 and the composition is essentially free of chlorine dioxide or chlorous acid. This invention further relates to a method for treating or preventing diseases and conditions of the oral cavity such as gingivitis, plaque, periodontal disease, herpetic lesions, and infections that may develop following dental procedures such as osseous surgery, tooth extraction, periodontal flap surgery, dental implantation, and scaling and root planing, in humans and other animals, by applying a safe and effective amount of the chlorite ion composition to the oral cavity. For example, a sub-gingival gel was prepared containing sodium chlorite (80%) 2.0%, poly(lactide-co-glycolide) 30.0%, and propylene carbonate 68.0%. The resulting gel-like fluid can be inserted into or around the periodontal pocket or gingival region via syringe.

ST chlorite topical oral pharmaceutical dentifrice mouthrinse; antibacterial antiinflammatory chlorite topical oral

IT **Antihistamines**
(**H2**; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Quaternary ammonium compounds, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Bone resorption
(alveolar; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Cytokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Syringes
(application by; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Redox reaction
(biochem., cellular, modifiers; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT **Dentifrices**
(**chewing gums**; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Hypochlorites
RL: MSC (Miscellaneous)
(chlorite-containing oral care compns. free of chlorine dioxide, chlorous acid, or hypochlorites)

IT Lipopolysaccharides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(complexing agents; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT **Dentifrices**
(**dental floss**, and tapes; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Chewing gum
(dentifrices; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(essential; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT **Dentifrices**
Drug delivery systems
(**gels**; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Gingiva, disease
Inflammation
(gingivitis; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Mouth, disease
(infection; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Herpesviridae
(lesions from; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Tooth
(loose; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Drug delivery systems
(lozenges; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Mouth
(mucosa; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Human herpesvirus
(oral lesions; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Infection
(oral; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Essential oils
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Tooth, disease
(plaque; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT **Dentifrices**
(**powders**; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Drug delivery systems
(sprays, oral; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT **Dentifrices**
Mouthwashes
(topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Analgesics
Anti-inflammatory agents
Antimicrobial agents
Gingiva
Immunostimulants
Periodontium, disease
Tongue
(topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Chlorites
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)
IT Amino acids, biological studies
Antibodies and Immunoglobulins
Antigens
Bacteriocins
Chlorophylls, biological studies
Essential oils
Growth factors, animal
Hormones, animal, biological studies
Hydroxamic acids
Mineral elements, biological studies
Phenols, biological studies
Sulfonamides
Vitamins

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT Human
Pet animal
(topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases in humans and pets)

IT Drug delivery systems
(topical, oral; topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT 56-03-1D, Biguanide, derivs.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(bisbiquanides; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT 10049-04-4, Chlorine dioxide 13898-47-0, Chlorous acid 14380-61-1, Hypochlorite
RL: MSC (Miscellaneous)
(chlorite-containing oral care compns. free of chlorine dioxide, chlorous acid, or hypochlorites)

IT 81669-70-7, Metalloproteinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT 7439-97-6D, Mercury, compds.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(mercurials; topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT 7758-19-2, Sodium chlorite 14998-27-7, Chlorite
RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. comprising chlorite for prevention or treatment of oral cavity diseases)

IT 50-23-7, Hydrocortisone 50-78-2, Aspirin 50-81-7, Vitamin C, biological studies 53-86-1, Indomethacin 55-56-1, Chlorhexidine 59-02-9, α-Tocopherol 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-67-6, Niacin, biological studies 60-54-8, Tetracycline 87-17-2, Salicylanilide 94-09-7, Benzocaine 97-53-0, Eugenol 123-03-5, Cetylpyridinium chloride 124-43-6 128-37-0, Butylated hydroxytoluene, biological studies 137-58-6, Lidocaine 141-94-6, Hexetidine 149-91-7, Gallic acid, biological studies 303-98-0, Coenzyme Q10 443-48-1, Metronidazole 538-71-6, Domiphen bromide 564-25-0, Doxycycline 616-91-1, N-Acetylcysteine 644-62-2, Meclofenamic acid 1404-04-2, Neomycin 1406-11-7, Polymyxin 2447-54-3, Sanguinarine 2785-54-8, Tetradecylpyridinium chloride 3380-34-5, Triclosan 5104-49-4, Flurbiprofen 6303-21-5D, Phosphinic acid, amides 7440-31-5D, Tin, compds. 7440-66-6D, Zinc, compds. 7553-56-2, Iodine, biological studies 7681-49-4, Sodium fluoride, biological studies 7757-79-1, Potassium nitrate, biological studies 8063-07-8, Kanamycin 9001-63-2, Lysozyme 9025-70-1, Dextranase 9075-84-7, Mutanase 10118-90-8, Minocycline 10476-85-4, Strontium chloride 11103-57-4, Vitamin A 14769-73-4, Levamisole 15687-27-1, Ibuprofen 18323-44-9, Clindamycin 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22573-93-9, Alexidine 26787-78-0, Amoxicillin 35014-84-7, N-Tetradecyl-4-ethylpyridinium chloride 36322-90-4, Piroxicam 51481-61-9, Cimetidine 66357-35-5, Ranitidine 71138-71-1, Octapinol 71251-02-0, Octenidine 72909-34-3, PQQ 74103-06-3, Ketorolac 74469-00-4, Augmentin 76824-35-6, Famotidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine 79874-76-3, Delmopinol 83184-43-4, Mifentidine 85554-61-6D, Furanone, derivs.
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(topical oral care compns. comprising chlorite for prevention or treatment of oral cavity diseases)

L34 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:31304 HCAPLUS
DN 134:90937
ED Entered STN: 12 Jan 2001
TI Oral delivery system compositions comprising organosiloxanes using a removable backing strip
IN Ye, Hai; Buckley, Christopher David; Yue, Jiang
PA The **Procter** & **Gamble** Company, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0009/00
ICS A61K-0007/16
CC 62-7 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2001001958	A1	20010111	2000WO-US18188	20000630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA---2373868	AA	20010111	2000CA-2373868	20000609
WO2001001939	A1	20010111	2000WO-US15890	20000609
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO2001001940	A1	20010111	2000WO-US15891	20000609
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP---1196136	A1	20020417	2000EP-0941306	20000609
EP---1196136	B1	20050413		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR2000012122	A	20020507	2000BR-0012122	20000609
JP2003525210	T2	20030826	2001JP-0507436	20000609
NZ----516272	A	20031128	2000NZ-0516272	20000609
AU----769263	B2	20040122	2000AU-0056027	20000609
RU---2222315	C2	20040127	2002RU-0102712	20000609
AT----292953	E	20050415	2000AT-0941306	20000609
ES---2240109	T3	20051016	2000ES-0941306	20000609
CA---2375093	AA	20010111	2000CA-2375093	20000630
AU2000059074	A5	20010122	2000AU-0059074	20000630
AU----768471	B2	20031211		
BR2000012145	A	20020430	2000BR-0012145	20000630
EP---1200064	A1	20020502	2000EP-0945084	20000630
EP---1200064	B1	20030502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO, MK, CY, AL				
	AT----238766	E	20030515	2000AT-0945084	20000630
	JP2003531814	T2	20031028	2001JP-0507453	20000630
	RU---2223746	C2	20040220	2002RU-0102710	20000630
	ZA2001010448	A	20020724	2001ZA-0010448	20011220
	US---6589512	B1	20030708	2001US-0019029	20011220
	NO2002000004	A	20020228	2002NO-0000004	20020102
	NO2002000005	A	20020228	2002NO-0000005	20020102
	US---6649147	B1	20031118	2002US-0019032	20020320
	HK---1046633	A1	20051202	2002HK-0107134	20020926
	HK---1047035	A1	20040305	2002HK-0107161	20020927
PRAI	1999WO-US15130	A	19990702		
	1999WO-US15131	A	19990702		
	2000WO-US15890	A	20000609		
	2000WO-US15891	A	20000609		
	2000WO-US18188	W	20000630		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001001958	ICM	A61K-0009/00
	ICS	A61K-0007/16
	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
CA---2373868	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
WO2001001939	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
WO2001001940	IPCI	A61K0007-16 [ICM]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K007/16D14; A61Q011/00

EP---1196136	IPCI	A61K0007-16 [ICM,6]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
BR2000012122	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2003525210	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-20 [ICS,7]; A61K0033-16 [ICS,7]; A61K0033-40 [ICS,7]; A61K0045-00 [ICS,7]; A61K0047-00 [ICS,7]; A61K0047-06 [ICS,7]; A61K0047-08 [ICS,7]; A61K0047-10 [ICS,7]; A61K0047-14 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-32 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0003-02 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-10 [ICS,7]; A61P0031-22 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0039-06 [ICS,7]; A61P0039-00 [ICS,7,C*]; A61P0043-00 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
NZ----516272	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K [I,S]
AU----769263	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
RU---2222315	IPCI	A61K0006-08 [ICM,7]; A61K0006-02 [ICM,7,C*]; A61K0007-16 [ICS,7]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00
AT----292953	IPCI	A61K0007-16 [ICM,7]
ES---2240109	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00
CA---2375093	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];

		A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AU2000059074	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
BR2000012145	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
EP---1200064	IPCI	A61K0009-00 [ICM,6]; A61K0007-16 [ICS,6]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AT----238766	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
JP2003531814	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0009-70

		[ICS,7]; A61K0031-4164 [ICS,7]; A61K0033-40 [ICS,7]; A61K0047-02 [ICS,7]; A61K0047-04 [ICS,7]; A61K0047-06 [ICS,7]; A61K0047-08 [ICS,7]; A61K0047-32 [ICS,7]; A61K0047-34 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0025-04 [ICS,7]; A61P0025-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-12 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0043-00 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
RU---2223746	IPCI	A61K0007-16 [ICM,7]; A61K0009-20 [ICS,7]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
ZA2001010448	IPCI	A61K [ICM,7]
US---6589512	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,C*]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000; 424/052.000; 424/053.000; 424/054.000; 424/058.000
	ECLA	A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/41L; A61K008/891; A61Q011/00
NO2002000004	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
NO2002000005	IPCI	A61K [ICM,7]
US---6649147	IPCI	A61K0007-16 [ICM,7]; A61K0009-70 [ICS,7]; A61C0013-23 [ICS,7]; A61C0013-225 [ICS,7,C*]
	IPCR	A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000; 424/401.000; 424/414.000; 424/443.000; 424/447.000; 433/217.100; 433/228.100
	ECLA	A61C019/06B; A61K008/02; A61K008/25; A61K008/26; A61K008/41L; A61K008/891; A61K009/00M18D; A61Q011/00
HK---1046633	IPCI	A61K [ICM,7]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00
HK---1047035	IPCI	A61K [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19;

A61K008/20; A61K008/22; A61K008/25; A61K008/26;
A61K008/31; A61K008/35; A61K008/37; A61K008/70;
A61K008/891; A61K009/00M18D

AB A delivery system for delivering an oral care substance to the oral cavity comprises a removable backing strip having sufficient flexibility so as to be readily conformable to an oral surface when the delivery system is placed there against and an oral care composition applied to the strip of material such that when the delivery system is placed on the oral surface the oral care composition contacts the oral surface. The oral care composition contains an organosiloxane resin, a rheol. modifier and at least 1 oral care substance wherein the oral care composition remains on the oral surface after the backing strip is removed. Further disclosed are such delivery systems in which the oral care composition further comprises fluid diorganopolysiloxane-based polymers; such compns. may further comprise carriers for solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymers. Thus, a composition contained MQ resin-1170-002 25, dimethicone gum 12.5, sodium percarbonate 17, oral care substance 44.5, and Bentone clay 1%.

ST organosiloxane oral delivery backing strip; polysiloxane percarbonate oral delivery backing strip

IT **Antihistamines**
(**H2**; oral delivery system comprising organosiloxane using removable backing strip)

IT Silicone rubber, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-Me, Me vinyl, SE 63; oral delivery system comprising organosiloxane using removable backing strip)

IT Silicone rubber, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-Me, SE 30; oral delivery system comprising organosiloxane using removable backing strip)

IT Analgesics
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antiviral agents
Dentifrices
Flavoring materials
Gums and Mucilages
Nutrients
Opacifiers
Paper
Pigments, nonbiological
Surfactants
Sweetening agents
Tooth
(oral delivery system comprising organosiloxane using removable backing strip)

IT Chelates
Chlorites
Clays, biological studies
Hydrocarbon oils
Peroxides, biological studies
Peroxy acids
Peroxysulfates
Polysiloxanes, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral delivery system comprising organosiloxane using removable backing strip)

IT Drug delivery systems
(oral; oral delivery system comprising organosiloxane using removable backing strip)

IT Group IIIA element compounds

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(perborates; oral delivery system comprising organosiloxane using removable backing strip)

IT 1343-98-2D, Silicic acid, organosilylated
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MQ derivs.; oral delivery system comprising organosiloxane using removable backing strip)

IT 87-99-0, Xylitol 563-69-9D, Carbonoperoxoic acid, derivs. 3313-92-6, Sodium percarbonate 7631-86-9, Silica, biological studies 7681-49-4, Sodium Fluoride, biological studies 9002-88-4, Polyethylene 9006-65-9, Dimethicone 9016-00-6, Poly[oxy(dimethylsilylene)] 16984-48-8, Fluoride, biological studies 31900-57-9, Polydimethyl siloxane 42557-10-8, Dow Corning 200/350 318238-22-1, MQ 1170-002
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral delivery system comprising organosiloxane using removable backing strip)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Kedrowski, B; US---5866630 A 1999 HCAPLUS
(2) Procter & Gamble; WO---9855079 A 1998 HCAPLUS
(3) Sanvordeker, D; US---4900552 A 1990
(4) Viccaro, J; US---5427770 A 1995 HCAPLUS

L34 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:31293 HCAPLUS
DN 134:90928
ED Entered STN: 12 Jan 2001
TI Systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery
IN Yue, Jiang; Mitra, Sekhar
PA The Procter & Gamble Company, USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/16
CC 62-6 (Essential Oils and Cosmetics)

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2001001942	A1	20010111	2000WO-US18189	20000630
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA---2373868	AA	20010111	2000CA-2373868	20000609
	WO2001001939	A1	20010111	2000WO-US15890	20000609
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO2001001940	A1	20010111	2000WO-US15891	20000609
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

```
            MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
            SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    EP---1196136          A1    20020417    2000EP-0941306          20000609
    EP---1196136          B1    20050413
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    BR2000012122          A     20020507    2000BR-0012122          20000609
    JP2003525210          T2    20030826    2001JP-0507436          20000609
    NZ----516272          A     20031128    2000NZ-0516272          20000609
    AU----769263          B2    20040122    2000AU-0056027          20000609
    RU---2222315          C2    20040127    2002RU-0102712          20000609
    AT----292953          E     20050415    2000AT-0941306          20000609
    ES---2240109          T3    20051016    2000ES-0941306          20000609
    CA---2373983          AA    20010111    2000CA-2373983          20000630
    AU2000059075          A5    20010122    2000AU-0059075          20000630
    EP---1196137          A1    20020417    2000EP-0945085          20000630
    EP---1196137          B1    20041222
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    AT----285220          E     20050115    2000AT-0945085          20000630
    ZA2001010448          A     20020724    2001ZA-0010448          20011220
    US---6589512          B1    20030708    2001US-0019029          20011220
    NO2002000005          A     20020228    2002NO-0000005          20020102
    US---6692727          B1    20040217    2002US-0019031          20020320
    HK---1046633          A1    20051202    2002HK-0107134          20020926
PRAI 1999WO-US15130       A     19990702
    1999WO-US15131        A     19990702
    2000WO-US15890        A     20000609
    2000WO-US15891        A     20000609
    2000WO-US18189        W     20000630
```

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001001942	ICM	A61K-0007/16
	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
CA---2373868	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
WO2001001939	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];

		A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
WO2001001940	IPCI	A61K0007-16 [ICM]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K007/16D14; A61Q011/00
EP---1196136	IPCI	A61K0007-16 [ICM,6]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
BR2000012122	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2003525210	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-20 [ICS,7]; A61K0033-16 [ICS,7]; A61K0033-40 [ICS,7]; A61K0045-00 [ICS,7]; A61K0047-00 [ICS,7]; A61K0047-06 [ICS,7]; A61K0047-08 [ICS,7]; A61K0047-10 [ICS,7]; A61K0047-14 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-32 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0003-02 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-10 [ICS,7]; A61P0031-22 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0039-06 [ICS,7]; A61P0039-00 [ICS,7,C*]; A61P0043-00 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
NZ----516272	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K [I,S]
AU----769263	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
RU---2222315	IPCI	A61K0006-08 [ICM,7]; A61K0006-02 [ICM,7,C*]; A61K0007-16 [ICS,7]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00
AT----292953	IPCI	A61K0007-16 [ICM,7]

ES---2240109	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00
CA---2373983	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AU2000059075	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
EP---1196137	IPCI	A61K0007-16 [ICM,6]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
AT----285220	IPCI	A61K0007-16 [ICM,7]
ZA2001010448	IPCI	A61K [ICM,7]
US---6589512	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,C*]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000; 424/052.000; 424/053.000; 424/054.000; 424/058.000
	ECLA	A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/41L; A61K008/891; A61Q011/00
NO2002000005	IPCI	A61K [ICM,7]
US---6692727	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]; A61K0006-08 [ICS,7]; A61K0006-02 [ICS,7,C*]
	IPCR	A61K0006-02 [I,C*]; A61K0006-093 [I,A]; A61K0008-19 [I,C*]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/053.000; 424/049.000; 433/215.000; 433/216.000
	ECLA	A61K006/093; A61K008/26; A61K008/31; A61K008/34; A61K008/891; A61Q011/00
HK---1046633	IPCI	A61K [ICM,7]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22;

A61K008/26; A61K008/31; A61K008/35; A61K008/37;
A61K008/70; A61K008/891; A61Q011/00

AB Disclosed is a system for delivering an oral care substance to the oral cavity comprising: (a) a delivery composition comprised of: (i) an organosiloxane resin; (ii) a volatile carrier capable of solubilizing the organosiloxane resin; (iii) a rheol. modifier; and (iv) at least one oral care substance; and (b) a protective composition comprised of: (i) an organosiloxane resin; and (ii) a volatile carrier capable of solubilizing the organosiloxane resin. Further disclosed is a system for delivering an oral care substance to the oral cavity comprising: (a) a delivery composition comprised of: (i) an organosiloxane resin; (ii) a fluid diorganopolysiloxane-based polymer; (iii) a volatile carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer; (iv) a rheol. modifier; and (v) at least one oral care substance; and (b) a protective composition comprised of: (i) an organosiloxane resin; and (ii) a volatile carrier capable of solubilizing the organosiloxane resin. The protective composition may further comprise a fluid diorganopolysiloxane-based polymer and/or a rheol. modifier. Still further disclosed is a method of using these systems. A hydrophobic oral care composition contained organosiloxane resin (MQ resin) 25, silicone gum (dimethicone gum) 12.5, oral care substance (sodium percarbonate) 17, volatile carrier (isododecane) 44.5, and bentone clay (Bentone 27) 1%.

ST siloxane resin delivery oral care dentifrice

IT **Antihistamines**
(**H2**; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

IT Tooth
(color; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

IT Tooth
(enamel; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

IT Chlorites
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(metal salts; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

IT Group IIIA element compounds
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(perborates; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

IT Polyamide fibers, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(powders; systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

IT Analgesics
Antimicrobial agents
Antioxidants
Antiviral agents
Chelating agents
Dentifrices
Dyes
Flavoring materials
Opacifiers
Pigments, nonbiological
Surfactants
Sweetening agents
(systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

IT Clays, biological studies
Hydrocarbon oils
Peroxides, biological studies
Peroxy acids
Peroxysulfates

Polysiloxanes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

IT 87-99-0, Xylitol 109-60-4, Propyl acetate 141-78-6, Ethyl acetate, biological studies 563-69-9, Carbonoperoxoic acid 7631-86-9, Silica, biological studies 9002-88-4, Polyethylene 9006-65-9, Dimethicone 9016-00-6, Dimethylpolysiloxane 9016-00-6D, Polydimethylsiloxane, polyalkylene oxide-modified 12691-60-0, (Bentone 27) 16984-48-8, Fluoride ion, biological studies 31807-55-3, (Isododecane) 31900-57-9, Polydimethylsiloxane 31900-57-9D, Polydimethylsiloxane, polyalkylene oxide-modified 56091-38-4, Bentone gel ipm 163702-07-6, Methyl nonafluorobutyl ether 163702-08-7 219484-64-7, Hfe 7100
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(systems comprising organosiloxane resins for delivering oral care substances and for prolonging such delivery)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Hill, I; US---5651959 A 1997 HCAPLUS
(2) Kedrowski, B; US---5866630 A 1999 HCAPLUS
(3) Viccaro, J; US---5427770 A 1995 HCAPLUS

L34 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:31292 HCAPLUS
DN 134:90935
ED Entered STN: 12 Jan 2001
TI Compositions comprising organosiloxane resins for delivering xylitol to the oral cavity
IN Yue, Jiang; Mitra, Sekhar
PA The **Procter** & **Gamble** Company, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/16
CC 62-7 (Essential Oils and Cosmetics)
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2001001941	A1	20010111	2000WO-US18187	20000630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA---2373868	AA	20010111	2000CA-2373868	20000609
WO2001001939	A1	20010111	2000WO-US15890	20000609
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO2001001940	A1	20010111	2000WO-US15891	20000609
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				

```
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    EP---1196136          A1    20020417    2000EP-0941306          20000609
    EP---1196136          B1    20050413
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    BR2000012122          A     20020507    2000BR-0012122          20000609
    JP2003525210          T2    20030826    2001JP-0507436          20000609
    NZ----516272          A     20031128    2000NZ-0516272          20000609
    AU----769263          B2    20040122    2000AU-0056027          20000609
    RU---2222315          C2    20040127    2002RU-0102712          20000609
    AT----292953          E     20050415    2000AT-0941306          20000609
    ES---2240109          T3    20051016    2000ES-0941306          20000609
    AU2000059073          A5    20010122    2000AU-0059073          20000630
    ZA2001010448          A     20020724    2001ZA-0010448          20011220
    US---6589512          B1    20030708    2001US-0019029          20011220
    NO2002000005          A     20020228    2002NO-0000005          20020102
    HK---1046633          A1    20051202    2002HK-0107134          20020926
PRAI 1999WO-US15130       A     19990702
    1999WO-US15131        A     19990702
    2000WO-US15890        A     20000609
    2000WO-US15891        A     20000609
    2000WO-US18187        W     20000630
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 2001001941    ICM    A61K-0007/16
                  IPCI   A61K0007-16 [ICM,7]
                  IPCR   A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02
                         [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A];
                         A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22
                         [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];
                         A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35
                         [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];
                         A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00
                         [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  ECLA   A61K006/02; A61K008/02; A61K008/19; A61K008/20;
                         A61K008/22; A61K008/25; A61K008/26; A61K008/31;
                         A61K008/35; A61K008/37; A61K008/70; A61K008/891;
                         A61K009/00M18D; A61K009/00M20B; A61Q011/00
CA---2373868      IPCI   A61K0007-16 [ICM,7]
                  IPCR   A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19
                         [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A];
                         A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30
                         [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A];
                         A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72
                         [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
WO2001001939      IPCI   A61K0007-16 [ICM,7]
                  IPCR   A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02
                         [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A];
                         A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22
                         [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];
                         A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35
                         [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A];
                         A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00
                         [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A];
                         A61Q0011-00 [I,C*]
                  ECLA   A61K006/02; A61K008/02; A61K008/19; A61K008/20;
                         A61K008/22; A61K008/25; A61K008/26; A61K008/31;
                         A61K008/35; A61K008/37; A61K008/70; A61K008/891;
                         A61K009/00M18D; A61K009/00M20B; A61Q011/00
WO2001001940      IPCI   A61K0007-16 [ICM]
                  IPCR   A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19
```

		[I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K007/16D14; A61Q011/00
EP---1196136	IPCI	A61K0007-16 [ICM,6]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
BR2000012122	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2003525210	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0007-20 [ICS,7]; A61K0033-16 [ICS,7]; A61K0033-40 [ICS,7]; A61K0045-00 [ICS,7]; A61K0047-00 [ICS,7]; A61K0047-06 [ICS,7]; A61K0047-08 [ICS,7]; A61K0047-10 [ICS,7]; A61K0047-14 [ICS,7]; A61K0047-24 [ICS,7]; A61K0047-32 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0003-02 [ICS,7]; A61P0003-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-10 [ICS,7]; A61P0031-22 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0039-06 [ICS,7]; A61P0039-00 [ICS,7,C*]; A61P0043-00 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
NZ----516272	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K [I,S]
AU----769263	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
RU---2222315	IPCI	A61K0006-08 [ICM,7]; A61K0006-02 [ICM,7,C*]; A61K0007-16 [ICS,7]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00
AT----292953	IPCI	A61K0007-16 [ICM,7]
ES---2240109	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22;

		A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00
AU2000059073	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
ZA2001010448	IPCI	A61K [ICM,7]
US---6589512	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0008-19 [I,C*]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-41 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000; 424/052.000; 424/053.000; 424/054.000; 424/058.000
	ECLA	A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/41L; A61K008/891; A61Q011/00
NO2002000005	IPCI	A61K [ICM,7]
HK---1046633	IPCI	A61K [ICM,7]
	ECLA	A61K006/02; A61K008/19; A61K008/20; A61K008/22; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61Q011/00

AB Disclosed is a composition for delivering xylitol to the oral cavity, comprising: (a) an organosiloxane resin; (b) a volatile carrier capable of solubilizing the organosiloxane resin; (c) a rheol. modifier; and (d) an effective amount of xylitol. The present invention is also directed to such compns. comprising: (a) an organosiloxane resin; (b) a fluid diorganopolysiloxane-based polymer; (c) a volatile carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer; (d) a rheol. modifier; and (e) an effective amount of xylitol. The compns. herein may further comprise an addnl. oral care substance. Further disclosed is a method of using these compns. A hydrophobic oral care composition contained organosiloxane resin (MQ resin) 25.5, silicone gum (dimethicone gum) 12.5, xylitol 4.5, volatile carrier (isododecane) 56.5, and bentone clay (Bentone 27) 1%.

ST organosiloxane resin xylitol delivery oral cavity

IT **Antihistamines**
(**H2**; compns. comprising organosiloxane resins for delivering xylitol to oral cavity)

IT Analgesics
Anti-inflammatory agents
Antimicrobial agents
Antioxidants
Antiviral agents
Chelating agents
Dentifrices
Dyes
Flavoring materials
Mouth
Nutrients
Opacifiers
Pigments, nonbiological
Solvents
Surfactants
Sweetening agents
(compns. comprising organosiloxane resins for delivering xylitol to

oral cavity)
IT Clays, biological studies
Hydrocarbon oils
Polysiloxanes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(compns. comprising organosiloxane resins for delivering xylitol to oral cavity)
IT 87-99-0, Xylitol 7631-86-9, Silica, biological studies 9002-88-4, Polyethylene 9006-65-9, Dimethicone 9016-00-6, Poly[oxy(dimethylsilylene)] 16984-48-8, Fluoride ion, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(compns. comprising organosiloxane resins for delivering xylitol to oral cavity)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Hill, I; US---4950479 A 1990 HCAPLUS
(2) Hill, I; US---5009881 A 1991 HCAPLUS
(3) Hill, I; US---5032387 A 1991 HCAPLUS

L34 ANSWER 18 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:31291 HCAPLUS
DN 134:90934
ED Entered STN: 12 Jan 2001
TI Compositions comprising organosiloxane resins for delivering oral care substances
IN Yue, Jiang; Crisanti, Mark Matthew; Majeti, Satyanarayana; Burgess, Steven Carl; Reno, Elizabeth Ann; Li, Li; Mitra, Sekhar
PA The **Procter** & **Gamble** Company, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0007/16
CC 62-7 (Essential Oils and Cosmetics)
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2001001939	A1	20010111	2000WO-US15890	20000609
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA---2373867	AA	20010111	2000CA-2373867	20000609
AU2000056026	A5	20010122	2000AU-0056026	20000609
AU----769802	B2	20040205		
BR2000012522	A	20020326	2000BR-0012522	20000609
EP---1196135	A1	20020417	2000EP-0941305	20000609
EP---1196135	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR-200103821	T2	20020422	2001TR-0003821	20000609
AT----252365	E	20031115	2000AT-0941305	20000609
RU---2225706	C2	20040320	2002RU-0102711	20000609
JP2004513065	T2	20040430	2001JP-0507435	20000609
ES---2204630	T3	20040501	2000ES-0941305	20000609
CA---2373983	AA	20010111	2000CA-2373983	20000630
CA---2375093	AA	20010111	2000CA-2375093	20000630
WO2001001941	A1	20010111	2000WO-US18187	20000630
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				

```
        IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
        MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
        SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
    RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
        DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
        CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO2001001958          A1    20010111    2000WO-US18188          20000630
    W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
        CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
        IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
        MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
        SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
    RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
        DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
        CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
WO2001001942          A1    20010111    2000WO-US18189          20000630
    W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
        CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
        IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
        MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
        SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
    RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
        DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
        CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU2000059073          A5    20010122    2000AU-0059073          20000630
AU2000059074          A5    20010122    2000AU-0059074          20000630
AU----768471          B2    20031211
AU2000059075          A5    20010122    2000AU-0059075          20000630
EP---1196137          A1    20020417    2000EP-0945085          20000630
EP---1196137          B1    20041222
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO
BR2000012145          A     20020430    2000BR-0012145          20000630
    EP---1200064      A1    20020502    2000EP-0945084          20000630
    EP---1200064      B1    20030502
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
    AT----238766      E     20030515    2000AT-0945084          20000630
    JP2003531814      T2    20031028    2001JP-0507453          20000630
    ES---2199168      T3    20040216    2000ES-0945084          20000630
    AT----285220      E     20050115    2000AT-0945085          20000630
    ZA2001010449      A     20020711    2001ZA-0010449          20011220
    ZA2001010447      A     20020930    2001ZA-0010447          20011220
    US---6569408      B1    20030527    2001US-0019038          20011220
    NO2002000004      A     20020228    2002NO-0000004          20020102
    NO2002000006      A     20020228    2002NO-0000006          20020102
    US---6649147      B1    20031118    2002US-0019032          20020320
    US---6692727      B1    20040217    2002US-0019031          20020320
    HK---1047033      A1    20041015    2002HK-0107124          20020926
    HK---1047035      A1    20040305    2002HK-0107161          20020927
PRAI 1999WO-US15130   A     19990702
    1999WO-US15131    A     19990702
    2000WO-US15890    W     20000609
    2000WO-US15891    A     20000609
    2000WO-US18187    W     20000630
    2000WO-US18188    W     20000630
    2000WO-US18189    W     20000630
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 2001001939    ICM    A61K-0007/16
                  IPCI   A61K0007-16 [ICM,7]
                  IPCR   A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02
                         [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A];
                         A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22
                         [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A];
```

		A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
CA---2373867	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AU2000056026	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
BR2000012522	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
EP---1196135	IPCI	A61K0007-16 [ICM,6]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
TR-200103821	IPCI	A61K0007-16 [ICM,7]

	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AT----252365	IPCI	A61K0007-16 [ICM,7]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
RU---2225706	IPCI	A61K0007-16 [ICM,7]; A61K0006-00 [ICS,7]; A61K0009-70 [ICS,7]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
JP2004513065	IPCI	A61K0007-16 [ICM,7]; A61K0007-00 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	FTERM	4C083/AB172; 4C083/AB211; 4C083/AB222; 4C083/AB231; 4C083/AB232; 4C083/AB241; 4C083/AB242; 4C083/AB272; 4C083/AB282; 4C083/AB321; 4C083/AB331; 4C083/AB332; 4C083/AB371; 4C083/AB411; 4C083/AB412; 4C083/AB431; 4C083/AB432; 4C083/AB441; 4C083/AB442; 4C083/AB472; 4C083/AC011; 4C083/AC012; 4C083/AC032; 4C083/AC101; 4C083/AC102; 4C083/AC171; 4C083/AC172; 4C083/AC211; 4C083/AC212; 4C083/AC341; 4C083/AC342; 4C083/AC461; 4C083/AC742; 4C083/AC862; 4C083/AD021; 4C083/AD071; 4C083/AD072; 4C083/AD091; 4C083/AD092; 4C083/AD151; 4C083/AD152; 4C083/AD162; 4C083/AD241; 4C083/AD261; 4C083/AD451; 4C083/BB60; 4C083/CC41; 4C083/DD22; 4C083/EE32; 4C083/EE33; 4C083/EE34; 4C083/EE35; 4C083/EE36; 4C083/EE37
ES---2204630	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
CA---2373983	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22

		[I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
CA---2375093	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
WO2001001941	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
WO2001001958	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00
WO2001001942	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D; A61K009/00M20B; A61Q011/00

AU2000059073	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AU2000059074	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AU2000059075	IPCI	A61K0007-16 [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
EP---1196137	IPCI	A61K0007-16 [ICM,6]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]
BR2000012145	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
EP---1200064	IPCI	A61K0009-00 [ICM,6]; A61K0007-16 [ICS,6]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00

		[I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AT----238766	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
JP2003531814	IPCI	A61K0007-16 [ICM,7]; A61K0007-18 [ICS,7]; A61K0009-70 [ICS,7]; A61K0031-4164 [ICS,7]; A61K0033-40 [ICS,7]; A61K0047-02 [ICS,7]; A61K0047-04 [ICS,7]; A61K0047-06 [ICS,7]; A61K0047-08 [ICS,7]; A61K0047-32 [ICS,7]; A61K0047-34 [ICS,7]; A61P0001-02 [ICS,7]; A61P0001-00 [ICS,7,C*]; A61P0025-04 [ICS,7]; A61P0025-00 [ICS,7,C*]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-12 [ICS,7]; A61P0031-00 [ICS,7,C*]; A61P0043-00 [ICS,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
ES---2199168	IPCI	A61K0009-00 [ICM,4]; A61K0007-16 [ICS,4]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
AT----285220	IPCI	A61K0007-16 [ICM,7]
ZA2001010449	IPCI	A61K [ICM,7]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
ZA2001010447	IPCI	A61K [ICM,7]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
US---6569408	IPCI	A61K0007-16 [ICM,7]; A61K0006-08 [ICS,7]; A61K0006-02 [ICS,7,C*]; A61C0005-00 [ICS,7]; C09K0003-00 [ICS,7]
	IPCR	A61K0006-02 [I,C*]; A61K0006-093 [I,A]; A61K0008-72

		[I,C*]; A61K0008-89 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000; 433/217.100; 433/228.100; 523/116.000; 523/118.000
	ECLA	A61K006/093; A61K008/89; A61Q011/00
NO2002000004	IPCI	A61K0009-00 [ICM,7]; A61K0007-16 [ICS,7]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
NO2002000006	IPCI	A61K [ICM,7]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
US---6649147	IPCI	A61K0007-16 [ICM,7]; A61K0009-70 [ICS,7]; A61C0013-23 [ICS,7]; A61C0013-225 [ICS,7,C*]
	IPCR	A61C0019-00 [I,C*]; A61C0019-06 [I,A]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,C*]; A61K0008-22 [I,A]; A61K0008-26 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/049.000; 424/401.000; 424/414.000; 424/443.000; 424/447.000; 433/217.100; 433/228.100
	ECLA	A61C019/06B; A61K008/02; A61K008/25; A61K008/26; A61K008/41L; A61K008/891; A61K009/00M18D; A61Q011/00
US---6692727	IPCI	A61K0007-16 [ICM,7]; A61K0007-20 [ICS,7]; A61K0006-08 [ICS,7]; A61K0006-02 [ICS,7,C*]
	IPCR	A61K0006-02 [I,C*]; A61K0006-093 [I,A]; A61K0008-19 [I,C*]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-34 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	NCL	424/053.000; 424/049.000; 433/215.000; 433/216.000
	ECLA	A61K006/093; A61K008/26; A61K008/31; A61K008/34; A61K008/891; A61Q011/00
HK---1047033	IPCI	A61K [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D
HK---1047035	IPCI	A61K [ICM,7]
	IPCR	A61K0006-02 [I,A]; A61K0006-02 [I,C*]; A61K0008-02 [I,A]; A61K0008-02 [I,C*]; A61K0008-19 [I,A]; A61K0008-19 [I,C*]; A61K0008-20 [I,A]; A61K0008-22 [I,A]; A61K0008-25 [I,A]; A61K0008-26 [I,A]; A61K0008-30 [I,C*]; A61K0008-31 [I,A]; A61K0008-35 [I,A]; A61K0008-37 [I,A]; A61K0008-70 [I,A]; A61K0008-72 [I,C*]; A61K0008-891 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
	ECLA	A61Q011/00; A61K006/02; A61K008/02; A61K008/19; A61K008/20; A61K008/22; A61K008/25; A61K008/26; A61K008/31; A61K008/35; A61K008/37; A61K008/70; A61K008/891; A61K009/00M18D

AB Disclosed is a composition for delivering an oral care substance to the oral

cavity, comprising: (a) an organosiloxane resin; (b) a volatile carrier capable of solubilizing the organosiloxane resin; (c) a rheol. modifier; and (d) at least one oral care substance. The present invention is also directed to such compns. comprising: (a) an organosiloxane resin; (b) a fluid diorganopolysiloxane polymer; (c) a volatile carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane polymer; (d) a rheol. modifier; and (e) at least one oral care substance. Further disclosed is a method of using these compns. A hydrophobic oral care composition contained organosiloxane resin (MQ resin) 25, silicone gum (dimethicone gum) 12.5, oral care substance 17, volatile carrier (isododecane) 44.5, and bentone clay (Bentone 27) 1%.

ST oral care organosiloxane resin dentifrice

IT **Antihistamines**
(**H2**; compns. comprising organosiloxane resins for delivering oral care substances)

IT Tooth
(color; compns. comprising organosiloxane resins for delivering oral care substances)

IT Analgesics
Antimicrobial agents
Antioxidants
Antiviral agents
Chelating agents
Dentifrices
Flavoring materials
Pigments, nonbiological
Surfactants
Sweetening agents
(compns. comprising organosiloxane resins for delivering oral care substances)

IT Acrylic polymers, biological studies
Clays, biological studies
Hydrocarbon oils
Mica-group minerals, biological studies
Peroxides, biological studies
Peroxy acids
Peroxysulfates
Siloxanes (nonpolymeric)
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(compns. comprising organosiloxane resins for delivering oral care substances)

IT Tooth
(enamel; compns. comprising organosiloxane resins for delivering oral care substances)

IT Chlorites
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(metal salts; compns. comprising organosiloxane resins for delivering oral care substances)

IT Group IIIA element compounds
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(perborates; compns. comprising organosiloxane resins for delivering oral care substances)

IT Silk
(powders; compns. comprising organosiloxane resins for delivering oral care substances)

IT Polyamide fibers, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(powders; compns. comprising organosiloxane resins for delivering oral care substances)

IT Mica-group minerals, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(titanium; compns. comprising organosiloxane resins for delivering oral care substances)

IT 64-17-5, Hydrocarbon oils, biological studies 78-93-3, Hydrocarbon oils, biological studies 87-99-0, Xylitol 109-60-4, Propyl acetate 141-78-6, Ethyl acetate, biological studies 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 563-69-9, Carbonoperoxoic acid 1309-37-1, Red iron oxide, biological studies 1314-13-2, Zinc oxide, biological studies 1327-43-1, Aluminum magnesium silicate 1332-37-2, Iron oxide, biological studies 1343-88-0, Magnesium silicate 7631-86-9, Silica, biological studies 7787-59-9, Bismuth oxychloride 9002-88-4, Polyethylene 9004-34-6, Crystalline cellulose, biological studies 9005-25-8, Starch, biological studies 9006-65-9, Dimethicone 9016-00-6, Dimethylpolysiloxane 9016-00-6D, Polydimethylsiloxane, polyalkylene oxide-modified 12227-89-3, Black iron oxide 12691-60-0, (Bentone 27) 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 16984-48-8, Fluoride ion, biological studies 31807-55-3, (Isododecane) 31900-57-9, Polydimethylsiloxane 31900-57-9D, Polydimethylsiloxane, polyalkylene oxide-modified 51274-00-1, Yellow iron oxide 56091-38-4, Bentone gel ipm 57455-37-5, Ultramarine 163702-07-6, Methyl nonafluorobutyl ether 163702-08-7, Methyl nonafluoroisobutyl ether 219484-64-7, Hfe 7100
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(compns. comprising organosiloxane resins for delivering oral care substances)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Hill, I; US---5651959 A 1997 HCAPLUS
(2) Kedrowski, B; US---5866630 A 1999 HCAPLUS
(3) Viccaro, J; US---5427770 A 1995 HCAPLUS

L34 ANSWER 19 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:144704 HCAPLUS
DN 132:185445
ED Entered STN: 03 Mar 2000
TI Oral liquid mucoadhesive compositions
IN Dobrozsi, Douglas Joseph
PA The **Procter** & **Gamble** Company, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0009/10
ICS A61K-0047/02
CC 63-6 (**Pharmaceuticals**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2000010529	A1	20000302	1999WO-US19202	19990824
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US---6319513	B1	20011120	1999US-0361533	19990727
	CA---2338704	AA	20000302	1999CA-2338704	19990824
	CA---2338704	C	20041102		
	AU---9955809	A1	20000314	1999AU-0055809	19990824
	AU----761968	B2	20030612		
	BR---9913178	A	20010515	1999BR-0013178	19990824
	EP---1107733	A1	20010620	1999EP-0942429	19990824
	EP---1107733	B1	20050727		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

```
             IE, SI, LT, LV, FI, RO
     TR-200100628          T2    20011022    TR 2001-200100628       19990824
     JP2002523354          T2    20020730    2000JP-0565851          19990824
     AT----300282          E     20050815    1999AT-0942429          19990824
     NO2001000832          A     20010219    2001NO-0000832          20010219
PRAI 1998US-097578P        P     19980824
     1999WO-US19202        W     19990824
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 2000010529    ICM    A61K-0009/10
                  ICS    A61K-0047/02
                  IPCI   A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02
                         [I,A]; A61K0047-02 [I,C*]
                  ECLA   A61K009/00M14; A61K009/00M18D; A61K009/00N2; A61K047/02
 US---6319513     IPCI   A61F0013-02 [ICM,7]
                  IPCR   A61K0047-02 [I,A]; A61K0047-02 [I,C*]
                  NCL    424/434.000; 424/435.000
                  ECLA   A61K047/02
 CA---2338704     IPCI   A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02
                         [I,A]; A61K0047-02 [I,C*]
 AU---9955809     IPCI   A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02
                         [I,A]; A61K0047-02 [I,C*]
 BR---9913178     IPCI   A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02
                         [I,A]; A61K0047-02 [I,C*]
 EP---1107733     IPCI   A61K0009-10 [ICM,6]; A61K0047-02 [ICS,6]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02
                         [I,A]; A61K0047-02 [I,C*]
                  ECLA   A61K009/00M14; A61K009/00M18D; A61K009/00N2; A61K047/02
 TR-200100628     IPCI   A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
 JP2002523354     IPCI   A61K0045-08 [ICM,7]; A61K0045-00 [ICM,7,C*];
                         A61K0047-02 [ICS,7]; A61P0001-00 [ICS,7]; A61P0001-02
                         [ICS,7]; A61P0001-04 [ICS,7]; A61P0009-00 [ICS,7];
                         A61P0011-00 [ICS,7]; A61P0011-08 [ICS,7]; A61P0011-10
                         [ICS,7]; A61P0011-14 [ICS,7]; A61P0023-00 [ICS,7];
                         A61P0025-04 [ICS,7]; A61P0025-00 [ICS,7,C*];
                         A61P0043-00 [ICS,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02
                         [I,A]; A61K0047-02 [I,C*]
 AT----300282     IPCI   A61K0009-10 [ICM,7]; A61K0047-02 [ICS,7]
                  ECLA   A61K009/00M14; A61K009/00M18D; A61K009/00N2; A61K047/02
 NO2001000832     IPCI   A61K0009-10 [ICM,7]
                  IPCR   A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-02
                         [I,A]; A61K0047-02 [I,C*]
```

AB The present invention relates to a oral, or intranasal pharmaceutical mucoretentive, aqueous liquid composition comprising 2-50%, by weight of the composition, of colloidal particles of silica, titanium dioxide, clay, and mixts. and a safe and effective amount of a drug selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antihistamines, sensory agents, gastrointestinal agents, and mixts. The composition has a sedimentation volume ratio of >0.90 and the triggered viscosity ratio of the composition is at least about 1.2. The present invention further relates to a method of coating the alimentary canal or nasal mucosa, in particular to a method of preventing or treating symptoms of upper respiratory tract infections or upper respiratory tract tissue irritation or damage, by administering a safe and effective amount of the above composition Thus, a formulation contained dried Al(OH)3 gel powder antacid 7, Cab-O-Sil M5 8.3, and water to 100%.

ST oral liq mucoadhesive titanium dioxide; silica oral liq mucoadhesive

IT **Antihistamines**
(**H2**; oral liquid mucoadhesive compns.)

IT Drugs
(gastrointestinal; oral liquid mucoadhesive compns.)
IT Drug delivery systems
(liqs., oral; oral liquid mucoadhesive compns.)
IT Plant (Embryophyta)
(medicinal, exts.; oral liquid mucoadhesive compns.)
IT Drug delivery systems
(nasal sprays; oral liquid mucoadhesive compns.)
IT Analgesics
Antacids
Antidiarrheals
Antihistamines
Antitussives
Bronchodilators
Cholinergic antagonists
Decongestants
Expectorants
Laxatives
Mouthwashes
Particle size distribution
Viscosity
(oral liquid mucoadhesive compns.)
IT Esophagus
(sphincter; oral liquid mucoadhesive compns.)
IT Drug delivery systems
(syrups; oral liquid mucoadhesive compns.)
IT Anesthetics
(topical; oral liquid mucoadhesive compns.)
IT 125-69-9, Dextromethorphan hydrobromide 2315-02-8, Oxymetazoline hydrochloride 7631-86-9, Silica, biological studies 13463-67-7, Titanium oxide, biological studies 14882-18-9, Bismuth subsalicylate 21645-51-2, Aluminum hydroxide (Al(OH)3), biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral liquid mucoadhesive compns.)
IT 9000-83-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proton-translocating, inhibitors; oral liquid mucoadhesive compns.)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Cedona Pharmaceuticals; EP---0517274 A 1992 HCAPLUS
(2) Laboratoires Human-Pharm SA; EP---0062578 A 1982 HCAPLUS
(3) The Procter & Gamble Company; US---5458879 A 1995 HCAPLUS
(4) The Procter & Gamble Company; WO---9523591 A 1995 HCAPLUS

L34 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:124044 HCAPLUS
DN 128:196683
ED Entered STN: 28 Feb 1998
TI Inhibiting undesirable taste in oral compositions
IN Nelson, Sandra Lynn
PA **Procter** & **Gamble** Company, USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0047/00
ICS A61K-0007/00
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): 17, 62
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9806436	A2	19980219	1997WO-US13472	19970728
	WO---9806436	A3	20001221		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,

```
            LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
            PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,
            VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
            GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
            GN, ML, MR, NE, SN, TD, TG
    US---5766622          A     19980616    1996US-0696711          19960814
    AU---9739676          A1    19980306    1997AU-0039676          19970728
    AU----724235          B2    20000914
    BR---9711159          A     19990817    1997BR-0011159          19970728
    EP---1077726          A2    20010228    1997EP-0937072          19970728
    EP---1077726          B1    20030312
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
    CN---1306440          A     20010801    1997CN-0197342          19970728
    JP2001527518          T2    20011225    1998JP-0509785          19970728
    AT----234115          E     20030315    1997AT-0937072          19970728
    CA---2263297          C     20031028    1997CA-2263297          19970728
    CA---2263297          AA    19980219
    ZA---9707082          A     19980304    1997ZA-0007082          19970808
    NO---9900685          A     19990412    1999NO-0000685          19990212
    KR2000030006          A     20000525    1999KR-0701291          19990218
PRAI 1996US-0696711       A     19960814
    1997WO-US13472        W     19970728
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 9806436       ICM    A61K-0047/00
                  ICS    A61K-0007/00
                  IPCI   A61K0047-00 [ICM,6]; A61K0007-00 [ICS,6]
                  IPCR   A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30
                         [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A];
                         A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16
                         [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A];
                         A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00
                         [I,C*]
                  ECLA   A23L001/227; A61Q011/00; A61K008/44; A61K008/55;
                         A61K009/00M18B; A61K009/00N2; A61K047/24
US---5766622      IPCI   A61K0031-74 [ICM,6]
                  IPCR   A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30
                         [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A];
                         A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16
                         [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A];
                         A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00
                         [I,C*]
                  NCL    424/440.000; 441/048.000; 441/049.000; 441/054.000;
                         514/974.000
                  ECLA   A23L001/227; A61K008/44; A61K008/55; A61K009/00M18B;
                         A61K009/00N2; A61K047/24; A61Q011/00
AU---9739676      IPCI   A61K0047-00 [ICM,6]; A61K0007-00 [ICS,6]
                  IPCR   A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30
                         [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A];
                         A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16
                         [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A];
                         A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00
                         [I,C*]
BR---9711159      IPCI   A61K0047-00 [ICM,6]; A61K0007-00 [ICS,6]
                  IPCR   A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30
                         [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A];
                         A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16
                         [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A];
                         A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00
                         [I,C*]
EP---1077726      IPCI   A61K0047-24 [ICM,6]; A61K0009-00 [ICS,6]; A61K0007-16
                         [ICS,6]
                  IPCR   A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30
                         [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A];
```

		A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
CN---1306440	IPCI	A61K0047-24 [ICM,7]; A61K0009-00 [ICS,7]; A61K0007-16 [ICS,7]
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
JP2001527518	IPCI	A61K0047-24 [ICM,7]; A61K0007-16 [ICS,7]
AT----234115	IPCI	A61K0047-24 [ICM,7]; A61K0009-00 [ICS,7]; A61K0007-16 [ICS,7]
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
CA---2263297	IPCI	A61K0047-24 [ICM,6]; A61K0007-16 [ICS,6]
ZA---9707082	IPCI	A23L [ICM,6]; A61K [ICS,6]
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
NO---9900685	IPCI	A61K0047-00 [ICM,6]; A61K0007-00 [ICS,6]
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]
KR2000030006	IPCI	A61K0047-24
	IPCR	A23L0001-226 [I,C*]; A23L0001-227 [I,A]; A61K0008-30 [I,C*]; A61K0008-44 [I,A]; A61K0008-55 [I,A]; A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0047-16 [N,C*]; A61K0047-18 [N,A]; A61K0047-24 [I,A]; A61K0047-24 [I,C*]; A61Q0011-00 [I,A]; A61Q0011-00 [I,C*]

AB The present invention relates to a method for inhibiting an undesirable taste in oral compns. such as foods, beverages, and pharmaceuticals. The present invention also relates to oral and pharmaceutical compns. comprising undesirable tasting compds. wherein undesirable tastes are inhibited by the addition of a phosphorylated amino acid, such as phosphotyrosine, phosphoserine, phosphothreonine, and mixts. thereof, to the oral and pharmaceutical compns. Liquid cough/cold compns. for oral administration contained ibuprofen arginate 1, chlorpheniramine maleate 0.02, pseudoephedrine·HCl 0.3, phosphotyrosine 2, ethanol (95%) 25, propylene glycol 25, Na citrate 2, citric acid 0.25, liquid sugar 25, glycerin 7, colorants 0.009, flavors 0.5, and water to 100 % weight/volume

ST taste masking phosphorylated amino acid; phosphotyrosine antitussive liq taste masking

IT **Antihistamines**
(**H2**; taste masking in oral compns. using phosphorylated amino acids)

IT Drug delivery systems
Drug delivery systems
(liqs., oral; taste masking in oral compns. using phosphorylated amino acids)

IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phosphorylated; taste masking in oral compns. using phosphorylated amino acids)
IT Nutrients
(supplements; taste masking in oral compns. using phosphorylated amino acids)
IT Analgesics
Anesthetics
Antacids
Anti-inflammatory agents
Antibacterial agents
Antidiarrheals
Antiemetics
Antihistamines
Antimicrobial agents
Antipyretics
Antitussives
Antiviral agents
Appetite depressants
Beverages
Bronchodilators
Cholinergic antagonists
Decongestants
Dentifrices
Expectorants
Food
Fungicides
Laxatives
Mouthwashes
(taste masking in oral compns. using phosphorylated amino acids)
IT Peroxides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(taste masking in oral compns. using phosphorylated amino acids)
IT 407-41-0 1114-81-4 21820-51-9, Phosphotyrosine 57469-82-6
RL: BUU (Biological use, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(taste masking in oral compns. using phosphorylated amino acids)
IT 93-14-1, Glyceryl guaiacolate 103-90-2, Acetaminophen 113-92-8, Chlorpheniramine maleate 125-69-9, Dextromethorphan hydrobromide 345-78-8, Pseudoephedrine hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(taste masking in oral compns. using phosphorylated amino acids)

L34 ANSWER 21 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:13835 HCAPLUS
DN 128:93192
ED Entered STN: 10 Jan 1998
TI Use of H2-antagonists for the manufacture of a topical composition for the treatment of colds
IN **Singer, Robert Ernest, Jr.**
PA **Procter** and **Gamble** Company, USA
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0031/00
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9747292	A1	19971218	1997WO-US09977	19970610
	W: AU, BR, CA, CN, JP, KR, MX, SG				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA---2257990	AA	19971218	1997CA-2257990	19970610
	AU---9733069	A1	19980107	1997AU-0033069	19970610

	CN---1221338	A	19990630	1997CN-0195430	19970610
	BR---9709792	A	19990810	1997BR-0009792	19970610
	JP--11513035	T2	19991109	1997JP-0501751	19970610
	EP----954294	A1	19991110	1997EP-0928916	19970610
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
PRAI	1996US-0662389	A	19960612		
	1997WO-US09977	W	19970610		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9747292	ICM	A61K-0031/00
	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
	ECLA	A61K031/341; A61K031/426
CA---2257990	IPCI	A61K0045-00 [ICM,6]; A61K0007-16 [ICS,6]; A61K0031-34 [ICS,6]; A61K0031-415 [ICS,6]
AU---9733069	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
CN---1221338	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
BR---9709792	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
JP--11513035	IPCI	A61K0045-00 [ICM,6]; A61K0007-16 [ICS,6]; A61K0009-06 [ICS,6]; A61K0031-00 [ICS,6]; A61K0031-34 [ICS,6]; A61K0031-415 [ICS,6]; A61K0031-425 [ICS,6]; A61K0031-435 [ICS,6]; A61K0047-32 [ICS,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]
EP----954294	IPCI	A61K0031-00 [ICM,6]
	IPCR	A61K0031-341 [I,A]; A61K0031-341 [I,C*]; A61K0031-426 [I,A]; A61K0031-426 [I,C*]

AB Oral compns. for topical application contain an H2 antagonist to provide protection against colds and flu. A toothpaste containing cimetidine and a tooth gel containing mifentidine were prepared

ST H2 antagonist pharmaceutical cold flu

IT Common cold
Dentifrices
Influenza
Mouthwashes
(H2-antagonists for the manufacture of a topical composition for the treatment of colds)

IT **Antihistamines**
(**H2**; **H2**-antagonists for the manufacture of a topical composition for the treatment of colds)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dilactone-based; H2-antagonists for the manufacture of a topical composition for the treatment of colds)

IT Drug delivery systems
(topical; H2-antagonists for the manufacture of a topical composition for the treatment of colds)

IT 26780-50-7, Glycolide-lactide copolymer 51481-61-9, Cimetidine 55273-05-7, Impromidine 66357-35-5, Ranitidine 69014-14-8, Tiotidine 69014-64-8, ICIA-5165 69539-53-3, Etintidine 73278-54-3, Lamtidine 75438-42-5, ORF-17578 76824-35-6, Famotidine 76956-02-0, Loxtidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine 78441-82-4, BMY-25271 78441-84-6, BL-6341A 78628-28-1, Pifatidine 80343-63-1, Sufotidine 83184-43-4, Mifentidine 83903-06-4, Lupitidine 84071-15-8, Ramixotidine 84545-30-2, ICI-162846 85195-15-9, L-643728 85604-00-8, Zaltidine 86134-80-7, SKF-94482 87107-94-6, BL-6548 89077-71-4, BMY-25405 89250-13-5, DA-4634 90287-93-7, SR 58042 93064-63-2, D-16637 94662-53-0, WY-45727 96153-56-9, Bisfentidine 99248-32-5,

Donetidine 100981-43-9, Ebrotidine 104428-51-5 105805-28-5
108498-50-6, FRG-8701 118288-08-7, FRG-8813
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(H2-antagonists for the manufacture of a topical composition for the treatment of colds)

L34 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:540271 HCAPLUS
DN 127:140227
ED Entered STN: 25 Aug 1997
TI Oral care compositions containing peptides with anti-adherence activity
IN Charbonneau, Duane Larry; Baker, Timothy Robert; Murawaski, Sandra Lou; Ward, Susan Ruth
PA **Procter & Gamble** Company, USA
SO Brit. UK Pat. Appl., 42 pp.
CODEN: BAXXDU
DT Patent
LA English
IC ICM C07K-0007/06
ICS A61K-0007/16; C07K-0007/64
CC 62-7 (Essential Oils and Cosmetics)
Section cross-reference(s): 34
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB---2307476	A1	19970528	1996GB-0011500	19960603
PRAI 1995US-0466542	A	19950606		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
GB 2307476	ICM	C07K-0007/06
	ICS	A61K-0007/16; C07K-0007/64
	IPCI	C07K0007-06 [ICM,6]; A61K0007-16 [ICS,6]; C07K0007-64 [ICS,6]; C07K0007-00 [ICS,6,C*]
	IPCR	C07K0007-00 [I,C*]; C07K0007-06 [I,A]
	ECLA	A61K008/64; A61Q011/00; C07K007/06A

AB There is a number of peptides which prevent bacteria adhering to teeth are disclosed. Dimers and/or cyclomonomers of these peptides are preferred because they have enhanced stability in the acid conditions of the mouth. The peptides may be employed in oral compns. such as dentifrices and mouth-washes to inhibit the growth of dental plaque. A tooth paste contained Tyr-Trp-Phe-Trp-Tyr-Gln (preparation given) 0.10, sorbitol 42.00, saccharin sodium 0.13, FD$C Blue 0.05, precipitated silica 20.00, sodium fluoride 0.24, flavor 0.900, sodium alkyl sulfate 1.00, phosphoric acid 0.4, Carbomer 940 0.25, xanthan gum 0.5, titanium oxide 0.5, and water q.s. 100%.
ST oral care compn peptide prepn antiadherence; antiplaque toothpaste peptide prepn
IT **Antihistamines**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**H2**; oral care compns. containing peptides with anti-adherence activity)
IT Chewing gum
(antiplaque dentifrices; oral care compns. containing peptides with anti-adherence activity)
IT **Dentifrices**
Mouthwashes
Mouthwashes
(**antiplaque**; oral care compns. containing peptides with anti-adherence activity)
IT **Dentifrices**
Dentifrices
(**chewing gums**, **antiplaque**; oral care compns. containing peptides with anti-adherence activity)
IT Chewing gum

(dentifrices, antiplaque; oral care compns. containing peptides with anti-adherence activity)
IT Adhesion, biological
(inhibitors; oral care compns. containing peptides with anti-adherence activity)
IT Tooth
(oral care compns. containing peptides with anti-adherence activity)
IT Anti-inflammatory agents
Peptides, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oral care compns. containing peptides with anti-adherence activity)
IT 50-78-2, Aspirin 53-86-1, Indomethacin 644-62-2, Meclofenamic acid 5104-49-4, Flurbiprofen 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 36322-90-4, Piroxicam 74103-06-3, Ketorolac
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oral care compns. containing peptides with anti-adherence activity)
IT 193199-43-8P 193199-47-2P 193199-51-8P 193199-56-3P 193199-60-9P 193199-63-2P 193199-66-5P 193199-69-8P 193199-72-3P 193199-75-6P 193199-78-9P 193199-81-4P 193199-84-7P 193199-87-0P 193199-89-2P 193199-92-7P 193199-97-2P 193200-01-0P 193200-05-4P 193200-09-8P 193200-12-3P 193200-16-7P 193200-20-3P 193200-22-5P 193200-25-8P 193200-27-0P
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(oral care compns. containing peptides with anti-adherence activity)
IT 13726-85-7 13734-34-4 13734-41-3 15761-38-3 18942-46-6 47355-10-2 193200-36-1 193200-39-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(oral care compns. containing peptides with anti-adherence activity)

L34 ANSWER 23 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:307478 HCAPLUS
DN 120:307478
ED Entered STN: 11 Jun 1994
TI Use of histamine H-2 antagonists for treatment of gingivitis or periodontitis
IN **Singer, Robert E.**; Ebel, James P.
PA **Procter** and **Gamble** Co., USA
SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 868,805.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K-0007/16
ICS A61K-0007/18; A61K-0007/22
INCL 424052000
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): **1**
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---5294433	A	19940315	1993US-0019782	19930305
	WO---9320815	A1	19931028	1993WO-US02673	19930324
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU---9339304	A1	19931118	1993AU-0039304	19930324
	CN---1082400	A	19940223	1993CN-0105692	19930415
	US---5364616	A	19941115	1993US-0171494	19931222
PRAI	1992US-0868805	A2	19920415		
	1993US-0019782	A	19930305		
	1993WO-US02673	A	19930324		

CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

US 5294433	ICM	A61K-0007/16
	ICS	A61K-0007/18; A61K-0007/22
	INCL	424052000
	IPCI	A61K0007-16 [ICM,5]; A61K0007-18 [ICS,5]; A61K0007-22 [ICS,5]
	IPCR	A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41 [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A]; A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425 [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*]; A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505 [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
	NCL	424/052.000; 424/049.000; 424/054.000
WO---9320815	IPCI	A61K0031-41 [ICM,5]; A61K0031-415 [ICS,5]; A61K0031-34 [ICS,5]; A61K0031-425 [ICS,5]; A61K0031-44 [ICS,5]; A61K0031-445 [ICS,5]; A61K0031-505 [ICS,5]
	IPCR	A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41 [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A]; A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425 [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*]; A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505 [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
AU---9339304	IPCI	A61K0031-41 [ICM,5]; A61K0031-415 [ICS,5]; A61K0031-34 [ICS,5]; A61K0031-425 [ICS,5]; A61K0031-44 [ICS,5]; A61K0031-445 [ICS,5]; A61K0031-505 [ICS,5]
	IPCR	A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41 [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A]; A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425 [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*]; A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505 [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
CN---1082400	IPCI	A61K0007-16 [ICM,5]; A61K0031-275 [ICS,5]; A61K0031-415 [ICS,5]; A61K0031-155 [ICS,5]; A61K0031-44 [ICS,5]
	IPCR	A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41 [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A]; A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425 [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*]; A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505 [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
US---5364616	IPCI	A61K0007-16 [ICM,5]; A61K0007-18 [ICS,5]; A61K0007-22 [ICS,5]
	IPCR	A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41 [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A]; A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425 [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*]; A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505 [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
	NCL	424/052.000; 424/049.000; 424/054.000; 514/399.000; 514/406.000; 514/900.000; 514/902.000

AB Gingivitis or periodontitis is treated by topical administration, to gingival tissues of the oral cavity, of a composition comprising a safe and effective amount of a selective histamine H-2 receptor antagonist. Oral care compns. (toothpastes, etc.) containing the H-2 antagonists are disclosed. The H-2 antagonist may be cimetidine, ranitidine, famotidine, nizatidine, etc.

ST gingivitis treatment histamine H2 antagonist; toothpaste histamine H2 antagonist gingivitis

IT **Dentifrices**
Mouthwashes
(with histamine H2 antagonist, for gingivitis or periodontitis treatment)

IT **Antihistaminics**
(**H2**, for gingivitis or periodontitis treatment)
IT Pharmaceutical dosage forms
(controlled-release, polymers, with histamine H2 antagonist, for gingivitis or periodontitis treatment)
IT Gingiva
(disease, gingivitis, treatment of, histamine H2 antagonist for)
IT Periodontium
(disease, periodontitis, treatment of, histamine H2 antagonist for)
IT **Dentifrices**
(**gels**, with histamine H2 antagonist, for gingivitis or periodontitis treatment)
IT 51481-61-9, Cimetidine 55273-05-7, Impromidine 66357-35-5, Ranitidine
69014-14-8, Tiotidine 69014-64-8, ICIA-5165 69539-53-3, Etintidine
73278-54-3, Lamtidine 75438-42-5, ORF-17578 76824-35-6, Famotidine
76956-02-0, Loxtidine 76963-41-2, Nizatidine 78273-80-0, Roxatidine
78441-82-4, BMY-25271 78441-84-6, BL-6341A 78628-28-1, Pifatidine
80343-63-1, Sufotidine 83184-43-4, Mifentidine 83903-06-4, Lupitidine
84071-15-8, Ramixotidine 84545-30-2, ICI-162846 85195-15-9, L 643728
85604-00-8, Zaltidine 86134-80-7, BMY-25368 87107-94-6, BL-6548
89077-71-4, BMY-25405 89250-13-5, DA-4634 90287-93-7, SR 58042
93064-63-2, D 16637 94662-53-0, Wy-45727 96153-56-9, Bisfentidine
99248-32-5, Donetidine 100981-43-9, Ebrotidine 104428-51-5, HB 408
105805-28-5, HE 30256 108498-50-6, FRG-8701 118288-08-7, FRG-8813
RL: BIOL (Biological study)
(for gingivitis or periodontitis treatment)
IT 155057-88-8 155057-90-2
RL: BIOL (Biological study)
(mouthwash with, for gingivitis or periodontitis treatment)
IT 155057-87-7 155057-89-9
RL: BIOL (Biological study)
(toothpaste with, for gingivitis or periodontitis treatment)

L34 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:678396 HCAPLUS
DN 119:278396
ED Entered STN: 25 Dec 1993
TI Dental compositions containing H2 histamine antagonists for treatment of gingivitis and periodontitis
IN **Singer, Robert E.**; Ebel, James P.
PA **Procter** and **Gamble** Co., USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K-0031/41
ICS A61K-0031/415; A61K-0031/34; A61K-0031/425; A61K-0031/44; A61K-0031/445; A61K-0031/505
CC 62-7 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9320815	A1	19931028	1993WO-US02673	19930324
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US---5294433	A	19940315	1993US-0019782	19930305
	AU---9339304	A1	19931118	1993AU-0039304	19930324
PRAI	1992US-0868805	A	19920415		
	1993US-0019782	A	19930305		
	1993WO-US02673	A	19930324		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES

noble jarrell 06/07/2006

WO 9320815	ICM	A61K-0031/41
	ICS	A61K-0031/415; A61K-0031/34; A61K-0031/425; A61K-0031/44; A61K-0031/445; A61K-0031/505
	IPCI	A61K0031-41 [ICM,5]; A61K0031-415 [ICS,5]; A61K0031-34 [ICS,5]; A61K0031-425 [ICS,5]; A61K0031-44 [ICS,5]; A61K0031-445 [ICS,5]; A61K0031-505 [ICS,5]
	IPCR	A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41 [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A]; A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425 [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*]; A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505 [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
US---5294433	IPCI	A61K0007-16 [ICM,5]; A61K0007-18 [ICS,5]; A61K0007-22 [ICS,5]
	IPCR	A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41 [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A]; A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425 [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*]; A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505 [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]
	NCL	424/052.000; 424/049.000; 424/054.000
AU---9339304	IPCI	A61K0031-41 [ICM,5]; A61K0031-415 [ICS,5]; A61K0031-34 [ICS,5]; A61K0031-425 [ICS,5]; A61K0031-44 [ICS,5]; A61K0031-445 [ICS,5]; A61K0031-505 [ICS,5]
	IPCR	A61K0031-34 [I,A]; A61K0031-34 [I,C*]; A61K0031-41 [I,A]; A61K0031-41 [I,C*]; A61K0031-415 [I,A]; A61K0031-415 [I,C*]; A61K0031-425 [I,A]; A61K0031-425 [I,C*]; A61K0031-44 [I,A]; A61K0031-44 [I,C*]; A61K0031-445 [I,A]; A61K0031-445 [I,C*]; A61K0031-505 [I,A]; A61K0031-505 [I,C*]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]

AB Dental compns. containing H2 histamine antagonists are used for treatment of gingivitis and periodontitis. A dental solution contained ranitidine 1.00, flavors 0.10, Polysorbate-80 0.25, Na saccharin 0.05, methylparaben 0.20, propylparaben 0.10, and water q.s. 100%.

ST dental compn H2 histamine antagonists gingivitis; periodontitis dental compn H2 histamine antagonists; ranitidine dental soln periodontitis gingivitis

IT **Dentifrices**
Mouthwashes
(H2 histamine antagonists in, for treatment of gingivitis and periodontitis)

IT Bactericides, Disinfectants, and Antiseptics
Inflammation inhibitors
Diphosphates
Fluorides, biological studies
RL: BIOL (Biological study)
(dental composition containing H2 histamine antagonists and, for treatment of gingivitis and periodontitis)

IT **Antihistaminics**
(**H2**, dental composition containing, for treatment of gingivitis and periodontitis)

IT Pharmaceutical dosage forms
(controlled-release, for placement in periodontal pocket, H2 histamine antagonists in)

IT Gingiva
(disease, gingivitis, treatment of, with dental composition containing H2 histamine antagonists)

IT Periodontium
(disease, periodontitis, treatment of, with dental composition containing H2 histamine antagonists)

IT **Dentifrices**
(**gels**, H2 histamine antagonists in, for treatment of gingivitis and periodontitis)

```
IT   Periodontium
        (pocket, placement of H2 histamine antagonists in, controlled-release
        pharmaceutical containing)
IT   50-78-2, Aspirin   53-86-1, Indomethacin   644-62-2, Meclofenamic acid
     5104-49-4, Flurbiprofen   15687-27-1   22071-15-4   22204-53-1, Naproxen
     36322-90-4, Piroxicam   74103-06-3, Ketorolac
     RL: BIOL (Biological study)
        (dental composition containing H2 histamine antagonists and, for treatment of
        gingivitis and periodontitis)
IT   51481-61-9, Cimetidine   55273-05-7, Impromidine   66357-35-5, Ranitidine
     69014-14-8, Tiotidine   69014-64-8, ICIA-5165   69539-53-3, Etintidine
     73278-54-3, Lamtidine   75438-42-5, ORF-17578   76824-35-6, Famotidine
     76956-02-0, Loxtidine   76963-41-2, Nizatidine   78273-80-0, Roxatidine
     78441-82-4, BMY-25271   78441-84-6, BL-6341A   78628-28-1, Pifatidine
     80343-63-1   83184-43-4, Mifentidine   83903-06-4, Lupitidine
     84071-15-8, Ramixotidine   84545-30-2, ICI-162846   85195-15-9
     85604-00-8, Zaltidine   86134-80-7, SKF-94482   87107-94-6, BL-6548
     89077-71-4, BMY-25405   89250-13-5, DA-4634   90287-93-7, SR 58042
     93064-63-2, D 16637   94662-53-0, Wy-45727   96153-56-9   99248-32-5,
     Donetidine   100981-43-9, Ebrotidine   104428-51-5, HB 408   105805-28-5,
     HE 30256   108498-50-6, FRG-8701   118288-08-7, FRG-8813
     RL: BIOL (Biological study)
        (dental composition containing, for treatment of gingivitis and periodontitis)


=> d his

     (FILE 'HOME' ENTERED AT 09:22:39 ON 06 JUL 2006)

     FILE 'HCAPLUS' ENTERED AT 09:22:55 ON 06 JUL 2006
L1            1 US2000-607602/AP,PRN
                E DOYLE M/AU
L2           75 E3,E13
                E DOYLE MATT/AU
L3           26 E4-6
                E HUNTER RINDERLE/AU
L4            8 E5
                E SINGER R/AU
L5          105 E3,E7
                E SINGER ROB/AU
L6           67 E4,E11-14
L7        12952 (PROCTER (L)GAMBLE)/CS,PA
                E TOOTHPASTE/CT
                E E3+ALL
                E E2
L8         9351 E3-13
                E E3+ALL
L9         9351 E2
                E TOOTH, DISEASE/CT
L10        2230 E3-13
                E E3+ALL
L11        5601 E11+OLD
L12         539 L10-11 (L) (INHIBIT? OR SUPPRESS? OR MODULAT? OR DOWNREGULAT? O
L13        9787 L8-9,L12
                E DENTAL FLOSS/CT
                E E3+ALL
                E MOUTHWASH/CT
                E E3+ALL
                E MOUTHWASH/CT
L14        3858 E3-9
                E E4+ALL
L15        3898 E2+OLD
                E MOUTH, DISEASE/CT
L16        1398 E3-16
                E E3+ALL
L17        8646 E10+NT
```

```
L18         1200 L16-17 (L) (INHIBIT? OR SUPPRESS? OR MODULAT? OR DOWNREGULAT? O
L19        12282 L13-15,L18
L20         6381 L19 AND PHARM?/SC,SX
L21          163 L20 AND L1-7
                 E H2/CT
                 E H2 ANTAG/CT
                 E E5+ALL
                 E E2
                 E ANTIHISTAMINES/CT
                 E E3+ALL
L22         1994 E4+OLD,NT (L)H2
                 E H2 ANTAG/CT
L23           16 L21 AND L22
L24           28 L20 AND L22
L25           16 L24 AND L1-7
L26           12 L24 NOT L25
L27            4 L26 AND (PY<=2000 OR AY<=2000 OR PRY<=2000)
L28           36 L19 AND L22
L29           24 L28 AND L1-7
L30           12 L28 NOT L29
L31           12 L26-27,L30
                 SEL AN 1-4 7 10-11
L32            7 E1-14 AND L31
                 SEL AN 3-5 7
L33            4 E15-22 AND L32
L34           24 L25,L29

=> b wpix
FILE 'WPIX' ENTERED AT 14:19:17 ON 06 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED:          3 JUL 2006      <20060703/UP>
MOST RECENT DERWENT UPDATE:     200642        <200642/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
    PLEASE VISIT:
 http://www.stn-international.de/training_center/patents/stn_guide.pdf <

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf <<<

>>> FOR FURTHER DETAILS ON THE FORTHCOMING DERWENT WORLD PATENTS
    INDEX ENHANCEMENTS PLEASE VISIT:
http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<
'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d all abex tech l18 tot

L18  ANSWER 1 OF 5  WPIX  COPYRIGHT 2006 THE THOMSON CORP on STN
AN   2004-439858 [41]   WPIX
CR   2004-439857 [41]
DNC  C2004-164676
TI   Oral care dentifrice composition for treatment of oral conditions,
     includes particulate retentive agent comprising water-soluble hydrophilic
     gums and/or polymers, and oral care carrier.
DC   A96 B06 B07 D21
IN   BEST, J M; BURGESS, S C; EVERSOLE, S L; FALLER, R V; SCOTT, D C
PA   (PROC) PROCTER & GAMBLE CO; (BEST-I) BEST J M;
     (BURG-I) BURGESS S C; (EVER-I) EVERSOLE S L; (FALL-I) FALLER R V; (SCOT-I)
     SCOTT D C
CYC  108
```

PI US--2004101494 A1 20040527 (200441)* 21 A61K-009-68
WO--2004047785 A1 20040610 (200441) EN A61K-007-16 <--
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
AU--2003293110 A1 20040618 (200471) A61K-007-16 <--
EP-----1565154 A1 20050824 (200556) EN A61K-007-16 <--
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR
JP--2006509768 W 20060323 (200623) 40 A61K-008-00
ADT US--2004101494 A1 Provisional 2002US-429234P 20021126, 2003US-0706104 20031112; WO--2004047785 A1 2003WO-US37880 20031125; AU--2003293110 A1 2003AU-0293110 20031125; EP-----1565154 A1 2003EP-0790102 20031125, 2003WO-US37880 20031125; JP--2006509768 W 2003WO-US37880 20031125, 2004JP-0555783 20031125
FDT AU--2003293110 A1 Based on WO--2004047785; EP-----1565154 A1 Based on WO--2004047785; JP--2006509768 W Based on WO--2004047785
PRAI 2002US-429234P 20021126; 2003US-0706104 20031112
IC ICM **A61K-007-16**; A61K-008-00; A61K-009-68
ICS A61K-009-00; A61K-009-20; **A61Q-011-00**
AB US2004101494 A UPAB: 20060405
NOVELTY - An oral care dentifrice composition comprises a retentive agent comprising water soluble hydrophilic gums and/or polymers, and having a property of hydrating upon exposure to water or saliva forming an intact hydrated mass to provide a retention index of 1-4; and an oral care carrier. The composition is a non-cariogenic, chewable solid unit dosage from, and comprises water insoluble particulates.

DETAILED DESCRIPTION - An oral care dentifrice composition comprises a retentive agent (1-40 weight%) comprising water soluble hydrophilic gums and/or polymers, and having a property of hydrating upon exposure to water or saliva forming an intact hydrated mass to provide a retention index of 1-4; and an oral care carrier. The composition is a non-cariogenic, chewable solid unit dosage from, and comprises water insoluble particulates (less than 65 weight%).

INDEPENDENT CLAIMS are also included for:

(a) an oral care kit comprising an oral care dentifrice composition for topical, oral administration in a human or other animal, instructions, and a container;

(b) a method of buffering the oral cavity saliva or environment on or at the tooth surfaces of a subject, to a pH of 7-12, for at least 2 minutes, by administering topically to the oral cavity, an oral care composition;

(c) a method of providing sustained delivery of an oral care active, flavor, sensate or buffer, in the oral cavity of a subject, by administering topically, an oral care dentifrice composition.

USE - For treatment of oral conditions.

ADVANTAGE - The composition provides mechanical shear by chewing the solid unit dosage form and using a retentive agent. The retentive agent enhances deposition and adhesion of the composition to the teeth surfaces. The composition also provides pH buffering on or at the tooth surfaces, especially the sites where most caries form, the pits, fissures and occlusal surfaces of the teeth.

Dwg.0/3
FS CPI
FA AB; DCN
MC CPI: **A12-V04B**; B03-L; B04-C02A; B04-C02B; B04-C02B2; B04-C02D; B04-C02F; B04-C03; B04-N02; B05-A01B; B05-A02; B05-C04; B05-C07; B10-A07; B10-B02J; B10-B03B; B12-M10A; B12-M11B; B14-A01; B14-A04; B14-C03; B14-C08; **B14-L11**; **B14-N06A**; **D08-A05**; **D08-B08**
ABEX UPTX: 20040629
EXAMPLE - A chewable compressed tablet was prepared by mixing (wt.%)

sodium fluoride (0.243), sodium lauryl sulfate (1.5), silica (20), sodium saccharin (0.5), flavor (1.5), xanthan gum (2), microcrystalline cellulose (5), polyvinyl pyrrolidone (3), crosslinked sodium carboxymethyl (2), sorbitol (30), mannitol (33.257), and zinc stearate (1).

TECH UPTX: 20040629

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Property: The retention index is 2-4.

Preferred Composition: The retentive agent is present at 7-30 (preferably 11-18) wt.%.

Preferred Agent: The oral care active agent is anticalculus agent, anticaries agent (xylitol), fluoride ion source (stannous fluoride, sodium fluoride, indium fluoride, sodium monofluorophosphate), antimicrobial agents, dentinal desensitizing agents, anesthetic agents, antifungal agents, anti-inflammatory agents, selective H-2 antagonists, anticaries agents, remineralization agents, whitening agents, anti-erosion agents, vitamins, and/or minerals.

Preferred Concentration: The active agent is a fluoride ion source providing 200-300 ppm of fluoride ion. Preferred Form: The solid unit dosage form is a compressed tablet.

TECHNOLOGY FOCUS - POLYMERS - Preferred Material: The retentive agent is acacia, karaya gum, guar gum, gelatin, alginic acid or its salts, tragacanth, polyethylene glycol, polyethylene oxide, acrylamide polymers, cross linked polyacrylic acid, polyvinyl alcohol, ethylene oxide polymers, polyvinylpyrrolidone, cationic polyacrylamide polymers, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, xanthan gum, carrageenan, locust bean gum, gum Arabic, tragacanth gum, pullulan, pre-gelatinized and partially pre-gelatinized starch, hydrolyzed starch, maltodextrin and corn syrup solids, hydrogenated maltodextrin, hydrogenated starch hydrosylates, amylose, and/or amylopectin.

TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Material: The carrier can be water soluble buffers, sodium bicarbonate, sodium carbonate, phosphate buffer, trisodium phosphate, disodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, tetrasodium pyrophosphate, disodium pyrophosphate, tetrapotassium pyrophosphate, and/or salts of tripolyphosphates.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Material: The carrier can be amino acid buffers, alanine, glycine, and/or tris(hydroxymethyl)aminomethane.

L18 ANSWER 2 OF 5 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-141600 [14] WPIX
CR 1998-312139 [27]; 2000-412119 [35]; 2000-422852 [36]; 2001-417614 [44]; 2002-147973 [19]; 2002-266603 [31]; 2003-016005 [01]; 2004-388565 [36]
DNC C2004-056534
TI Promoting whole body health in human and animal subjects by topical administration of oral composition comprising stannous ion source, polymeric mineral surface active agent and oral carrier.
DC A96 B05 C03 D21
IN **DOYLE, M J**; GLANDORF, W M; **HUNTER-RINDERLE, S J**; WHITE, D J
PA (PROC) **PROCTER & GAMBLE CO**
CYC 1
PI US--2003206874 A1 20031106 (200414)* 17 A61K-007-16 <--
ADT US--2003206874 A1 CIP of 1996US-0754577 19961121, CIP of 1998US-0203216 19981130, Div ex 1999US-0451420 19991130, CIP of 2000US-0607240 20000630, CIP of 2000US-0710440 20001110, CIP of 2001US-0039620 20011024, 2003US-0454843 20030605
FDT US--2003206874 A1 CIP of US-----5939052, Div ex US-----6350436, CIP of US-----6555094
PRAI 2003US-0454843 20030605; 1996US-0754577 19961121;
1998US-0203216 19981130; 1999US-0451420 19991130;
2000US-0607240 20000630; 2000US-0710440 20001110;

2001US-0039620 20011024
IC ICM **A61K-007-16**
ICS **A61K-007-28**
AB US2003206874 A UPAB: 20041203
NOVELTY - Promoting whole body health in human and animal subjects comprises topically administering oral composition to the subject's oral cavity comprising stannous ion source, polymeric mineral surface-active agent and oral carrier.
USE - For promoting whole body health in human and animal subjects.
ADVANTAGE - Topical administration of oral composition inhibits the spread of pathogenic oral bacteria, associated bacterial toxins and endotoxins and resultant inflammatory cytokines and mediators into the bloodstream. It reduces the risk in developing cardiovascular disease, stroke, atherosclerosis, diabetes, severe respiratory infections, premature births and low-birth weight, post-partum dysfunction in neurologic and developmental functions and associated increased risk of mortality.
Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: A12-V01; B03-L; B04-C01G; B04-C02A2; B04-C02V; B04-C03; B04-H06; B04-J01; B05-A03A; B05-A03B; B05-B01N; B05-C05; B05-C07; B06-E05; B06-F01; B07-H; B10-A07; B10-A17; B10-A22; B10-C02; B10-C04C; B10-C04D; B10-D03; B10-E02; B10-E04C; B14-A01; B14-A02; B14-C01; B14-C03; B14-D07C; B14-G01; B14-L06; **B14-L11**; **B14-N06**; C03-L; C04-C01G; C04-C02A2; C04-C02V; C04-C03; C04-H06; C04-J01; C05-A03A; C05-A03B; C05-B01N; C05-C05; C05-C07; C06-E05; C06-F01; C07-H; C10-A07; C10-A17; C10-A22; C10-C02; C10-C04C; C10-C04D; C10-D03; C10-E02; C10-E04C; C14-C01; C14-D07C; C14-G01; C14-L06; **C14-L11**; **C14-N06**; **D08-A05**; **D08-B08**
ABEX UPTX: 20040226
EXAMPLE - A dual phase dentifrice was formed from a first phase containing (wt.%) water (2.768), glycerin (36.432), polyethylene glycol (1.500), propylene glycol (8.000), hydrated silica (28.000), xanthan gum (0.300), carboxymethyl cellulose (0.500), sodium alkylsulfate (4.000), sodium saccharin (1.000), glass H polyphosphate (1.000), flavor (0.300), benzoic acid (0.600) and sodium benzoate (0.600) and a second phase containing stannous fluoride (0.908), stannous chloride (3.000), sodium gluconate (4.160), color (0.300), water (21.840), flavor (1.000), glycerin (28.992), silica (23.000), sodium saccharin (0.300), 50% sodium hydroxide solution (1.000) and poloxamer (15.500).
TECH UPTX: 20040226
TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Components: The stannous ion source is stannous fluoride, stannous chloride, stannous acetate, stannous gluconate, stannous oxalate, stannous sulfate, stannous lactate and/or stannous tartrate. The stannous ion source provides 3000-15000 ppm stannous ions.

TECHNOLOGY FOCUS - POLYMERS - Preferred Components: The polymeric surface-active agent is phosphorylated polymer, preferably condensed polyphosphate having an average chain length of at least 4 (preferably 21). The polyphosphate is present at 1-35 wt.%.
TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The composition also contains additional therapeutic agent(s), e.g. antimicrobial agent, anti-inflammatory agent, hydrogen antagonist, metalloproteinase inhibitor, cytokine receptor antagonist, lipopolysaccharide complexing agent, tissue growth factor, immunostimulatory agent, cellular redox modifier, analgesic, hormone, vitamin and/or mineral. The antimicrobial agent is triclosan, triclosan monophosphate, chlorhexidine, alexidine, hexetidine, sanguinarine, benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridinium chloride, tetradecylpyridinium chloride, N-tetradecyl-4-ethylpyridinium chloride, octenidine, delmopinol, octapinol, nisin, zinc ion source, copper ion source, essential oil, furanone, bacteriocin and/or their salts.

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition may be in the form of mouth rinse, toothpaste, tooth gel, tooth powder, non-abrasive gel, chewing gum, mouth spray, lozenge or pet-chew product.

L18 ANSWER 3 OF 5 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2001-112498 [12] WPIX
CR 2001-102981 [11]; 2001-102982 [11]; 2001-102983 [11]; 2001-112494 [12]
DNC C2001-033516
TI Delivery system for delivering a substance to the oral cavity, comprising a removable backing strip and a composition comprising an organosiloxane resin, a rheology modifier and an oral care substance.
DC A26 A96 B07 C07 D21
IN BUCKLEY, C D; YE, H; YUE, J; CRISANTI, M M; JIANG, Y; MAJETI, S
PA (PROC) **PROCTER & GAMBLE CO**
CYC 92
PI WO---200101958 A1 20010111 (200112)* EN 39 A61K-009-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU---200059074 A 20010122 (200125) A61K-009-00
NO---200200004 A 20020228 (200223) A61K-000-00
EP-----1200064 A1 20020502 (200236) EN A61K-009-00
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
BR---200012145 A 20020430 (200237) A61K-009-00
SK---200101941 A3 20020806 (200261) A61K-009-00
CZ---200104709 A3 20020911 (200268) A61K-009-00
CN-----1360494 A 20020724 (200269) A61K-009-00
HU---200201620 A2 20020930 (200272) A61K-009-00
EP-----1200064 B1 20030502 (200330) EN A61K-009-00
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DE----60002471 E 20030605 (200345) A61K-009-00
JP--2003531814 W 20031028 (200373) 50 A61K-007-16 <--
US-----6649147 B1 20031118 (200376) A61K-007-16 <--
AU------768471 B 20031211 (200404) A61K-009-00
ES-----2199168 T3 20040216 (200416) A61K-009-00
RU-----2223746 C2 20040220 (200424) A61K-007-16 <--
CN-----1200684 C 20050511 (200641) A61K-007-16 <--
ADT WO---200101958 A1 2000WO-US018188 20000630; AU---200059074 A 2000AU-0059074 20000630; NO---200200004 A 2000WO-US018188 20000630, 2002NO-0000004 20020102; EP-----1200064 A1 2000EP-0945084 20000630, 2000WO-US18188 20000630; BR---200012145 A 2000BR-0012145 20000630, 2000WO-US18188 20000630; SK---200101941 A3 2000WO-US18188 20000630, 2001SK-0001941 20000630; CZ---200104709 A3 2000WO-US18188 20000630, 2001CZ-0004709 20000630; CN-----1360494 A 2000CN-0809984 20000630; HU---200201620 A2 2000WO-US18188 20000630, 2002HU-0001620 20000630; EP-----1200064 B1 2000EP-0945084 20000630, 2000WO-US18188 20000630; DE----60002471 E 2000DE-0602471 20000630, 2000EP-0945084 20000630, 2000WO-US18188 20000630; JP--2003531814 W 2000WO-US18188 20000630, 2001JP-0507453 20000630; US-----6649147 B1 2000WO-US18188 20000630, 2002US-0019032 20020320; AU------768471 B 2000AU-0059074 20000630; ES-----2199168 T3 2000EP-0945084 20000630; RU-----2223746 C2 2000WO-US18188 20000630, 2002RU-0102710 20000630; CN-----1200684 C 2000CN-0809937 20000609
FDT AU---200059074 A Based on WO---200101958; EP-----1200064 A1 Based on WO---200101958; BR---200012145 A Based on WO---200101958; SK---200101941 A3 Based on WO---200101958; CZ---200104709 A3 Based on WO---200101958; HU---200201620 A2 Based on WO---200101958; EP-----1200064 B1 Based on WO---200101958; DE----60002471 E Based on EP-----1200064, Based on WO---200101958; JP--2003531814 W Based on WO---200101958; US-----6649147 B1 Based on WO---200101958; AU------768471 B Previous Publ.

noble jarrell 06/07/2006

AU---200059074, Based on WO---200101958; ES-----2199168 T3 Based on EP-----1200064; RU-----2223746 C2 Based on WO---200101958

PRAI 2000WO-US15891 20000609; 1999WO-US15130 19990702; 1999WO-US15131 19990702; 2000WO-US15890 20000609

IC ICM A61K-000-00; **A61K-007-16**; A61K-009-00

ICS A61C-013-23; **A61K-007-18**; A61K-009-20; A61K-009-70; A61K-031-4164; A61K-033-40; A61K-047-02; A61K-047-04; A61K-047-06; A61K-047-08; A61K-047-32; A61K-047-34; A61P-001-02; A61P-025-04; A61P-029-00; A61P-031-04; A61P-031-12; A61P-043-00

AB WO 200101958 A UPAB: 20060629

NOVELTY - A new delivery system for delivering an oral care substance to the oral cavity comprises a removable backing strip and an oral care composition applied to the backing strip so that when the delivery system is placed on the oral surface, the oral care composition contacts the oral surface and remains on the surface after the backing strip is removed.

DETAILED DESCRIPTION - A new delivery system for delivering an oral care substance to the oral cavity comprises a removable backing strip and an oral care composition applied to the backing strip so that when the delivery system is placed on the oral surface the oral care composition contacts the oral surface and remains on the surface after the backing strip is removed .The backing strip has sufficient flexibility to be readily conformable to the oral surface. The oral care composition comprises an organosiloxane resin, a fluid diorganopolysiloxane-based polymer (optional), a rheology modifier and at least one oral care substance.

An INDEPENDENT CLAIM is included for a method for delivering an oral care substance to at least one surface of the oral cavity, comprising:

(a) applying the backing strip of the delivery system with the oral care composition coated to the surface(s) of the oral cavity;

(b) removing the backing strip from the surface(s) of the oral cavity or allowing the backing strip to dissolve in situ, where the oral care composition remains on the surface(s) of the oral cavity after the backing strip is removed.

ACTIVITY - Antimicrobial; analgesic; antiviral; antiinflammatory.

No biological data given.

MECHANISM OF ACTION - None given.

No biological data given.

USE - The delivery system is useful for delivering an oral care substances to the oral cavity.

Dwg.0/11

FS CPI

FA AB; DCN

MC CPI: A06-A00E3; **A12-V04B**; B04-C02; B04-C03B; B04-C03D; B05-A01B; B05-C07; B10-A17; B12-M05; B14-A01; B14-A02; B14-C01; B14-C03; **B14-L11**; **B14-N06**; C04-C02; C04-C03B; C04-C03D; C05-A01B; C05-C07; C10-A17; C12-M05; C14-A01; C14-A02; C14-C01; C14-C03; **C14-L11**; **C14-N06**; D08-A

ABEX UPTX: 20010302

ADMINISTRATION - The delivery system delivers the oral care composition orally.

EXAMPLE - Organosiloxane resin solution (43.7% MQ resin in isododecane) (25% parts resin) was mixed with fluid diorganopolysiloxane polymer solution (50% SE30 silicone gum in isododecane) (12.5 parts silicone gum). Sodium percarbonate (17 parts) as a dry powder, isododecane (44.5 parts) and bentone clay (1 part) were dispersed in the mixture to give a hydrophobic oral care composition which was used with a backing strip consisting of a piece of polyethylene film 0.013 mm. thick.

TECH UPTX: 20010302

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The organosiloxane resin is present at a level of 5-70%. The oral care substance comprises 0.01-50% of the oral care composition. The rheology modifier is present in the oral care composition at a level of about 0.1-30%. The composition further comprises a fluid diorganopolysiloxane-based polymer and a carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer. The ratio of

organosiloxane resin to fluid diorganopolysiloxane-based polymer is 10:1-1:10.
The oral care substance includes at least one oral care active selected from a teeth whitening active, an anti-tartar agent, a fluoride ion source, an anti-microbial agent, an anti-inflammatory agent, one or more nutrients, a mouth and throat product, an antioxidant, an H2 antagonist, an analgesic active, an anti-viral agent, flavoring agents, sweetening agents, sweetening agents, xylitol, opacifiers, coloring agents, surfactants, chelants, pigments or their mixtures. Preferably the oral care substance is a teeth whitening active selected from peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulfates or their mixtures.
The composition further comprises a carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer. The carrier is selected from hydrocarbon oils, volatile silicones, non-hydrocarbon solvents or their mixtures. The backing strip is water insoluble or water soluble. The water insoluble backing strip is a polymer film of nominal thickness less than about 0.1 mm., selected from polyethylene, ethylvinylacetate, polyesters, ethylvinyl alcohol, pullulan film or combinations of these and has a peel force of less than 50 g. The water soluble backing strip is selected from rice paper, pullulan paper, agar film, starch paper, natural gum or their mixtures.
Preferred Method: The oral care composition comprises a teeth whitening active and the oral cavity surface to which the composition is applied is the enamel of the teeth.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Composition: The organosiloxane resin is present at a level of 5-70%. The oral care substance comprises 0.01-50% of the oral care composition. The rheology modifier is present in the oral care composition at a level of about 0.1-30%. The composition further comprises a fluid diorganopolysiloxane-based polymer and a carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer. The ratio of organosiloxane resin to fluid diorganopolysiloxane-based polymer is 10:1-1:10.
The organosiloxane resin is selected from (CH3)3SiO)0.5 'M' units, (CH3)2SiO 'D' units, (CH3)SiO1.5 'T' units, SiO2 'Q' units or their mixtures. The rheology modifier is selected from organo modified clays, silica, polyethylene and mixtures of these. The fluid diorganopolysiloxane-based polymer comprises repeating units formula (R2SiO)n.
R = 1-6C monovalent hydrocarbon radical.
Preferably the fluid diorganopolysiloxane-based polymer is poly(dimethylsiloxane). The oral care substance includes at least one oral care active selected from a teeth whitening active, an anti-tartar agent, a fluoride ion source, an anti-microbial agent, an anti-inflammatory agent, one or more nutrients, a mouth and throat product, an antioxidant, an H2 antagonist, an analgesic active, an anti-viral agent, flavoring agents, sweetening agents, sweetening agents, xylitol, opacifiers, coloring agents, surfactants, chelants, pigments or their mixtures. Preferably the oral care substance is a teeth whitening active selected from peroxides, metal chlorites, perborates, percarbonates, peroxyacids, persulfates or their mixtures.
The composition further comprises a carrier capable of solubilizing the organosiloxane resin and the fluid diorganopolysiloxane-based polymer. The carrier is selected from hydrocarbon oils, volatile silicones, non-hydrocarbon solvents or their mixtures. The backing strip is water insoluble or water soluble. The water insoluble backing strip is a polymer film of nominal thickness less than about 0.1 mm, selected from polyethylene, ethylvinylacetate, polyesters, ethylvinyl alcohol, pullulan film or combinations of these and has a peel force of less than 50 g. The water soluble backing strip is selected from rice paper, pullulan paper, agar film, starch paper, natural gum or their mixtures.

L18 ANSWER 4 OF 5 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2000-224523 [19] WPIX
DNC C2000-068607

TI Oral mucoretentive composition for treating symptoms of upper respiratory tract infections comprises titanium dioxide and e.g. gastrointestinal agents, analgesics, decongestants and/or expectorants.
DC B07 P32
IN DOBROZSI, D J; DOBROZSI, J
PA (PROC) **PROCTER & GAMBLE CO**
CYC 88
PI WO---200010529 A1 20000302 (200019)* EN 35 A61K-009-10
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW
AU-----9955809 A 20000314 (200031) A61K-009-10
NO---200100832 A 20010219 (200128) A61K-000-00
BR-----9913178 A 20010515 (200130) A61K-009-10
EP-----1107733 A1 20010620 (200135) EN A61K-009-10
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
CZ---200100339 A3 20010613 (200138) A61K-009-10
US-----6319513 B1 20011120 (200174) A61F-013-02
CN-----1313756 A 20010919 (200202) A61K-009-10
KR--2001072678 A 20010731 (200209) A61K-047-02
HU---200103388 A2 20020128 (200222) A61K-009-10
MX--2001002001 A1 20010801 (200238) A61K-047-02
JP--2002523354 W 20020730 (200264) 51 A61K-045-08
AU------761968 B 20030612 (200349) A61K-009-10
KR------413877 B 20040107 (200427) A61K-047-02
CA-----2338704 C 20041102 (200474) EN A61K-009-10
EP-----1107733 B1 20050727 (200549) EN A61K-009-10
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
IN---200100061 P1 20050311 (200555) EN A61K-009-10
DE----69926377 E 20050901 (200558) A61K-009-10
PH--1199902125 B1 20050103 (200629) A61K-009-10
CN-----1195494 C 20050406 (200641) A61K-009-10
ADT WO---200010529 A1 1999WO-US019202 19990824; AU-----9955809 A 1999AU-0055809 19990824; NO---200100832 A 1999WO-US019202 19990824, 2001NO-0000832 20010219; BR-----9913178 A 1999BR-0013178 19990824, 1999WO-US19202 19990824; EP-----1107733 A1 1999EP-0942429 19990824, 1999WO-US19202 19990824; CZ---200100339 A3 1999WO-US19202 19990824, 2001CZ-0000339 19990824; US-----6319513 B1 Provisional 1998US-097578P 19980824, 1999US-0361533 19990727; CN-----1313756 A 1999CN-0809860 19990824; KR--2001072678 A 2001KR-0701965 20010215; HU---200103388 A2 1999WO-US19202 19990824, 2001HU-0003388 19990824; MX--2001002001 A1 2001MX-0002001 20010223; JP--2002523354 W 1999WO-US19202 19990824, 2000JP-0565851 19990824; AU------761968 B 1999AU-0055809 19990824; KR------413877 B 1999WO-US19202 19990824, 2001KR-0701965 20010215; CA-----2338704 C 1999CA-2338704 19990824, 1999WO-US19202 19990824; EP-----1107733 B1 1999EP-0942429 19990824, 1999WO-US19202 19990824; IN---200100061 P1 2001IN-DN00061 20010123, 1999WO-US19202 ; DE----69926377 E 1999DE-0626377 19990824, 1999EP-0942429 19990824, 1999WO-US19202 19990824; PH--1199902125 B1 1999PH-0002125 19990823; CN-----1195494 C 1999CN-0809860 19990824
FDT AU-----9955809 A Based on WO---200010529; BR-----9913178 A Based on WO---200010529; EP-----1107733 A1 Based on WO---200010529; CZ---200100339 A3 Based on WO---200010529; HU---200103388 A2 Based on WO---200010529; JP--2002523354 W Based on WO---200010529; AU------761968 B Previous Publ. AU-----9955809, Based on WO---200010529; KR------413877 B Previous Publ. KR--2001072678, Based on WO---200010529; CA-----2338704 C Based on WO---200010529; EP-----1107733 B1 Based on WO---200010529; DE----69926377 E Based on EP-----1107733, Based on WO---200010529
PRAI 1998US-097578P 19980824; 1999US-0361533 19990727
IC ICM A61F-013-02; A61K-000-00; A61K-009-10; A61K-045-08; A61K-047-02
ICS A61P-001-00; A61P-001-02; A61P-001-04; A61P-009-00; A61P-011-00; A61P-011-08; A61P-011-10; A61P-011-14; A61P-023-00; A61P-025-04;

A61P-043-00

AB WO 200010529 A UPAB: 20021105

NOVELTY - Oral mucoretentive pharmaceutical composition comprises titanium dioxide and e.g. gastrointestinal agents, analgesics, decongestants and/or expectorants.

DETAILED DESCRIPTION - A per oral or oral mucoretentive, aqueous liquid, pharmaceutical composition comprises:

(a) 2-50 weight% of the composition, of colloidal particles of titanium dioxide; and

(b) gastrointestinal agents, analgesics, decongestants, expectorants, antitussives, antihistamines, bronchodilators, topical anesthetics, sensory agents, oral care agents and/or miscellaneous respiratory agents.

The composition has a sedimentation volume ratio of greater than 0.90 when measured after 48 hours, a triggered viscosity ratio of at least 1.2. The gastrointestinal agent is selected from anticholinergics, H2-receptor antagonists, laxatives, gastroprotectants, gastrokinetic and prokinetic agents, proton pump inhibitors, antidiarrheals, agents effective for the treatment of H. pylori, polyanionic agents and/or plant extracts effective for the treatment of gastrointestinal disorders.

An INDEPENDENT CLAIM is also included for an intranasal mucoretentive, aqueous liquid, pharmaceutical composition comprising:

(a) 2-50 weight% of the composition, of colloidal particles of titanium dioxide; and (b) gastrointestinal agents, analgesics, decongestants, expectorants, antitussives, antihistamines, bronchodilators, topical anesthetics, sensory agents, oral care agents and/or miscellaneous respiratory agents. The composition has a sedimentation volume ratio of greater than 0.90 when measured after 48 hours and triggered viscosity ratio of at least 1.2.

ACTIVITY - Drug-Delivery; Oral; Gastrointestinal-Gen.; Analgesic; Expectorant; Antitussive; Anesthetic; Antidiarrheic; Laxative; Antibacterial; Respiratory-Gen.

A mucroretentive intranasal spray decongestant composition comprised (weight%): oxymetazoline. HCl (0.05), titanium dioxide (6.8), tyloxapol (0.035), dibasic sodium phosphate (0.02), monobasic potassium phosphate (0.065), xanthan gum (0.025), benzalkonium chloride (0.04), chlorhexidine gluconate (0.26), disodium EDTA (0.01) and purified water (qs. 100%). A subject with congestion sprayed 5-500 micro l of the above solution into each nostril 3 times daily. The flow properties and triggering of the formulation with the mucus lining in the nasal passage caused the formulation and active oxymetazoline to be retained within the region of the inflamed nasal turbinates, providing a more prolonged decongesting effect on the intranasal blood vessels.

MECHANISM OF ACTION - Antihistamine-H2; Bronchodilator; Parasympatholytic; H-ATPase-Inhibitor.

USE - The composition is useful for coating the alimentary canal or nasal mucosa in particular for preventing or treating symptoms of upper respiratory tract infections or upper respiratory tract tissue irritation or damage. The formulations provide coating and protection of the mouth, esophagus, oropharynx and/or the stomach for relief of irritation, pain and discomfort associated with ailments of the gastrointestinal tract such as sore throat. The formations can also provide a matrix to deliver an active ingredient in more intimate, concentrated and sustained contact with the irritated area.

ADVANTAGE - The formulations provide prolonged and improved coating and protection.

Dwg.0/1

FS CPI GMPI

FA AB; DCN

MC CPI: B04-A10; B05-A02; B05-A03B; B07-D09; B10-A17; B10-A22; B10-C02; B10-E02; B12-M07; B14-A01; B14-C01; B14-C08; B14-E02; B14-E09; B14-E10; B14-K01; **B14-L11**; B14-N05

ABEX UPTX: 20000419

ADMINISTRATION - Dosage is 1-300 mg/kg/day administered orally, topically applied to the oral cavity or intranasally.

TECH UPTX: 20000419

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The

composition has a sedimentation volume ratio of greater than 0.95 (preferably greater than 0.98) when measured after 48 hours. The composition has a triggered viscosity ratio of at least 1.4 (preferably at least 1.5). The level of titanium dioxide is 3-15 wt.%. The titanium dioxide has a mean particle size of less than 1 microm. The composition has a shear viscosity of greater than 2000 (preferably greater than 7500) Pa.s.

L18 ANSWER 5 OF 5 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 1998-052011 [05] WPIX
DNC C1998-017800
TI Use of H2-antagonist especially cimetidine or ranitidine - in formulations to reduce incidence of colds and similar illnesses.
DC A96 B03 B05
IN **SINGER, R E**
PA (PROC) **PROCTER & GAMBLE CO**
CYC 26
PI WO-----9747292 A1 19971218 (199805)* EN 15 A61K-031-00
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU BR CA CN JP KR MX SG
AU-----9733069 A 19980107 (199820) A61K-031-00
CN-----1221338 A 19990630 (199944) A61K-031-00
EP------954294 A1 19991110 (199952) EN A61K-031-00
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
BR-----9709792 A 19990810 (199953) A61K-031-00
JP----11513035 W 19991109 (200004) 18 A61K-045-00
MX-----9810660 A1 19990401 (200055) A61K-031-00
ADT WO-----9747292 A1 1997WO-US009977 19970610; AU-----9733069 A 1997AU-0033069 19970610; CN-----1221338 A 1997CN-0195430 19970610; EP------954294 A1 1997EP-0928916 19970610, 1997WO-US09977 19970610; BR-----9709792 A 1997BR-0009792 19970610, 1997WO-US09977 19970610; JP----11513035 W 1997WO-US09977 19970610, 1998JP-0501751 19970610; MX-----9810660 A1 1998MX-0010660 19981214
FDT AU-----9733069 A Based on WO-----9747292; EP------954294 A1 Based on WO-----9747292; BR-----9709792 A Based on WO-----9747292; JP----11513035 W Based on WO-----9747292
PRAI 1996US-0662389 19960612
IC ICM A61K-031-00; A61K-045-00
ICS **A61K-007-16**; A61K-009-06; A61K-031-34; A61K-031-415; A61K-031-425; A61K-031-435; A61K-047-32
AB WO 9747292 A UPAB: 19980202
Use of an H2 antagonist in the manufacture of topical formulations to reduce the incidence of colds and similar illnesses is new.

The antagonist is preferably cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, luptidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728 or HB-4-08 (especially cimetidine or ranitidine)

USE - Topical application of an H2 antagonist to the gingival or oral mucosal tissues reduces the incidence of colds in susceptible individuals. Effective amounts are 5 g mouthwash or 0.5 g toothpaste. Contact of the composition with oral cavity soft tissue afflicted with gingivitis or periodontitis should be for at least 15 (especially 30-60) seconds. The composition is rinsed out with water following contact. Frequency of contact is once per week to four times per day, especially once or twice per day.

ADVANTAGE - For individuals with heart disease, hypertension, diabetes or thyroid disorders, oral drugs such as decongestants could pose a risk of unfavourable drug interactions and may cause an adverse reaction. It is therefore desirable to deliver relief from specific nasal symptoms via compositions without the need for such active agents.
Dwg.0/0
FS CPI

FA AB; DCN
MC CPI: A12-V01; B07-D09; **B14-L11**; B14-N05; **B14-N06B**

=> d all abex tech l24 tot

L24 ANSWER 1 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **2005-057753** [06] WPIX
DNC C2005-019961
TI Use of composition comprising purified enantiomer of chiral phenothiazine, in medicament for inhibiting osteoclasts for treating or preventing e.g. osteoporosis.
DC B02 D21
IN BOLAND, E J; MCDONOUGH, J
PA (SWRI) SOUTHWEST RES INST; (TEXA) UNIV TEXAS SYSTEM
CYC 108
PI WO--2004110458 A1 20041223 (200506)* EN 48 A61K-031-5415
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
ADT WO--2004110458 A1 2004WO-US015416 20040517
PRAI 2003US-471155P 20030516
IC ICM A61K-031-5415
ICS A61P-019-10
AB WO2004110458 A UPAB: 20050126
NOVELTY - Use of a composition (A) comprising a purified enantiomer of a chiral phenothiazine (A1), is claimed in a medicament for inhibiting osteoclasts for treating or preventing a disease or condition associated with bone loss.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for

(1) inhibiting osteoclasts which comprises contacting a population of cells (having osteoclasts) in vitro with a composition which comprises a purified enantiomer of a chiral phenothiazine;

(2) inhibiting osteoclastic resorption of bone tissue which comprises contacting an in vitro bone tissue sample with a composition which comprises a purified enantiomer of a chiral phenothiazine, to inhibit osteoclasts in the bone tissue sample, and

(3) a therapeutic kit which comprises at least a first container, a purified enantiomer of a chiral phenothiazine to inhibit osteoclasts and a second, distinct anti-osteoclastic or anti-osteoporotic agent.

ACTIVITY - Osteopathic; Antiinflammatory; Antiasthmatic; Antiallergic; Respiratory-Gen.; Antiparkinsonian; Antiemetic.

Tests are described, but no results are given.

MECHANISM OF ACTION - Osteoclast inhibitor; Histamine H1 receptor antagonist; Histamine H2 receptor antagonist.

USE - (A1) are useful for the inhibition of osteoclastic resorption of bone and for the treatment or prevention of bone loss (periodontitis and osteoporosis) or conditions associated with bone loss in post-menopausal female and for the treatment or prevention of bone loss in an animal having or at risk for developing bone loss (all claimed). Promethazine is used as an antiemetic, antihistamine and antipsychotic agent. Promethazine is also useful for the treatment of asthma, allergic conditions, respiratory tract diseases and Parkinson's diseases.

ADVANTAGE - The method reduces bone loss and treats or prevents periodontitis, osteoporosis and associated disorders with higher efficacy and lower risk of side effects.

Dwg.0/6
FS CPI
FA AB; GI; DCN
MC CPI: B06-F04; B14-E05; B14-G02A; B14-J01A3; B14-J01B3; B14-K01; B14-K01A; B14-L06; B14-L09; B14-L10; **B14-L11**; B14-N01; **B14-N06B**; **D08-A05**

ABEX UPTX: 20050126
ADMINISTRATION - The dosage of (A1) is 0.5 mg/day, orally.
TECH UPTX: 20050126
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method :(A) comprises an enantiomerically pure enantiomer of a chiral phenothiazine. (A1) is a substantially or enantiomerically purified (-) enantiomer of ethopropazine or (+) enantiomer of promethazine. (A1) is a phenothiazine derivative of formula (I), preferably promethazine, ethopropazine, propiomazine or trimeprazine.
R1-R3 = upto 6C alkyl;
X = 1-5C alkyl or 1-5C alkenyl, and
R4 = N-(R5)3 or S-R5, and
R5 = H, 1-4C alkyl or 1-4C alkenyl, cyclic alkylene or heterocyclic alkylene comprising a N or S heteroatom.
The population of cells comprising osteoclasts is an in vitro bone tissue sample. (A1) and the second, distinct anti-osteoclastic or anti-osteoporotic agent are within a single container or distinct containers in the kit. The kit further comprises instructions for using the kit in the manufacture of a medicament for treating or preventing bone loss.

L24 ANSWER 2 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **2004-690507** [67] WPIX
DNC C2004-244692
TI Prophylactic or therapeutic agent of teeth grinding or its related disease e.g. dropping off or headache caused by breaking/shaking of temporomandibular arthrosis, contains gastric acid secretion inhibitor as active ingredient.
DC B02
IN MIYAWAKI, S; YAMAMOTO, T
PA (EISA) EISAI CO LTD; (MIYA-I) MIYAWAKI S; (YAMA-I) YAMAMOTO T
CYC 109
PI WO--2004080487 A1 20040923 (200467)* JA 28 A61K-045-00
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
EP-----1611901 A1 20060104 (200603) EN A61K-045-00
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR
JP--2005503460 X 20060608 (200638) 17 A61K-045-00
ADT WO--2004080487 A1 2004WO-JP000939 20040130; EP-----1611901 A1 2004EP-0706869 20040130, 2004WO-JP00939 20040130; JP--2005503460 X 2004WO-JP00939 20040130, 2005JP-0503460 20040130
FDT EP-----1611901 A1 Based on WO--2004080487; JP--2005503460 X Based on WO--2004080487
PRAI 2003JP-0068755 20030313
IC ICM A61K-045-00
ICS A61K-031-4427; A61K-031-4439; A61P-001-00; A61P-001-02; A61P-001-04; A61P-019-00; A61P-019-02; A61P-019-08; A61P-021-00; A61P-025-00; A61P-025-04; A61P-029-00; A61P-043-00; C07D-401-00; C07D-401-12
AB WO2004080487 A UPAB: 20041019
NOVELTY - A prophylactic or therapeutic agent for treating teeth grinding or its related diseases contains a proton pump-inhibitor, a histamine H2 receptor antagonist and/or an acid pump antagonist as an active ingredient.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) prevention or treatment of tooth grinding and its related diseases by administering an agent as above; and
(2) use of a gastric acid secretion inhibitor for the manufacture of a prophylactic or therapeutic agent for tooth grinding and its related diseases.

ACTIVITY - Analgesic; Antiarthritic; Antiallergic; Vulnerary; Osteopathic.

Change of pH of esophagus in a teeth grinding patient while sleeping, and temporal muscle activity were measured and the effect of proton pump inhibitor (sodium salt of rabeprazole) was evaluated by a double blind test. The frequency of jaw movement accompanied by rhythmic temporal muscle activity decreased remarkably by the administration of the proton pump inhibitor.

MECHANISM OF ACTION - Gastric-Secretion-Inhibitor; Proton-Pump-Inhibitor; Antihistamine-H2; Acid-Pump-Inhibitor.

No suitable test details are given.

USE - For preventing and treating teeth grinding and its related diseases e.g. dropping off or headaches caused by breaking/shaking of temporomandibular arthrosis, hypersensitivity of teeth, occlusal trauma, occlusal wear of teeth, wedge-shaped defect of teeth, gingival retraction, odontoschism, root resorption, alveolar-bone absorption, masseter enlargement, mastication, myalgia and crown repair (claimed).

ADVANTAGE - The agent suppresses the backflow of gastric acid into the esophagus. The combination of proton pump inhibitor and histamine H2 receptor antagonist has a synergistic effect.

DESCRIPTION OF DRAWING(S) - The graph (A) shows the temporal muscle activity while sleeping (4 hours) after administering proton pump inhibitor and (B) the frequency of pH episode per hour in each case after administering the proton pump inhibitor, where p value is less than 0.0001 on left side indicated by four stars and p value is less than 0.001 on right side indicated by three stars, in 8 patients.

Dwg.2/3

FS CPI

FA AB; GI; DCN

MC CPI: B06-D05; B06-D08; B07-A01; B07-D05; B07-D09; B07-F01; B14-C01; B14-E07; **B14-L11**; **B14-N06B**; B14-S09

ABEX UPTX: 20041019

ADMINISTRATION - Administration of proton pump inhibitor is 0.01-100 mg/day/adult, orally. Administration of sodium salt of rabeprazole is 0.1-10 mg/day/adult. Administration of omeprazole is 0.1-20 mg/day, magnesium salt of esomeprazole is 0.1-20 mg/day, lansoprazole is 0.1-30 mg/day, and pantoprazole is 0.1-40 mg/day.

Administration of histamine H2 receptor antagonist is 1-800 mg/day/adult, orally. Administration of cimetidine is 1-800 (50-400) mg/day/adult. Administration of ranitidine is 5-300 (30-150) mg/day/adult. Administration of famotidine is 1-40 (5-20) mg/day/adult. Administration of roxatidine acetate hydrochloride is 5-150 (25-75) mg/day/adult. Administration of nizatidine is 30-300 (50-150) mg/day/adult. Administration of lafutidine is 0.5-20 (2.5-10) mg/day/adult.

EXAMPLE - No relevant examples given.

TECH UPTX: 20041019

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Active Ingredients: The agent preferably contains a proton pump inhibitor, a histamine H2 receptor antagonist and/or an acid pump antagonist, preferably a proton pump inhibitor and a histamine H2 receptor antagonist, more preferably a proton pump inhibitor as active ingredient.

The proton pump inhibitor is rabeprazole, omeprazole, esomeprazole, lansoprazole, pantoprazole, tenatoprazole, its salts and/or hydrates, preferably sodium salt of rabeprazole.

The histamine H2 receptor antagonist is cimetidine, ranitidine, famotidine, roxatidine, nizatidine and/or its salt.

L24 ANSWER 3 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN **2001-122754** [13] WPIX

DNC C2001-035515

TI Treatment of inflammation, e.g. psoriasis, asthma, cancer or infections, comprises administration of alcoholic curcumin composition to inhibit phosphorylase kinase.

DC B05 C03

IN HENG, M C Y

PA (HENG-I) HENG M C Y
CYC 91
PI WO---200070949 A1 20001130 (200113)* EN 169 A01N-031-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
AU---200050353 A 20001212 (200115) A01N-031-00
US--2001051184 A1 20011213 (200204) A61K-009-00
ADT WO---200070949 A1 2000WO-US013929 20000519; AU---200050353 A
2000AU-0050353 20000519; US--2001051184 A1 1999US-0315856 19990520
FDT AU---200050353 A Based on WO---200070949
PRAI 1999US-0315856 19990520
IC ICM A01N-031-00; A61K-009-00
ICS A01N-031-14; A01N-033-02; A01N-035-00; A01N-043-08; A01N-055-08;
A61K-009-16; A61K-009-26; A61K-009-50; A61K-009-62; A61K-031-045;
A61K-031-075; A61K-031-12; A61K-031-135; A61K-031-34; A61K-033-00;
A61K-033-14; A61K-033-26; A61K-035-78
AB WO 200070949 A UPAB: 20010307
NOVELTY - Treating inflammation by administering soluble curcumin in solutions containing alcohol(s) to mammals to detectably inhibit phosphorylase kinase in mammalian blood or tissues.

DETAILED DESCRIPTION - Inflammation in mammals is treated by inhibiting glycogen breakdown and generation of adenosine triphosphate (ATP) through phosphorylase kinase inhibition in order to inhibit the energy supply for cellular activities such as cell migration and proliferation, cytokine and growth factor secretion and gene transcription by administering soluble curcumin in solutions containing alcohol(s) to detectably inhibit phosphorylase kinase in mammalian blood or tissues.

An INDEPENDENT CLAIM is included for compositions comprising:

(a) curcumin, a curcuminoid or a curcumin derivative in a solution containing alcohol(s);

(b) an additional component(s) chosen from vitamin D3 or its analogs, vitamin A or its derivatives or analogs, a calmodulin inhibitor, an antiinflammatory drug, a calcium channel blocker, an H1 or H2 histamine blocker, an antioxidant or free radical scavenger, a polyphenolic compound, a monoterpene, genistein, a soybean-derived lectin or dehydrozingerone; and

(c) a pharmaceutically acceptable carrier.

ACTIVITY - Antiinflammatory; antipsoriatic; vulnerary; dermatological; antiallergic; antibacterial; fungicide; virucide; antiarthritic; immunosuppressive; arteriosclerotic; nootropic; neuroprotective; hepatotrophic; osteopathic; gynecological; cytostatic; antiparasitic; antidiabetic; protozoacide; anthelmintic; anti-HIV.

MECHANISM OF ACTION - The soluble curcumin inhibits:

(1) migration of gamma / delta T cells occurring 30 minutes-4 hours after the inflammatory stress;

(2) migration of neutrophils beginning 18-24 hours after the inflammatory stress;

(3) migration of macrophages beginning about 24 hours after the inflammatory stress; and/or

(4) migration of alpha / beta T cells and other cells such as eosinophils beginning 48-72 hours after the inflammatory stress.

Glycogen breakdown inhibitor; phosphorylase kinase inhibitor; ATP generation inhibitor (all claimed).

USE - The methods are used to treat inflammation in mammals, especially humans or socially or economically important animals such as cows, horses, sheep, pigs, goats, dogs or cats. They are used to treat conditions or diseases including psoriasis, skin wounds, burns, scalds, scars, chemical-,radiation- and sun-induced skin injury, smoking-induced skin injury, allergic and hypersensitive reactions, hay fever, periodontal disease, gingivitis, eczema, skin infections (bacterial, viral, fungal, mycoplasma), arthritis, systemic lupus erythematosus, connective tissue diseases, atherosclerosis, Alzheimer's disease, the inflammatory process

that occurs during partial or complete blockage of an artery such as a coronary artery, gastritis, chronic hepatitis, chronic divertimentos, osteomyelitis, inflammatory bowel diseases, pelvic inflammatory disease, chronic prostatitis, sinusitis, neuritis, neuropathies, radiation- and smoking-induced injury, benign and malignant tumors, including metastatic tumors, of tissues such as breast, prostate, lung, skin, brain, liver, pancreas, gastric, intestinal, colon, kidney, bladder, cervix, ovary, uterus, central nervous system, sinuses, ears, eyes, bone and thyroid, melanomas, leukemias, lymphomas, infections caused by bacteria, superficial fungi, deep fungi, viruses, mycoplasmas and parasites, diabetes and neurodegenerative conditions (claimed). They may be used to treat infections caused by dermatophytes, sporotrichium, Histoplasma, blastomyces, herpes simplex virus, varicella zoster virus, adenovirus, human immunodeficiency virus (HIV), nematodes, other worms, other pathogenic parasites such as organisms causing filariasis, schistosomiasis and malaria.

Dwg.0/16

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-G; B03-L; B04-A10; B04-B01B; B05-B01A; B05-B02C; B06-A02; B07-A01; B10-B01B; B10-B03B; B10-B04B; B10-E04C; B10-E04D; B10-F01; B10-F02; B10-J02; B14-A01; B14-A02; B14-A03; B14-A04; B14-B02; B14-B03; B14-C03; B14-C09; B14-D06; B14-E10B; B14-E10C; B14-F01E; B14-F02B2; B14-F07; B14-G02A; B14-H01; B14-J01; B14-J01A4; B14-L06; B14-L10; **B14-L11**; B14-M01; B14-N01; B14-N04; **B14-N06B**; B14-N07A; B14-N12; B14-N17; B14-S04; B14-S08; B14-S12; C03-A; C03-G; C03-L; C04-A10; C04-B01B; C05-B01A; C05-B02C; C06-A02; C07-A01; C10-B01B; C10-B03B; C10-B04B; C10-E04C; C10-E04D; C10-F01; C10-F02; C10-J02; C14-A01; C14-A02; C14-A03; C14-A04; C14-B02; C14-B03; C14-C03; C14-C09; C14-D06; C14-E10B; C14-E10C; C14-F01E; C14-F02B2; C14-F07; C14-G02A; C14-H01; C14-J01; C14-J01A4; C14-L06; C14-L10; **C14-L11**; C14-M01; C14-N01; C14-N04; **C14-N06B**; C14-N07A; C14-N12; C14-N17; C14-S04; C14-S08; C14-S12

ABEX UPTX: 20010307

ADMINISTRATION - Administration may be in liposomes and may be topical, ocular, nasal, oral, pharyngeal, rectal, vaginal, bladder, urethral, bronchial or parenteral (claimed). Dosage is 250 mg-2 g curcumin daily orally or in topical gels at concentrations of 0.1-2% concentration. . Administration may be in combination with vitamin D3 or its analogs, vitamin A or its derivatives or analogs, a calmodulin inhibitor, an antiinflammatory drug, a calcium channel blocker, an H1 or H2 histamine blocker, an antioxidant or free radical scavenger, a polyphenolic compound, a monoterpene, genistein, a soybean-derived lectin or dehydrozingerone (claimed).

TECH UPTX: 20010307

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Method: The alcohol is a 1-6 (especially 1-3) C alcohol, that is preferably saturated or monohydric, especially ethanol (preferred), 1-propanol or 2-propanol. The curcumin is administered as a boron complex, preferably a difluoroboron complex, a mixed complex in which the 2 F atoms of a difluorobroon complex are replaced with the carboxyl oxygens of oxalic acid, a mixed complex in which the 2 F atoms of a difluoroboron complex are replaced with a carboxyl group and a hydroxyl group of citric acid, a mixed complex in which the 2 F atoms of a difluoroboron complex are replaced with the two hydroxyl groups of dibenzyl tartramide or a mixed complex in which the 2 F atoms of a difluoroboron complex are replaced with a second molecule of curcumin. The soluble curcumin is curcumin or a curcuminoid derivative.

L24 ANSWER 4 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN **1988-316468** [45] WPIX

CR 1988-355373 [50]; 1990-009109 [02]

DNC C1988-139816

TI Cimetidine containing methacrylate copolymer to improve palatability - comprise copolymer of di methylamino ethyl methacrylate and neutral methacrylic acid ester(s).

DC A96 B03
IN FRANCE, G; LEONARD, G S; PEARMAIN, K E
PA (SMIK) SMITH KLINE FRENCH LAB
CYC 21
PI EP------290229 A 19881109 (198845)* EN 11
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
GB-----2204489 A 19881116 (198846)
WO-----8808703 A 19881117 (198847) EN
W: AU DK JP KR US
WO-----8808704 A 19881117 (198847) EN
W: AU DK JP KR US
AU-----8817140 A 19881206 (198913)
AU-----8817141 A 19881206 (198913)
ZA-----8803212 A 19890329 (198918)
DK-----8807264 A 19881228 (198920)
DK-----8807265 A 19881228 (198920)
PT-------87422 A 19890531 (198925)
PT-------87423 A 19890531 (198925)
JP----01503385 W 19891116 (199001)
JP----02500747 W 19900315 (199017)
GB-----2204489 B 19901114 (199046)
EP------290229 B 19910731 (199131)
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
DE-----3863963 G 19910905 (199137)
CA-----1304685 C 19920707 (199233) A61K-031-415
CA-----1304686 C 19920707 (199233) A61K-031-415
US-----5169640 A 19921208 (199252) 4 A61K-009-26
US-----5188839 A 19930223 (199310) 4 A61K-009-16
ES-----2040339 T3 19931016 (199346) A61K-031-415
JP----94045540 B2 19940615 (199422) 5 A61K-031-415
JP-----2721219 B2 19980304 (199814) 3 A61K-031-415
KR-----9611236 B1 19960821 (199924) A61K-031-415
ADT EP------290229 A 1988EP-0304007 19880504; GB-----2204489 A 1988GB-0010477 19880504; WO-----8808703 A 1988WO-GB000350 19880504; WO-----8808704 A 1988WO-GB000349 19880504; ZA-----8803212 A 1988ZA-0003212 19880505; JP----01503385 W 1988JP-0503930 19880504; JP----02500747 W 1988JP-0503931 19880504; CA-----1304685 C 1988CA-0566093 19880506; CA-----1304686 C 1988CA-0566094 19880506; US-----5169640 A 1988WO-GB000350 19880504, 1989US-0297197 19890104; US-----5188839 A 1988WO-GB00349 19880504, 1989US-0295190 19890104; ES-----2040339 T3 1988EP-0304007 19880504; JP----94045540 B2 1988JP-0503931 19880504, 1988WO-GB00350 19880504; JP-----2721219 B2 1988JP-0503930 19880504, 1988WO-GB00349 19880504; KR-----9611236 B1 1988WO-GB00349 19880504, 1989KR-0700007 19890106
FDT US-----5169640 A Based on WO-----8808704; US-----5188839 A Based on WO-----8808703; ES-----2040339 T3 Based on EP------290229; JP----94045540 B2 Based on JP----02500747, Based on WO-----8808704; JP-----2721219 B2 Previous Publ. JP----01503385, Based on WO-----8808703
PRAI 1988GB-0010477 19880504; 1987GB-0010965 19870508; 1987GB-0010966 19870508
REP 5.Jnl.Ref; No-SR.Pub
IC ICM A61K-009-16; A61K-009-26; A61K-031-415
ICS A61K-009-20; A61K-031-41
AB EP 290229 A UPAB: 19970502
Pharmaceutical granule comprises cimetidine (I) and 2-20 (5-15), especially 10 weight % (on (I)) of a copolymer of dimethylaminoethyl methacrylate and neutral methacrylic acid esters. Also claimed is a solid pharmaceutical dosage form comprising the granule and opt. also an antacid or alginate.

USE/ADVANTAGE - (I) is a histamine H2-antagonist, useful in treatment of duodenal, gastric, recurrent and stomal ulceration, and reflux oesophagitis, and in the management of patients at high risk from haemorrhage of the upper gastrointestinal tract. The granule is palatable and has good dissolution characteristics in the stomach, and is especially useful in production of chewable tablets. The granule does not need to contain a high loading of sugar, and advantageously contains no sugar at all.

Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: A04-D09; A04-F06E5; A12-V01; B04-C03B; B07-D09; **B12-D06A**;
B12-D07; B12-E08; **B12-L04**; B12-M11D

L24 ANSWER 5 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **1987-110237** [16] WPIX
DNC C1987-045823
TI New 2-substd.-quinoline derivs. - having leukotriene antagonist activity, useful as anti-asthmatic, antiinflammatory, anti-allergic and cyto-protective agents.
DC B02
IN LEGER, S; YOUNG, R N; ZAMBONI, R
PA (MERI) MERCK FROSST CANADA INC
CYC 15
PI EP------219308 A 19870422 (198716)* EN 23
R: AT BE CH DE FR GB IT LI LU NL SE
JP----62093277 A 19870428 (198722)
DK-----8604875 A 19870417 (198746)
ES-----2002037 A 19880701 (198924)
EP------219308 B 19911023 (199143)
R: AT BE CH DE FR GB IT LI LU NL SE
DE-----3682160 G 19911128 (199149)
CA-----1298838 C 19920414 (199224) C07D-215-02
ADT EP------219308 A 1986EP-0307785 19861008; JP----62093277 A 1986JP-0244299 19861016; ES-----2002037 A 1985ES-0787942 19851016; CA-----1298838 C 1986CA-0520525 19861015
PRAI 1985US-0787942 19851016
REP 8.Jnl.Ref; A3...8741; EP----110405; EP----181568; FR---2445319; FR---2578540; GB---2002764; GB----321738; JP--61246164; No-SR.Pub; US---4325959; US---4464533; EP----200101
IC ICM C07D-215-02
ICS A61K-031-47; C07D-215-14; C07D-307-00; C07D-405-10

AB EP 219308 A UPAB: 19930922
Quinoline derivs. of formula (I) and their pharmaceutically acceptable salts are new. Y = -(CR2=CR2)n-, -(CC)n-, -CR2R2-X-, -X-CR2R2-, -CR2R2-X-CR2R2-, X, CO, -N(R2)-CO-, -CO-N(R2)- or a gp. of formula (a); each R1 = H, halo, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF3, OR2, SR2, SOR2, SO2R2, N(R2)2, CHO, COOR2, COR2, C(OH)(R2)2, CN, NO2, or opt. substd. phenyl, benzyl or phenethyl; each R2 = H, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF3; or opt. substd. phenyl, benzyl or phenethyl; R3 = -(A)m-(CR6=CR6)p-(CR2R4)m-Q; R4 = H, halo, NO2, CN, OR2, SR2, N(R2)2 or 1-8C alkyl; R5 = -(CH2)s-C(R6)2-(CH2)s-R7; each R6 = H or 1-4C alkyl; R7 = mono- or bi-cyclic heterocyclyl containing 3-12C and 1-2 of N, S and/or O, each ring being 5- or 6-membered; or W-R8; R8 = hydrocarbyl or acyl (derived from an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom) and contains up to 21C; R9 = OR10, SR10 or N(R10)2 (SiC); R10 = H, 1-6C alkyl, COR11, phenyl or benzyl; R11 = H, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF3, phenyl, benzyl or phenethyl; R12 = R2 gp. or halo; m = 0-8; n = 1-2; p = 0-1; s = 0-3; A = -C(R4)2- or CO; Q = COOR2, tetrazolyl, COOR5, CONHSO2R11, CN or CON(R10)2; it can also be NHSO2R11 when, in R3, m+m+p is greater than 0; or, when Q = COOH and R3 contains R4 where R4 = OH, SH or NHR2, then Q+R4 completes a heterocyclic ring (with loss of H2O); W = O, S or NH; X = O, S, SO, SO2 or NR2.
USE - (I) are antagonists of the slow reacting substance of anaphylaxis (SRS-A), especially leukotriene D4. They also exhibit moderate inhibition of leukotriene biosynthesis. Thus (I) can be used as antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents, and for treating allergic rhinitis, chronic bronchitis and skin diseases such as psoriasis and atopic exzema.
0/0
FS CPI
FA AB
MC CPI: B06-D02; B12-A07; B12-C10; B12-D01; B12-D02; B12-D06;
B12-D06A; B12-D07; B12-E08; B12-F01B; B12-F02; B12-G01A;
B12-G01B1; B12-G02; B12-G03; B12-J01; B12-J05; B12-K02; B12-K06;

B12-L04; N02-F02

L24 ANSWER 6 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 1987-110236 [16] WPIX
DNC C1987-045822
TI New 2-phenyl alkenyl or alkynyl-quinoline derivs. - having leukotriene antagonist activity, useful as e.g. anti-asthmatic, antiinflammatory, anti-allergic and cyto-protective agents.
DC B02
IN LEGER, S; YOUNG, R N; ZAMBONI, R
PA (MERI) MERCK FROSST CANADA INC
CYC 13
PI EP------219307 A 19870422 (198716)* EN 13
R: AT BE CH DE FR GB IT LI NL SE
JP----62093276 A 19870428 (198722)
DK-----8604876 A 19870417 (198746)
ES-----2002038 A 19880701 (198924)
ADT EP------219307 A 1986EP-0307779 19861008; JP----62093276 A 1986JP-0244300 19861016; ES-----2002038 A 1985ES-0788180 19851016
PRAI 1985US-0788180 19851016
REP A3...8741; EP----110405; EP----181568; No-SR.Pub
IC A61K-031-47; C07D-215-14
AB EP 219307 A UPAB: 19930922
Quinoline derivs. of formula (I) and their pharmaceutically acceptable salts are new. Y is -(CR2:CR2)n- or (C:C)n; each R1 is H, halo, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF3, OR2, SR2, SOR2, SO2R2, N(R2)2, CHO or COOR2, COR2, C(OH)(R2)2, CN, NO2 or opt. substd. phenyl, benzyl or phenethyl; each R2 is H, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF3 or opt. substd. phenyl, benzyl or phenethyl: R3 is -(A)m-(CR2R2)m-(CR2R4)m-CR2R (sic); provided that R3 is not CHO when it is para to Y; each R4 is H, halo, NO2, OR2, SR2, N(R2)2 or 1-8C alkyl or (R4)2 is O:, A is CO or C(R2)(OR6), R6 is H, 1-6C alkyl, COR7, phenyl or benzyl, R7 is H, 1-8C alkyl, 2-8C alkenyl, 2-8C alkynyl, CF3, phenyl, benzyl or phenethyl; each m is 0-8, provided that at least one is not 0; n is 1-2.
USE - (I) are antagonists of the slow reacting substance of araphylaxis (SR5-A), especially leukotriene D4. They also exhibit moderate inhibition of leukotriene biosynthesis. Thus (I) can be used as antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents and for treating allergic rhinitis, chronic bronchitis and skin diseases such as psoriasis and atopic eczema.
0/0
FS CPI
FA AB
MC CPI: B06-D02; B12-A07; B12-C10; B12-D01; B12-D02; B12-D06; **B12-D06A**; B12-D07; B12-E08; B12-F01C; B12-F02; B12-G01; B12-G01A; B12-G01B1; B12-G02; B12-G03; B12-J01; B12-J05; B12-K02; B12-K06; **B12-L04**

L24 ANSWER 7 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 1986-126580 [20] WPIX
DNC C1986-053995
TI Heterocyclic phenoxy derivs. - are histamine hydrogen receptor antagonists used for treatment of e.g. vascular headache.
DC B03
IN BROWN, T H; MITCHELL, R C; SMITH, I R; YOUNG, R C
PA (SMIK) SMITH KLINE FRENCH LAB; (YOUN-I) YOUNG R C
CYC 29
PI EP------181163 A 19860514 (198620)* EN 30
R: AT BE CH DE FR GB IT LI LU NL SE
AU-----8549113 A 19860508 (198626)
JP----61115069 A 19860602 (198628)
NO-----8504368 A 19860526 (198628)
DK-----8505009 A 19860504 (198631)
HU-------38926 T 19860728 (198635)
FI-----8504275 A 19860504 (198636)
PT-------81405 A 19861105 (198650)

CN----85108132 A 19860716 (198713)
ES-----8702385 A 19870316 (198716)
ZA-----8508400 A 19870504 (198729)
US-----4681883 A 19870721 (198731)
ES-----8706643 A 19870916 (198741)
CA-----1260468 A 19890926 (198944)
EP------181163 B 19891220 (198951) EN
R: AT BE CH DE FR GB IT LI LU NL SE
DE-----3574872 G 19900125 (199005)
IL-------76871 A 19900429 (199026)
US-----4952589 A 19900828 (199037)
KR-----9302490 B1 19930402 (199419) C07D-401-12
DK------168763 B 19940606 (199426) C07D-277-82
JP----95064816 B2 19950712 (199532) 1 C07D-213-74

ADT EP------181163 A 1985EP-0307929 19851031; JP----61115069 A 1985JP-0248670 19851105; ES-----8702385 A 1985ES-0548448 19851031; ZA-----8508400 A 1985ZA-0008400 19851101; US-----4681883 A 1985US-0788261 19851017; ES-----8706643 A 1986ES-0555013 19860516; US-----4952589 A 1987US-0057470 19870603; KR-----9302490 B1 1985KR-0008130 19851101; DK------168763 B 1985DK-0005009 19851031; JP----95064816 B2 1985JP-0248670 19851105

FDT DK------168763 B Previous Publ. DK-----8505009; JP----95064816 B2 Based on JP----61115069

PRAI 1984GB-0027878 19841103; 1985GB-0017714 19850713

REP A3...8708; EP----143630; EP-----50407; No-SR.Pub; US---4447611

IC A61K-031-33; A61K-031-41; A61K-031-42; A61K-031-43; A61K-031-44; C07D-013-60; C07D-015-16; C07D-031-12; C07D-213-74; C07D-215-38; C07D-217-22; C07D-219-08; C07D-231-12; C07D-233-88; C07D-235-30; C07D-239-42; C07D-263-48; C07D-263-58; C07D-277-82; C07D-295-08; C07D-401-10; C07D-401-12; C07D-403-12; C07D-413-12; C07D-417-12
ICM C07D-213-74; C07D-277-82; C07D-401-12
ICS A61K-031-33; A61K-031-41; A61K-031-415; A61K-031-42; A61K-031-425; A61K-031-43; A61K-031-44; A61K-031-445; A61K-031-47; C07D-013-60; C07D-015-16; C07D-031-12; C07D-213-89; C07D-215-38; C07D-215-42; C07D-217-22; C07D-219-08; C07D-231-12; C07D-233-64; C07D-233-88; C07D-235-12; C07D-235-30; C07D-239-42; C07D-239-86; C07D-239-94; C07D-263-48; C07D-263-58; C07D-277-42; C07D-295-08; C07D-401-10; C07D-403-12; C07D-413-12; C07D-417-12

AB EP 181163 A UPAB: 19930922

(A) Heterocyclic phenoxy derivs. of formula (I) and their salts are used in the mfr. of a medicament for the treatment of vascular headache. R1, R2=1-4C alkyl or NR1R2 is a pyrrolidino, piperidino or hexahydroazepino ring; Y=1-4C alkyl; n=2-5; m= 0-1; provided that when m=1, z=gp. (a) or (b). X=N or CR6; X1=O, S or NR9; R3-R8=H, 1-6C alkyl, 1-6C alkoxy, phenyl, halo, benzyl or benzyloxy; R9=H or 1-6C alkyl; any two of R3-R8 on adjacent atoms may form a benzene ring opt. substd. by 1-3 of 1-6C alkyl, 1-6C alkoxy, halo, phenyl, benzyl or benzyloxy; provided that when X'=O, R7, R8=H, 1-6C alkyl, phenyl or benzyl or are joined to form an opt. substd. benzene ring; when m=0, z=gp. (c). one of V and W is N and the other is C; R10, R11=H, 1-6C alkyl, phenyl, benzyl, 1-6C alkoxy or halo or when W is N and the O(CH2)n chain is joined to V, R10, R11=joined to form a benzene ring opt. substd. by 1-3 of 1-6C alkyl, 1-6C alkoxy, halo, phenyl or benzyl. (B) Also claimed are cpds. of formula (I) with the additional proviso that R9 is not H, when R7, R8 are joined to form a benzene ring (i.e. (Ia)).

27 Cpds. (I) and their salts are specifically claimed e.g. 2-(3-(3-(piperidinomethyl) phenoxy) propylamino) benzoxazole (Ib), 3-(3-(3-(piperidinomethyl) phenoxy) propylamino) pyridine; and 2-(3-(3-(piperidinomethyl) phenoxy) propyl)-1H -benzimidazole.

USE - (I) are histamine H2-receptor antagonists (used for the treatment of vascular headache (claimed)) and/or cerebral conditions. (I) can be used to treat skin inflammation, ocular inflammation and inflammatory bowel disease. Unit dose of (I) is 10-1000 mg, 1-100 mg, 0.1-5 mg, by oral, parenteral, inhalation admin. respectively. The daily adult dose of (Ia) is 10-1000 (pref. 50-500) mg orally or 0.1-100 mg by inhalation.

0/0

FS CPI
FA AB
MC CPI: B06-H; B07-H02; B07-H03; B12-A07; B12-C10; **B12-D06A**;
B12-D07; B12-E01; B12-J01; **B12-L04**

=> d all abex tech 161 tot

L61 ANSWER 1 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-154370 [15] WPIX
CR 1999-045477 [04]; 2000-523864 [47]; 2000-628197 [60]; 2002-187718 [24]; 2002-195694 [25]; 2002-215675 [27]; 2002-239190 [29]; 2005-766005 [78]
DNC C2004-061365
TI Tooth whitening substance formed into thin layer, comprises polyox resin and tooth whitening active.
DC A96 B07 D21 E37
IN DIRKSING, R S; MAJETI, S; RENO, E A; ROHMAN, F J; SAGEL, P A
PA (PROC) **PROCTER & GAMBLE CO**
CYC 1
PI US--2003211056 A1 20031113 (200415)* 12 A61K-007-20 <--
ADT US--2003211056 A1 CIP of 1997US-0870664 19970606, CIP of 1998US-0042909 19980317, Cont of 1998US-0196364 19981119, Cont of 2000US-0605220 20000628, Cont of 2001US-0681729 20010529, 2003US-0410037 20030409
FDT US--2003211056 A1 CIP of US-----5894017, Cont of US-----6096328, CIP of US-----6136297, Cont of US-----6551579
PRAI 1998US-0196364 19981119; 1997US-0870664 19970606;
1998US-0042909 19980317; 2000US-0605220 20000628;
2001US-0681729 20010529; 2003US-0410037 20030409
IC ICM **A61K-007-20**
AB US2003211056 A UPAB: 20060106
NOVELTY - A tooth whitening substance (14) formed into a thin layer, comprises a polyox resin and a tooth whitening active. The poloyox resin adheres the thin layer to teeth for a time to allow the tooth whitening active to act upon the teeth.
USE - For whitening a tooth.
ADVANTAGE - The invention is low cost, is comfortable to wear, can deliver a sufficient amount of tooth whitening active to teeth, and allows the tooth whitening active to act upon the teeth.
DESCRIPTION OF DRAWING(S) - The figure is a perspective view of the flat strip of material coated with an oral care substance for treating teeth and gums.
Delivery system 10
Strip of material 12
Tooth whitening substance 14
Dwg.2/10
FS CPI
FA AB; GI; DCN
MC CPI: **A12-V04B**; B04-C02A; B04-C03; B05-A01B; B05-B02C; B05-C07; B05-C08; B06-F01; B07-A01; B10-A07; B10-E04C; **B12-M02A**; **B14-N06**; D08-A; **D08-B08**; E05-A; E06-F01; E07-A01; E31-A05; E31-E; E33-B
ABEX UPTX: 20040302
SPECIFIC COMPOUNDS - The tooth whitening active is hydrogen peroxide.

EXAMPLE - An oral composition comprising 2.5% hydroxyethyl cellulose, 0.09% sodium fluoride, 0.05% sodium saccharin, 0.1% ranitidine and purified water (balance) was prepared by routine processing methods.
TECH UPTX: 20040302
TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Material: The tooth whitening active is peroxides, metal chlorites, perborates, percarbonates and/or peroxyacids.
Preferred Composition: The tooth whitening substance comprises 0.5-20 wt.% tooth whitening active and 10-95 wt.% of material from glycerin, sorbitol, polyethylene glycol, propylene glycol, or polyhydric alcohols.
Preferred Component: The tooth whitening substance further comprises water.

Preferred Parameter: The thin layer has a length of 2-12 cm.

L61 ANSWER 2 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2002-154684 [20] WPIX
DNC C2002-048360
TI Topical oral composition useful for promoting whole body health in humans and other animals comprises a host-response modulating agent and a carrier.
DC B05 C03 D21
IN **DOYLE, M J; HUNTER-RINDERLE, S J; SINGER, R E**
PA (PROC) **PROCTER & GAMBLE CO**
CYC 95
PI WO---200202096 A2 20020110 (200220)* EN 47 A61K-031-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
AU---200171544 A 20020114 (200237) A61K-031-00
EP-----1294367 A2 20030326 (200323) EN A61K-031-00
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
JP--2004501966 W 20040122 (200411) 89 A61K-045-00
MX--2003000043 A1 20031201 (200470) A61K-031-00
CN-----1536989 A 20041013 (200508) A61K-031-00
AU--2001271544 A8 20050915 (200569) A61K-031-00
ADT WO---200202096 A2 2001WO-US020515 20010628; AU---200171544 A 2001AU-0071544 20010628; EP-----1294367 A2 2001EP-0950569 20010628, 2001WO-US20515 20010628; JP--2004501966 W 2001WO-US20515 20010628, 2002JP-0506718 20010628; MX--2003000043 A1 2001WO-US20515 20010628, 2003MX-0000043 20021219; CN-----1536989 A 2001CN-0811860 20010628; AU--2001271544 A8 2001AU-0271544 20010628
FDT AU---200171544 A Based on WO---200202096; EP-----1294367 A2 Based on WO---200202096; JP--2004501966 W Based on WO---200202096; MX--2003000043 A1 Based on WO---200202096; AU--2001271544 A8 Based on WO---200202096
PRAI **2000US-0607602 20000630**
IC ICM A61K-031-00; A61K-045-00
ICS **A61K-007-16**; A61K-009-06; A61K-009-08; A61K-009-12; A61K-009-20; A61K-009-68; A61K-031-341; A61K-031-407; A61K-031-4164; A61K-031-426; A61K-031-662; A61K-045-06; A61P-001-02; A61P-003-02; A61P-029-00; A61P-043-00
AB WO 200202096 A UPAB: 20020402
NOVELTY - A topical oral composition comprises a host-response modulating agent and carrier. The host-response modulating agent is anti-inflammatory agent, H2-antagonist, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamin and nutrient key to maintenance of a host response balance and/or inhibitor of activation of NF-kB.

ACTIVITY - Cardiant; Cerebroprotective; Antiarteriosclerotic; Antidiabetic.

MECHANISM OF ACTION - None given.

USE - For the manufacture of a medicament for promoting whole body health in human and animal subjects (claimed); in mediating host reaction to the presence of periodontal pathogen in oral cavity as well as toxins and endotoxin released by these pathogens and the inflammatory cytokines and mediators promoted by these pathogens; to reduce the risk in development of cardiovascular disease, stroke, atherosclerosis, diabetes, serve respiratory infections, premature births and low birth weight, post-partum dysfunction in neurologic and development functions and associated increased risk of mortality.

ADVANTAGE - The composition reduces the development of fatty arterial streaks, atherosclerotic plagues, progressive plate development, thinning of the fibrous cap on atherosclerotic plagues, etc; reduces carotid arterial (intimal) wall thickness; reduces the exposure of the lower respiratory track to the inhalation of bacterial pathogens; reduces alterations in circulating hematocrit, hemoglobin, while blood cell count

and/or platelet counts; reduces the incidence of dis-regulation in blood/serum levels of inflammatory mediators/cytokines such as TNF-alpha, IL-6, CD-14 and IL-1; reduces the incidence of dis-regulating of blood/serum levels of acute phase reactants and markers of metabolic dis-regulation; reduces dis-regulation glucose metabolism and to of blood lipid levels including blood or serum cholesterol, triglycerides, LDL, HDL, VLDL, Apolipoprotein B and/or Apolipoprotein A-1
Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B03-A; B03-F; B03-H; B06-D01; B06-D04; B06-D16; B06-F03; B07-H; B10-B02A; B10-C04B; B10-C04C; B10-E02; B14-A01; B14-F01; B14-F07; B14-K01; B14-N05; B14-N16; B14-P03; B14-S04; C03-A; C03-F; C03-H; C06-D01; C06-D04; C06-D16; C06-F03; C07-H; C10-B02A; C10-C04B; C10-C04C; C10-E02; C14-A01; C14-F01; C14-F07; C14-K01; C14-N05; C14-N16; C14-P03; C14-S04; **D08-B08**
ABEX UPTX: 20020402

ADMINISTRATION - The Composition is administered through the subject's oral cavity in the form of a mouth-rinse, toothpaste, mouth gel, tooth powder, non-abrasive gel, chewing gum, mouth spray, lozenge and pet care product (claimed) for at least about 10 seconds (preferably 20 seconds to 10 minutes, more preferably 30 - 60 seconds) once per week to 4 times per day (preferably 3 - 4 times per day, especially once per day to twice per day). The composition can also be injected to the periodontal pocket.

EXAMPLE - A sub-gingival gel was prepared by dissolving (wt.%) poly(lactyl-co-glycolide)/50:50 copolymer (20) into propylene carbonate (68) and adding ranitidine (12) to the mixture. Subjects diagnosed to have both periodontitis and significantly elevated systemic blood levels of the apolipoprotein B associated with blood LDL levels were treated daily with the gel (0.35%) or with a placebo as control for 6 months. Analysis blood sample taken at a baseline before initiation of the study's treatment phase and again following 6 months of product usage, for levels of the apolipoprotein B showed a significant decrease for the subjects using the ranitidine dentifrice as compared to the placebo group.

TECH UPTX: 20020402

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition further comprises a therapeutic active agent. The H2-antagonist is cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaitidine, nizatidine, mifentidine, BMY-25368 (SKF-94482), BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728 and/or HB-408. The antiinflammatory agent is aspirin, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, aspirin, ketoprofen, piroxicam, meclofenamic acid, nordihydoguaiaretic acid and/or triclosan. The cell redox status modifier is Co-enzyme Q10, PQQ, Vitamin C, Vitamin E, Vitamin A, epi-gallo catechin gallate and/or anethole-dithiothione. The therapeutic active agent is antimicrobial/antiplaque agent, biofilm inhibiting agent, antibiotic, analgesic and local anesthetic agent, dentinal desensitizing agent and/or odor masking agent.

L61 ANSWER 3 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2002-147973 [19] WPIX
CR 1998-312139 [27]; 2000-412119 [35]; 2000-422852 [36]; 2002-266603 [31]; 2004-141600 [14]; 2004-388565 [36]
DNC C2002-045968
TI Topical oral composition useful for promoting whole body health in humans and other animals comprises an antimicrobial agent and a carrier.
DC B05 C03 D21
IN **DOYLE, M J; HUNTER-RINDERLE, S J; SINGER, R E** ; HUNTNER-RINDERLE, S J
PA (PROC) **PROCTER & GAMBLE CO**; (DOYL-I) DOYLE M J; (HUNT-I) HUNTER-RINDERLE S J; (SING-I) SINGER R E
CYC 96

PI WO---200202128 A2 20020110 (200219)* EN 40 A61K-033-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
AU---200171545 A 20020114 (200237) A61K-033-00
EP-----1294383 A2 20030326 (200323) EN A61K-033-00
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR
JP--2004517038 W 20040610 (200438) 75 A61K-031-14
MX--2003000041 A1 20031201 (200470) A61K-031-05
CN-----1522149 A 20040818 (200477) A61K-033-00
US--2005163727 A1 20050728 (200550) A61K-009-68
IN---200201484 P2 20050311 (200555) EN A61K-007-16 <--

ADT WO---200202128 A2 2001WO-US020516 20010628; AU---200171545 A 2001AU-0071545 20010628; EP-----1294383 A2 2001EP-0950570 20010628, 2001WO-US20516 20010628; JP--2004517038 W 2001WO-US20516 20010628, 2002JP-0506749 20010628; MX--2003000041 A1 2001WO-US20516 20010628, 2003MX-0000041 20021219; CN-----1522149 A 2001CN-0812035 20010628; US--2005163727 A1 Cont of 2000US-0607240 20000630, 2004US-0854065 20040525; IN---200201484 P2 2001WO-US20516 20010628, 2002IN-KN01484 20021202

FDT AU---200171545 A Based on WO---200202128; EP-----1294383 A2 Based on WO---200202128; JP--2004517038 W Based on WO---200202128; MX--2003000041 A1 Based on WO---200202128

PRAI 2000US-0607240 20000630; 2004US-0854065 20040525

IC ICM **A61K-007-16**; A61K-009-68; A61K-031-05; A61K-031-14; A61K-033-00
ICS A01N-033-12; **A61K-007-20**; **A61K-007-22**; A61K-031-085; A61K-031-155; A61K-031-44; A61K-031-4425; A61K-033-24; A61K-033-30; A61K-033-34; A61K-045-00; A61K-045-06; A61P-001-02; A61P-003-10; A61P-009-00; A61P-009-10; A61P-011-00; A61P-015-00; A61P-031-02

AB WO 200202128 A UPAB: 20051019
NOVELTY - A topical oral composition comprises an antimicrobial agent and a carrier.

DETAILED DESCRIPTION - A topical oral composition comprises an antimicrobial agent and carrier. The antimicrobial agent is stannous ion agent, triclosan, triclosan monophosphate, chlorhexidine, alexidine, hexetidine, sanguinarine, benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridinium chloride (CPC), tetradecylpyridinium chloride (TPC), N-tetradecyl-4-ethylpyridinium chloride (TDEPC), octenidine, delmopinol, octapinol, nisin, zinc ion agent, copper ion agent, essential oil, furanones, bacteriocins and/or its analog or salt (preferably stannous ion agent, triclosan, triclosan monophosphate, chlorhexidine, domiphen bromide, CPC, zinc ion agent, copper ion agent and/or essential oil).

ACTIVITY - Cardiant; Cerebroprotective; Antiarteriosclerotic; Antidiabetic; Antibacterial.

MECHANISM OF ACTION - Pathogenic oral bacteria inhibitor.

USE - For the manufacture of a medicament for promoting whole body health in human and animal subjects (claimed); for controlling bacterial mediated diseases and conditions present in the oral cavity and inhibiting spread into the bloodstream of pathogenic oral bacteria and associated bacterial toxins and endotoxin as well as the inflammatory cytokines and mediators promoted by these pathogens; to reduce the risk in development of cardiovascular disease, stroke, atherosclerosis, diabetes, serve respiratory infections, premature births and low birth weight, post-partum dysfunction in neurologic and development functions and associated increased risk of mortality.

ADVANTAGE - The composition reduces the development of fatty arterial streaks, atherosclerotic plagues, progressive plate development, thinning of the fibrous cap on arteriosclerotic plagues, etc; reduces carotid arterial (intimal) wall thickness; reduces the exposure of the lower

respiratory track to the inhalation of bacterial pathogens; reduces alterations in circulating hematocrit, hemoglobin, while blood cell count and/or platelet counts; reduces the incidence of dis-regulation in blood/serum levels of inflammatory mediators/cytokines such as TNF-alpha, IL-6, CD-14 and IL-1; reduces the incidence of dis-regulating of blood/serum levels of acute phase reactants and markers of metabolic dis-regulation; reduces dis-regulation glucose metabolism and to of blood lipid levels including blood or serum cholesterol, triglycerides, LDL, HDL, VLDL, Apolipoprotein B and/or Apolipoprotein A-1

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B01-C02; B02-C01; B02-K; B02-N; B02-P03; B02-T; B03-A; B03-F; B03-H; B04-B01B; B04-B01C1; B04-C01B; B05-A01B; B05-C02; B05-C07; B06-H; B07-H; B10-A04; B10-A08; B10-A17; B10-A18; B10-B02; B10-B04A; B10-C03; B10-C04B; B10-C04C; B10-D03; B10-E02; B14-A01; B14-F01; B14-F07; B14-K01; B14-N16; B14-P03; B14-S04; C01-C02; C02-C01; C02-K; C02-N; C02-P03; C02-T; C03-A; C03-F; C03-H; C04-B01B; C04-B01C1; C04-C01B; C06-H; C07-H; C10-A04; C10-A08; C10-A17; C10-A18; C10-B02; C10-B04A; C10-C03; C10-C04B; C10-C04C; C10-D03; C10-E02; C14-A01; C14-F01; C14-F07; C14-K01; C14-N16; C14-P03; C14-S04; **D08-B08**

ABEX UPTX: 20020321

ADMINISTRATION - The Composition is administered through the subject's oral cavity in the form of a mouth-rinse, toothpaste, tooth gel, tooth powder, non-abrasive gel, chewing gum, mouth spray, lozenge and pet core product (claimed) for at least about 10 seconds (preferably 20 seconds to 10 minutes, more preferably 30 - 60 seconds) once per week to 4 times per day (preferably 3 - 4 times per day, especially once per day to twice per day). The composition can also be injected to the periodontal pocket.

EXAMPLE - A mouthwash composition comprised (wt.%): stannous chloride (0.519), sodium gluconate (0,521), ethanol (10), glycerin (8), dibasic sodium phosphate heptahydrate (0.18), saccharin sodium (0.05), polysorbate 80 (0.3), FD and C Blue (0.02), flavor (0.15), sodium hydroxide (0.02) and water (balance) was prepared. No test was carried out.

TECH UPTX: 20020321

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition further comprises therapeutic agent (A). (A) is anti-inflammatory agent, H2-antagonist, metalloproteinase inhibitor, cytokine receptor antagonist, lipopolysaccharide complexing agent, tissue growth factor, immunostimulatory agent, cellular redox modifier, analgesic, hormone, vitamin and/or mineral (preferably anti-inflammatory agent, H2-antagonist, metalloproteinase inhibitor and/or cellular redox modifier, especially augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, aspirin, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, ketoprofen, piroxicam, meclofenamic acid, cimetidine, ranitidine, famotidine, roxatidine, nizatidine, mifentidine, iodine, sulfonamide, mercurial, bisbiguanide, phenolic, neomycin, kanamycin, clindamycin, eugenol, hydrocortisone, methotrexate, levamisole, strontium chloride, potassium nitrate, sodium fluoride, peppermint oil, chlorophyll, immunoglobulin, antigen, lidocaine, benzocaine, amino acid, essential fat, vitamin C, a-tocopherol, co-enzyme Q10, PQQ, Vitamin A, folate, N-acetyl cysteine, gallic acid, butylated hydroxytoluene, polymyxin, urea peroxide, hydroxamic acid derivative and/or phosphinic acid amide). The H2-antagonist is cimetidine, ranitidine, famotidine, roxatidine, nizatidine and/or mifentidine.

L61 ANSWER 4 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2002-147964 [19] WPIX

CR 1999-518721 [43]; 1999-540489 [45]; 1999-550822 [46]; 2002-147963 [19]

DNC C2002-045959

TI Topical oral composition useful for promoting whole body health in humans and other animals comprises chlorite ion and a carrier.

DC B05 C03 D21

IN **DOYLE, M J; HUNTER-RINDERLE, S J; SINGER, R E** ; WIMALASENA, R L

PA (PROC) **PROCTER & GAMBLE CO**
CYC 96
PI WO---200202063 A2 20020110 (200219)* EN 40 A61K-007-16 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
AU---200170218 A 20020114 (200237) A61K-007-16 <--
EP-----1294345 A2 20030326 (200323) EN A61K-007-16 <--
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR
CN-----1440268 A 20030903 (200380) A61K-007-16 <--
JP--2004501944 W 20040122 (200411) 76 A61K-007-16 <--
MX--2003000044 A1 20031201 (200470) A61K-007-16 <--
US-----6846478 B1 20050125 (200508) A61K-007-16 <--
AU--2001270218 A8 20050908 (200568) A61K-007-16 <--
IN---200201483 P2 20051202 (200623) EN A61K-007-16 <--
ADT WO---200202063 A2 2001WO-US020517 20010628; AU---200170218 A
2001AU-0070218 20010628; EP-----1294345 A2 2001EP-0948785 20010628,
2001WO-US20517 20010628; CN-----1440268 A 2001CN-0812028 20010628;
JP--2004501944 W 2001WO-US20517 20010628, 2002JP-0506686 20010628;
MX--2003000044 A1 2001WO-US20517 20010628, 2003MX-0000044 20021219;
US-----6846478 B1 Div ex 1998US-0032234 19980227, Div ex 1998US-0032237
19980227, Div ex 1998US-0032238 19980227, CIP of 2000US-0481624 20000112,
2000US-0607729 20000630; AU--2001270218 A8 2001AU-0270218 20010628;
IN---200201483 P2 2001WO-US20517 20010628, 2002IN-KN01483 20021202
FDT AU---200170218 A Based on WO---200202063; EP-----1294345 A2 Based on
WO---200202063; JP--2004501944 W Based on WO---200202063; MX--2003000044
A1 Based on WO---200202063; US-----6846478 B1 Div ex US-----6077502, Div
ex US-----6132702, Div ex US-----6251372, CIP of US-----6264924;
AU--2001270218 A8 Based on WO---200202063
PRAI 2000US-0607729 20000630; 1998US-0032234 19980227;
1998US-0032237 19980227; 1998US-0032238 19980227;
2000US-0481624 20000112
IC ICM **A61K-007-16**
ICS **A61K-007-20**
AB WO 200202063 A UPAB: 20060405
NOVELTY - A topical oral composition comprises chlorite ion and a carrier. The final composition has a final pH greater than 7 and free of chlorine dioxide or chlorous acid and is free of hypochlorite ions or hypochlorite salt.

ACTIVITY - Cardiant; Cerebroprotective; Antiarteriosclerotic; Antidiabetic; Antibacterial.

MECHANISM OF ACTION - Pathogenic oral bacteria inhibitor.

USE - For the manufacture of a medicament for promoting whole body health in human and animal subjects (claimed); for controlling bacterial mediated diseases and conditions present in the oral cavity and inhibiting spread into the bloodstream of pathogenic oral bacteria and associated bacterial toxins and endotoxin as well as the inflammatory cytokines and mediators promoted by these pathogens; to reduce the risk in development of cardiovascular disease, stroke, atherosclerosis, diabetes, serve respiratory infections, premature births and low birth weight, post-partum dysfunction in neurologic and development functions and associated increased risk of mortality.

ADVANTAGE - The composition reduces the development of fatty arterial streaks, atherosclerotic plagues, progressive plate development, thinning of the fibrous cap on atherosclerotic plagues, etc; reduces carotid arterial (intimal) wall thickness; reduces the exposure of the lower respiratory track to the inhalation of bacterial pathogens; reduces alterations in circulating hematocrit, hemoglobin, while blood cell count and/or platelet counts; reduces the incidence of dis-regulation in blood/serum levels of inflammatory mediators/cytokines such as TNF-alpha, IL-6, CD-14 and IL-1; reduces the incidence of dis-regulating of blood/serum levels of acute phase reactants and markers of metabolic

dis-regulation; reduces dis-regulation glucose metabolism and to of blood lipid levels including blood or serum cholesterol, triglycerides, LDL, HDL, VLDL, Apolipoprotein B and/or Apolipoprotein A-1
Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: B01-C02; B02-P03; B02-T; B03-A; B03-F; B03-H; B04-B01B; B04-B01C1; B04-C01B; B04-C01G; B05-A01B; B05-C02; B05-C07; B06-H; B07-H; B10-A04; B10-A08; B10-A17; B10-A18; B10-A22; B10-B02; B10-C04B; B10-C04C; B10-D03; B10-H01; B14-A01; B14-F01; B14-F07; B14-K01; B14-N16; B14-S04; C01-C02; C02-P03; C02-T; C03-A; C03-F; C03-H; C04-B01B; C04-B01C1; C04-C01B; C04-C01G; C05-A01B; C05-C02; C05-C07; C06-H; C07-H; C10-A04; C10-A08; C10-A17; C10-A18; C10-A22; C10-B02; C10-C04B; C10-C04C; C10-D03; C10-H01; C14-A01; C14-F01; C14-F07; C14-K01; C14-N16; C14-S04; D03-E09; D08-A
ABEX UPTX: 20020321
ADMINISTRATION - The Composition is administered through the subject's oral cavity in the form of a mouth-rinse, toothpaste, tooth gel, tooth powder, non-abrasive gel, chewing gum, mouth spray, lozenge and pet core product (claimed) for at least about 10 seconds (preferably 20 seconds to 10 minutes, more preferably 30 - 60 seconds) once per week to 4 times per day (preferably 3 - 4 times per day, especially once per day to twice per day). The composition can also be injected to the periodontal pocket.

EXAMPLE - An oral spray contained (wt.%) sodium chlorite (1.25), sodium bicarbonate (0.192), sodium carbonate (0.289) and water (balance) was prepared having a pH of approximately 10. Beagle dogs were applied with the spray (30 ml) through-out the mouth twice daily. After 9 months significant reduction in attachment loss were observed in the treated animals compared to those receiving the spray without sodium chlorite.
TECH UPTX: 20020321
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition comprises the chlorite ion (0.02 - 6 wt.%) and further comprises a therapeutic active agent (A). Preferred Components: (A) is antimicrobial/antiplaque agents, biofilm inhibiting agents, anti-inflammatory agents, H2-antagonists, metalloproteinase inhibitors, cytokine receptor antagonists, lipopolysaccharide complexing agents, tissue growth factors, immunostimulatory agents, cellular redox modifiers, analgesics, hormones, vitamins and/or minerals (preferably triclosan, chlorhexidine, alexidine, hexetidine, sanguinarine, benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridinium chloride (CPC), tetradecylpyridinium chloride (TPC), N-tetradecyl-4-ethylpyridinium chloride (TDEPC), octenidine, delmopinol, octapinol, nisin, zinc ion agents, stannous ion agents, essential oils, augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole; Aspirin, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, ketoprofen, piroxicam, meclofenamic acid, cimetidine, ranitidine, famotidine, roxatidine, nizatidine, mifentidine, iodine, sulfonamides, mercurials, bisbiguanides, phenolics, neomycin, kanmycins, clindamycin, eugenol, hydrocortisone, methotrexate, levamasole, strontium chloride, potassium nitrate, sodium fluoride, peppermint oil, chlorophyll, immunoglobulin, antigens, lidocaine, benzocaine, amino acids, essential fats, vitamin C, alpha-tocopherol, Co-enzyme Q10, pyrroloquinoline quinone (PQQ), vitamin A, Folate, N-acetyl cysteine, gallic acid, butylated hydroxytoluene, polymyxin, urea peroxide, hydroxamic acid derivatives, phosphinic acid amides, furanones, lysozyme, dextranases, mutanases and/or bacteriocins.

L61 ANSWER 5 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2002-147963 [19] WPIX
CR 1999-518721 [43]; 1999-540489 [45]; 1999-550822 [46]; 2002-147964 [19]
DNC C2002-045958
TI Composition for treating and preventing oral cavity disease e.g. inflammation of gingiva comprises chlorite ion and carrier.
DC B05 D21 P32 P34
IN **DOYLE, M J**; GOULBOURNE, E A; WIMALASENA, R L; WITT, J J; WONG, A L

PA (PROC) **PROCTER & GAMBLE CO**
CYC 96
PI WO---200202061 A2 20020110 (200219)* EN 37 A61K-007-00
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
NL OA PT SD SE SL SZ TR TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
US-----6350438 B1 20020226 (200220) A61K-007-16 <--
AU---200168743 A 20020114 (200237) A61K-007-00
EP-----1294347 A2 20030326 (200323) EN A61K-007-20 <--
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR
CN-----1446075 A 20031001 (200382) A61K-007-20 <--
JP--2004501942 W 20040122 (200411) 71 A61K-007-20 <--
MX--2003000042 A1 20031201 (200470) A61K-007-16 <--
IN---200201514 P2 20050311 (200555) EN A61K-007-00
ADT WO---200202061 A2 2001WO-US020614 20010628; US-----6350438 B1 CIP of
1998US-0032234 19980227, CIP of 1998US-0032237 19980227, CIP of
1998US-0032238 19980227, 2000US-0607242 20000630; AU---200168743 A
2001AU-0068743 20010628; EP-----1294347 A2 2001EP-0946731 20010628,
2001WO-US20614 20010628; CN-----1446075 A 2001CN-0811974 20010628;
JP--2004501942 W 2001WO-US20614 20010628, 2002JP-0506684 20010628;
MX--2003000042 A1 2001WO-US20614 20010628, 2003MX-0000042 20021219;
IN---200201514 P2 2001WO-US20614 20010628, 2002IN-KN01514 20021210
FDT US-----6350438 B1 CIP of US-----6077502, CIP of US-----6132702, CIP of
US-----6251372; AU---200168743 A Based on WO---200202061; EP-----1294347
A2 Based on WO---200202061; JP--2004501942 W Based on WO---200202061;
MX--2003000042 A1 Based on WO---200202061
PRAI 2000US-0607242 20000630; 1998US-0032234 19980227;
1998US-0032237 19980227; 1998US-0032238 19980227
IC ICM A61K-007-00; **A61K-007-16**; **A61K-007-20**
ICS **A61C-017-00**; **A61K-007-22**; **A61K-007-24**;
A61L-002-18
AB WO 200202061 A UPAB: 20050826
NOVELTY - A composition comprises chlorite ion (0.02 - 6 weight%) and a topical or oral carrier. The composition has a final pH of greater than 7.

ACTIVITY - Antiinflammatory.

MECHANISM OF ACTION - None given.

USE - For the manufacture of a medicament, as mouthrinse, toothpaste, non-abrasive gel or toothgel for treating and preventing oral cavity diseases in human and animal, e.g. at least one of inflammation of gingiva, inflammation of periodontal ligament, formation of periodontal pockets, bleeding and/or pus discharge from periodontal pockets, resorption of alveolar bone, loose teeth and loss of teeth; for aiding periodontal tissue healing and regeneration (all claimed).

ADVANTAGE - The composition is completely free of chlorine dioxide or chlorous acid and hypochlorite ions or hypochlorite salts. The composition has capability to retain in the tissue and slowly releases the chlorite ion to the tissue. The composition is also suitable for placing at the site in need of periodontal tissue healing or regeneration.

Dwg.0/0
FS CPI GMPI
FA AB; DCN
MC CPI: B01-C02; B02-C; B02-K; B02-N; B02-P03; B02-T; B03-A; B03-F; B03-H;
B04-B01C1; B04-C01B; B04-L04; B05-A01B; B05-B02A3; B05-C02; B06-H;
B07-H; B10-A04; B10-A08; B10-A17; B10-A18; B10-A22; B10-B02;
B10-C04B; B10-C04C; B10-E02; B14-N05; **D08-B08**
ABEX UPTX: 20020321
WIDER DISCLOSURE - The composition contains a minimal amount of chlorite ion.

ADMINISTRATION - The composition is administered orally. The composition is delivered as the mouthrinse to the periodontal pockets using a syringe, applicator or electromechanical device and is suitable for swishing in the mouth to cover other oral cavity tissues including tongue, gingival and

mucosal surfaces. The composition is also delivered in the form of toothpaste, non-abrasive gel or tooth gel by brushing teeth and tongue, gingival and mucosal surfaces (all claimed).

EXAMPLE - An oral spray formulation was prepared by mixing (wt%) 80%-sodium chlorite (1.25), sodium bicarbonate (0.192), sodium carbonate (0.289) and water (balance). The spray formulation had a pH of approximately 10. In an animal clinical study conducted among Beagle dogs, 30 ml of the spray formulation was applied evenly throughout the dog's mouth twice daily. After 9 months, significant reductions in attachment loss were observed in the treated animals compared to those receiving placebo(n=30), i.e. a spray solution containing the same above ingredients, but without sodium chlorite.

TECH UPTX: 20020321

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition further comprises a therapeutic active selected from antimicrobial/antiplaque agents, anti-inflammatory agents, H2-antagonists, metalloproteinase inhibitors, cytokine receptor antagonists, lipopolysaccharide complexing agents, tissue growth factors, immunostimulatory agents, cellular redox modifiers, biofilm inhibiting agents, analgesics, hormones, vitamins and/or minerals (preferably triclosan, chlorhexidine, alexidine; hexetidine, sanguinarine, benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridinium chloride (CPC), tetradecylpyridinium chloride (TPC), N-tetradecyl-4-ethylpyridinium chloride (TDEPC), octenidine, delmopinol, octapinol, nicin preparations, zinc ion agents, stannous ion agents, essential oils, augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole; aspirin, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, ketoprofen, piroxicam, meclofenamic acid, cimetidine, ranitidine, famotidine, roxatidine, nizatidine, mifentidine, iodine, sulfonamides, mercurials, bisbiguanides, phenolics, neomycin, kanamycin, clindamycin, eugenol, hydrocortisone, methotrexate, levamasole, strontium chloride, potassium nitrate, sodium fluoride, peppermint oil, chlorophyll, immunoglobulin, antigens, lidocaine, benzocaine, amino acids, essential fats, vitamin C, alpha-tocopherol, Co-enzyme Q10, PQQ, Vitamin A, folate, N-acetyl cysteine, gallic acid, butylated hydroxytoluene,polymyxin, urea peroxide, hydroxamic acid derivatives, phosphinic acid amides, furanones, lysozyme, dextranases, mutanases and/or bacteriocins).

L61 ANSWER 6 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **2000-564614** [52] WPIX
DNC C2000-168133
TI Composition for treating allergic diseases, e.g. asthma, allergic rhinitis, sneezing and itching runny nose, comprising neurokinin antagonist, H-3 antagonist and H-1 antagonist.
DC B03
IN ASLANIAN, R G; PIWINSKI, J J
PA (SCHE) SCHERING CORP
CYC 1
PI US-----6103735 A 20000815 (200052)* 9 A61K-031-44
ADT US-----6103735 A Provisional 1998US-103757P 19981009, 1999US-0412621 19991006
PRAI 1998US-103757P 19981009; 1999US-0412621 19991006
IC ICM A61K-031-44
ICS A61K-031-415; A61K-031-445
AB US 6103735 A UPAB: 20001018
NOVELTY - Antiallergic composition comprises a neurokinin antagonist or a derivative, an H-3 antagonist or a derivative and an H-1 antagonist or a derivative.

DETAILED DESCRIPTION - Pharmaceutical composition comprises a neurokinin antagonist or a derivative, an H-3 antagonist or a derivative and an H-1 antagonist or a derivative.

ACTIVITY - Anti-allergic; antiasthmatic; antitussive; antiinflammatory

MECHANISM OF ACTION - Neurokinin antagonist; H3 antagonist; H1 antagonist.

USE - The composition is useful for treating asthma, allergic rhinitis, sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, wheezing, sinusitis, coughs associated with postnasal drip symptoms and respiratory disorders associated with allergy. No activity examples given.
Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: B06-D13; B07-D05; B07-D09; B14-K01; B14-L09; B14-N02; B14-N03; B14-N04; B14-N05
ABEX UPTX: 20001018
ADMINISTRATION - Each unit dose preferably contains 1 to 1000 (especially 50 to 2000 mg, of neurokinin antagonist, 1 to 1000 (especially 1 to 50) mg of H-3 antagonist and 1 to 200 mg (especially 2 to 10) mg, of H-1 antagonist. Administration is e.g. oral.
TECH UPTX: 20001018
TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The neurokinin antagonist is preferably a piperidino-piperidine derivative of formula (I):
R = H, CH2CONH2, CH2CONHCH3, CH2CON(CH3)2 or a 4-hydroxypiperidine group of formula (i);
The H3 antagonist is preferably impromidine, burimamide, clobenpropit, impentamine, mifetidine, thioperamide, S-sopromidine, R-sopromidine, SKF-91486, GR-175737, GT-2016, GT2331, UCL-1199, 1H-imidazole-4-pentanamine, clozapine or N-(3,5-dichlorophenyl)-N'-((4-(1H-imidazol-4-yl)-methyl)-phenyl)-methyl)-urea. The H1 antagonist is preferably an ethanolamine, ethylenediamine, alkylamine, phenothiazine or piperidine, especially ceterizine, astemizole, azatadine, azelastine, acrivastine, bromopheniramine, chlorpheniramine, cyclizinene, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine or tripolidine. The composition may also include a decongestant, a cough suppressant and an expectorant.

L61 ANSWER 7 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **1998-052011** [05] WPIX
DNC C1998-017800
TI Use of H2-antagonist especially cimetidine or ranitidine - in formulations to reduce incidence of colds and similar illnesses.
DC A96 B03 B05
IN SINGER, R E
PA (PROC) PROCTER & GAMBLE CO
CYC 26
PI WO-----9747292 A1 19971218 (199805)* EN 15 A61K-031-00
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU BR CA CN JP KR MX SG
AU-----9733069 A 19980107 (199820) A61K-031-00
CN-----1221338 A 19990630 (199944) A61K-031-00
EP------954294 A1 19991110 (199952) EN A61K-031-00
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
BR-----9709792 A 19990810 (199953) A61K-031-00
JP----11513035 W 19991109 (200004) 18 A61K-045-00
MX-----9810660 A1 19990401 (200055) A61K-031-00
ADT WO-----9747292 A1 1997WO-US009977 19970610; AU-----9733069 A 1997AU-0033069 19970610; CN-----1221338 A 1997CN-0195430 19970610; EP------954294 A1 1997EP-0928916 19970610, 1997WO-US09977 19970610; BR-----9709792 A 1997BR-0009792 19970610, 1997WO-US09977 19970610; JP----11513035 W 1997WO-US09977 19970610, 1998JP-0501751 19970610; MX-----9810660 A1 1998MX-0010660 19981214
FDT AU-----9733069 A Based on WO-----9747292; EP------954294 A1 Based on WO-----9747292; BR-----9709792 A Based on WO-----9747292; JP----11513035 W Based on WO-----9747292
PRAI 1996US-0662389 19960612

IC ICM A61K-031-00; A61K-045-00
ICS **A61K-007-16**; A61K-009-06; A61K-031-34; A61K-031-415; A61K-031-425; A61K-031-435; A61K-047-32
AB WO 9747292 A UPAB: 19980202
Use of an H2 antagonist in the manufacture of topical formulations to reduce the incidence of colds and similar illnesses is new.
The antagonist is preferably cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, luptidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728 or HB-4-08 (especially cimetidine or ranitidine)
USE - Topical application of an H2 antagonist to the gingival or oral mucosal tissues reduces the incidence of colds in susceptible individuals. Effective amounts are 5 g mouthwash or 0.5 g toothpaste. Contact of the composition with oral cavity soft tissue afflicted with gingivitis or periodontitis should be for at least 15 (especially 30-60) seconds. The composition is rinsed out with water following contact. Frequency of contact is once per week to four times per day, especially once or twice per day.
ADVANTAGE - For individuals with heart disease, hypertension, diabetes or thyroid disorders, oral drugs such as decongestants could pose a risk of unfavourable drug interactions and may cause an adverse reaction. It is therefore desirable to deliver relief from specific nasal symptoms via compositions without the need for such active agents.
Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: A12-V01; B07-D09; B14-L11; B14-N05; **B14-N06B**

L61 ANSWER 8 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **1997-271850** [24] WPIX
DNC C1997-087391
TI Antiinflammatory oral composition for treatment of, e.g., gingivitis or periodontitis - comprises a histamine H2 receptor antagonist, such as ranitidine, and antimicrobial oils, such as methyl salicylate or eucalyptol.
DC B05 D21 E19 E37
IN PAN, P; RUBIN, M; STURDIVANT, L D
PA (WARN) WARNER LAMBERT CO
CYC 58
PI WO-----9716159 A1 19970509 (199724)* EN 22 A61K-007-16 <--
RW: AT BE CH DE DK EA ES FI FR GB GR IE IT LU MC NL PT SE
W: AL AU BB BG BR CA CN CZ EE GE HU IL IS JP KE KR LK LR LS LT LV MG MK MN MW MX NO NZ PL RO SD SG SI SK TR TT UA UG UZ VN
AU-----9674680 A 19970522 (199739) A61K-007-16 <--
ADT WO-----9716159 A1 1996WO-US016948 19961023; AU-----9674680 A 1996AU-0074680 19961023
FDT AU-----9674680 A Based on WO-----9716159
PRAI 1995US-0550045 19951030
REP US---5294433; US---5364616; WO---9204893; WO---9408560; WO---9418939
IC ICM **A61K-007-16**
ICS **A61K-007-26**; A61K-035-78
AB WO 9716159 A UPAB: 19970612
Antiinflammatory oral composition comprises a histamine H2 receptor antagonist and antimicrobial oils. Pref. the H2 receptor antagonist is selected from ranitidine, cimetidine, nizatidine, famotidine and salts of these; and the antimicrobial oils are selected from thymol, methyl salicylate, menthol, eucalyptol, spearmint oil, cinnamon oil, clove oil, rosemary oil and peppermint oil.
USE - The composition is useful for treating inflammation of the oral cavity, such as gingivitis or periodontitis. The composition is in a form suitable for oral topical administration, e.g., a toothpaste, mouthwash, spray or gel.

Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: B06-A02; B07-A01; B10-C03; B10-G02; B14-L09; **B14-N06B**; **D08-B08**; E06-A02; E07-A01; E10-E02E1; E10-E02F1

L61 ANSWER 9 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **1993-351341** [44] WPIX
DNC C1993-155879
TI Treatment of gingivitis or soft tissue aspects of periodontitis - by admin. of a selective H-2 antagonist especially cimetidine.
DC B05 D21
IN EBEL, J P; SINGER, R E
PA (PROC) PROCTER & GAMBLE CO
CYC 44
PI WO-----9320815 A1 19931028 (199344)* EN 36 A61K-031-41
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL OA PT SE
W: AU BB BG BR CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA VN
AU-----9339304 A 19931118 (199410) A61K-031-41
US-----5294433 A 19940315 (199411) 14 A61K-007-16 <--
US-----5364616 A 19941115 (199445) 14 A61K-007-16 <--
CN-----1082400 A 19940223 (199523) A61K-007-16 <--
BR-----1101010 A3 19991026 (200013) A61K-007-18 <--
ADT WO-----9320815 A1 1993WO-US002673 19930324; AU-----9339304 A 1993AU-0039304 19930324; US-----5294433 A CIP of 1992US-0868805 19920415, 1993US-0019782 19930305; US-----5364616 A CIP of 1992US-0868805 19920415, Div ex 1993US-0019782 19930305, 1993US-0171494 19931222; CN-----1082400 A 1993CN-0105692 19930415; BR-----1101010 A3 1997BR-1101010 19970514
FDT AU-----9339304 A Based on WO-----9320815; US-----5364616 A Div ex US-----5294433
PRAI 1992US-0868805 19920415; 1993US-0019782 19930305
REP 1.Jnl.Ref; WO---8904178
IC ICM **A61K-007-16**; **A61K-007-18**; A61K-031-41
ICS **A61K-007-22**; A61K-031-155; A61K-031-275; A61K-031-34; A61K-031-415; A61K-031-425; A61K-031-44; A61K-031-445; A61K-031-505
AB WO 9320815 A UPAB: 19931213
Prevention or treatment of gingivitis or soft tissue aspects of periodontitis comprises topical admin. to afflicted gingival mucosa of 0.01-10% of a selective H-2 antagonist.

Also claimed is (a) toothpaste or tooth gel compsn. comprising 0.1-10% H-2 antagonist and a carrier comprising a dental abrasive, surfactant, humectant, flavouring, or sweetener and water; and (b) a dentifrice compsn. comprising H-2 antagonist and a carrier comprising a dental abrasive and a flavouring or sweetener.

The pref. H-2 antagonist is e.g., cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, etc., especially cimetidine or ranitidine.

USE - For treatment and prevention of gingivitis and the soft tissue aspects of periodontitis.

Dwg.0/0
FS CPI
FA AB; DCN
MC CPI: B07-A01; B12-G01; **B12-L04**; **D08-A05**; D08-B06

L61 ANSWER 10 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **1992-331482** [40] WPIX
DNC C1992-147361
TI Medicaments containing salts of non-steroidal antiinflammatory drugs - with antihistamine(s) or sympathomimetic drugs and have enhanced stability yielding multi-symptom relief properties.
DC B05
IN FAWZI, M B; MAHJOUR, M
PA (WARN) WARNER LAMBERT CO
CYC 20

PI WO-----9215332 A1 19920917 (199240)* EN 40 A61K-045-06
RW: AT BE CH DE DK ES FR GB GR IT LU MC NL SE
W: AU CA JP
AU-----9212526 A 19921006 (199301) A61K-045-06
ZA-----9201583 A 19921125 (199302) 37 A61K-000-00
EP------574424 A1 19931222 (199351) EN A61K-045-06
R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
JP----06506198 W 19940714 (199432) 12 A61K-045-06
US-----5373022 A 19941213 (199504) 26 A61K-031-19
US-----5385941 A 19950131 (199511) 10 A61K-031-195
ADT WO-----9215332 A1 1992WO-US000164 19920110; AU-----9212526 A
1992AU-0012526 19920110, 1992WO-US00164 19920110; ZA-----9201583 A
1992ZA-0001583 19920303; EP------574424 A1 1992EP-0904732 19920110,
1992WO-US00164 19920110; JP----06506198 W 1992JP-0505311 19920110,
1992WO-US00164 19920110; US-----5373022 A Cont of 1991US-0664018 19910304,
1992US-0942108 19920908; US-----5385941 A Cont of 1991US-0664018 19910304,
Div ex 1992US-0942108 19920908, 1993US-0076910 19930615
FDT AU-----9212526 A Based on WO-----9215332; EP------574424 A1 Based on
WO-----9215332; JP----06506198 W Based on WO-----9215332
PRAI 1991US-0664018 19910304
REP GB---2120938; WO---8503443; WO---8504589; WO---8808302
IC ICM A61K-031-19; A61K-031-195; A61K-045-06
ICS A61K-031-135; A61K-031-415; A61K-031-445; A61K-031-55; A61K-031-60;
A61K-031-62
ICI A61K-031-19, A61K-031:135; A61K-031-60, A61K-031:135, A61K-031:19,
A61K-031:34, A61K-031:415, A61K-031:445, A61K-031:55; A61K-031-19,
A61K-031:135; A61K-031-60, A61K-031:135, A61K-031:19, A61K-031:34,
A61K-031:415, A61K-031:445, A61K-031:55; A61K-031-19, A61K-031:135;
A61K-031-60, A61K-031:135, A61K-031:19, A61K-031:34, A61K-031:415,
A61K-031:445, A61K-031:
AB WO 9215332 A UPAB: 19931115
New pharmaceutical compsns. contain salts of nonsteroidal antiinflammatory drugs (I) with antihistamines (II) or sympathomimetic drugs (III). The salts may be in crystalline form or in the form of an amorphous semisolid mass (so-called 'ion-pairs').

(I) is meclofenamic acid, salicylic acid (sic), sulindac, ibuprofen, naproxen or dichlorfinac. (II) is diphenhydramine, pseudoephedrine, ranitidine, loratidine, cimetidine, hismanal or terfenadine. (III) is a nasal decongestant or bronchodilator (no examples given). The salts are 1:1 salts.

USE/ADVANTAGE - The compsns. may be used to treat cough, cold, cold-like and/or flu symptoms. The salts avoid drug incompatibility problems and have different solubilities from the individual drugs, facilitating the preparation of sustained- or enhanced-release dosage form
Dwg.0/11
FS CPI
FA AB; DCN
MC CPI: B10-A10; B10-B03B; B12-D06; B12-D07; B12-K01; B12-K02; B12-K05;
B12-L04

L61 ANSWER 11 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **1992-147543** [18] WPIX
TI Polymorphonuclear leukocyte activator - contains histamine H1 and/or H2 receptor blocker for treating tinea pedis, haemorrhoids, periodontal diseases and intractable infections.
DC B04 C03 D21
PA (KAOS) KAO CORP
CYC 1
PI JP----04089428 A 19920323 (199218)* 6
ADT JP----04089428 A 1990JP-0199186 19900730
PRAI 1990JP-0199186 19900730
IC A61K-031-13; A61K-045-06
AB JP 04089428 A UPAB: 19931006
Polymorphonuclear leukocyte activator contains histamine H1 receptor blocker and/or histamine H2 receptor blocker.

USE/ADVANTAGE - Used for prevention and treatment of periodontal

diseases, tinea pedis, haemorrhoids, etc. The drug recovers the depressed phagocytosis in guinea pigs and cures experimentally induced periodontal diseases in dogs.

In an example, the drug for periodontal diseases comprises 0.1 weight% mepiramine HCl, 0.1 weight% ranitidine HCl, 1.0 weight% hydroxyethylcellulose and distilled water.va

0/0

FS CPI
FA AB; DCN
MC CPI: B07-A01; C07-A01; B07-D04C; C07-D04C; B12-A07; C12-A07; B12-D06; C12-D06; B12-J04; C12-J04; **B12-L03**; **C12-L03**; **D08-A05**; **D08-B08**

L61 ANSWER 12 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **1991-177535** [24] WPIX
CR 1994-263304 [32]
DNC C1991-076655
TI Treatment and prevention of retinopathy associated with diabetes - by administration to a mammal of antihistamine(s).
DC B05
IN GARDNER, T W; HOLLIS, T M
PA (PENN-N) PENNSYLVANIA RES CO
CYC 1
PI US-----5019591 A 19910528 (199124)*
ADT US-----5019591 A 1989US-0312693 19890217
PRAI 1989US-0312693 19890217
IC A61K-031-34
AB US 5019591 A UPAB: 19941010
Retinopathy associated with diabetes is treated and prevented by administration to a mammal of at least one antihistamine selected from diphenhydramine, terfenadine, mequitazine, astenizole, activastine, SCH 29851, SK & F 93944, clemastine, ketotifen, azatadine, oxatomide, azelastine, doxepine, piperoxan (933F), 929F, 1571F, mepyramine, chlorpheniramine, triprolidine, promethazine, burimamide, cimetidine, ranitidine, famotidine and nizatidine, and their derivs.

USE - Antihistamine is used in the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus.

In an example, in tests on rats having streptozotocin-induced diabetes, treatment with diphenhydramine hydrochloride (50 mg/kg. at 12 h. i.m.) or ranitidine (5 mg/kg. at 6 h. i.p.) or both concurrently indicates that activation of retinal histamine receptors is an important component of vitreal fluorescein isothiocyanate conjugated to bovine serum albumin (FITCBSA; accumulation in experimental diabetes. @(4pp Dwg.No.0/0)

0/0

FS CPI
FA AB; DCN
MC CPI: B06-H; B07-H; B10-B03B; B12-D06; B12-H05; **B12-L04**

L61 ANSWER 13 OF 13 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
AN **1988-316468** [45] WPIX
CR 1988-355373 [50]; 1990-009109 [02]
DNC C1988-139816
TI Cimetidine containing methacrylate copolymer to improve palatability - comprise copolymer of di methylamino ethyl methacrylate and neutral methacrylic acid ester(s).
DC A96 B03
IN FRANCE, G; LEONARD, G S; PEARMAIN, K E
PA (SMIK) SMITH KLINE FRENCH LAB
CYC 21
PI EP------290229 A 19881109 (198845)* EN 11
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
GB-----2204489 A 19881116 (198846)
WO-----8808703 A 19881117 (198847) EN
W: AU DK JP KR US
WO-----8808704 A 19881117 (198847) EN
W: AU DK JP KR US

```
     AU-----8817140 A  19881206 (198913)
     AU-----8817141 A  19881206 (198913)
     ZA-----8803212 A  19890329 (198918)
     DK-----8807264 A  19881228 (198920)
     DK-----8807265 A  19881228 (198920)
     PT-------87422 A  19890531 (198925)
     PT-------87423 A  19890531 (198925)
     JP----01503385 W  19891116 (199001)
     JP----02500747 W  19900315 (199017)
     GB-----2204489 B  19901114 (199046)
     EP------290229 B  19910731 (199131)
         R: AT BE CH DE ES FR GB GR IT LI LU NL SE
     DE-----3863963 G  19910905 (199137)
     CA-----1304685 C  19920707 (199233)              A61K-031-415
     CA-----1304686 C  19920707 (199233)              A61K-031-415
     US-----5169640 A  19921208 (199252)         4    A61K-009-26
     US-----5188839 A  19930223 (199310)         4    A61K-009-16
     ES-----2040339 T3 19931016 (199346)              A61K-031-415
     JP----94045540 B2 19940615 (199422)         5    A61K-031-415
     JP-----2721219 B2 19980304 (199814)         3    A61K-031-415
     KR-----9611236 B1 19960821 (199924)              A61K-031-415
ADT  EP------290229 A 1988EP-0304007 19880504; GB-----2204489 A 1988GB-0010477
     19880504; WO-----8808703 A 1988WO-GB000350 19880504; WO-----8808704 A
     1988WO-GB000349 19880504; ZA-----8803212 A 1988ZA-0003212 19880505;
     JP----01503385 W 1988JP-0503930 19880504; JP----02500747 W 1988JP-0503931
     19880504; CA-----1304685 C 1988CA-0566093 19880506; CA-----1304686 C
     1988CA-0566094 19880506; US-----5169640 A 1988WO-GB000350 19880504,
     1989US-0297197 19890104; US-----5188839 A 1988WO-GB00349 19880504,
     1989US-0295190 19890104; ES-----2040339 T3 1988EP-0304007 19880504;
     JP----94045540 B2 1988JP-0503931 19880504, 1988WO-GB00350 19880504;
     JP-----2721219 B2 1988JP-0503930 19880504, 1988WO-GB00349 19880504;
     KR-----9611236 B1 1988WO-GB00349 19880504, 1989KR-0700007 19890106
FDT  US-----5169640 A Based on WO-----8808704; US-----5188839 A Based on
     WO-----8808703; ES-----2040339 T3 Based on EP------290229; JP----94045540
     B2 Based on JP----02500747, Based on WO-----8808704; JP-----2721219 B2
     Previous Publ. JP----01503385, Based on WO-----8808703
PRAI 1988GB-0010477      19880504; 1987GB-0010965      19870508;
     1987GB-0010966      19870508
REP  5.Jnl.Ref; No-SR.Pub
IC   ICM  A61K-009-16; A61K-009-26; A61K-031-415
     ICS  A61K-009-20; A61K-031-41
AB   EP    290229 A UPAB: 19970502
     Pharmaceutical granule comprises cimetidine (I) and 2-20 (5-15), especially 10
     weight % (on (I)) of a copolymer of dimethylaminoethyl methacrylate and
     neutral methacrylic acid esters.  Also claimed is a solid pharmaceutical
     dosage form comprising the granule and opt. also an antacid or alginate.
          USE/ADVANTAGE - (I) is a histamine H2-antagonist, useful in treatment
     of duodenal, gastric, recurrent and stomal ulceration, and reflux
     oesophagitis, and in the management of patients at high risk from
     haemorrhage of the upper gastrointestinal tract. The granule is palatable
     and has good dissolution characteristics in the stomach, and is especially
     useful in production of chewable tablets.  The granule does not need to
     contain a high loading of sugar, and advantageously contains no sugar at
     all.
     Dwg.0/0
FS   CPI
FA   AB; DCN
MC   CPI: A04-D09; A04-F06E5; A12-V01; B04-C03B; B07-D09; B12-D06A; B12-D07;
          B12-E08; B12-L04; B12-M11D


=> d his

     (FILE 'HOME' ENTERED AT 13:11:33 ON 06 JUL 2006)

     FILE 'WPIX' ENTERED AT 13:16:27 ON 06 JUL 2006
```

noble jarrell 06/07/2006

```
L1            1 US2000-607602/AP,PRN
                E DOYLE M/AU
L2           85 E3,E11
                E HUNTER RINDERLE/AU
L3            7 E5
L4           27 E6,E15
                E SINGER R/AU
L5           84 E3,E6
L6        12569 (PROCTER (1N)GAMBLE)/CS,PA
L7        12588 PROC/PACO
                E PROC/PACO
                E E3+ALL
L8        21669 (A12-V04B OR B12-M02A OR C12-M02A OR D08-B08? OR B12-L03 OR C12
L9        13169 (P910 OR P911 OR P912 OR P923)/M0,M1,M2,M3,M4,M5,M6
L10        6110 (A61C015 OR A61C017)/IPC,IC,ICM,ICS,ICA,ICI
L11         240 A61Q011/IPC,IC,ICM,ICS,ICA,ICI
L12        8994 (A61K007-16 OR A61K007-18 OR A61K007-20 OR A61K007-22 OR A61K00
L13           4 (A61K007:16 OR A61K007:18 OR A61K007:20 OR A61K007:22 OR A61K00
L14       31915 L8-13
L15         325 (B12-D06A OR C12-D06A OR B14-L11 OR C14-L11)/MC
L16         671 L14 AND L1-7
L17          17 L14 AND L15
L18           5 L16 AND L15
L19          12 L17 NOT L18
L20           5 L19 NOT (PY>2000 OR AY>2000 OR PRY>2000)
                E B12-L04/MC
                E E3+ALL
L21           7 L19 NOT L20
                SEL AN 2-3 5
L22           3 E1-3 AND L21
                SEL AN 2-5 L20
L23           4 E4-7 AND L20
L24           7 L22-23
                E B12-L04/MC
                E E3+ALL
                E CIMETIDINE/CN
L25           4 E3-8
                E ETINIDINE/CN
                E ETINTIDINE/CN
L26           1 E3
                E RANITDINE/CN
                E RANITIDINE/CN
L27           3 E3-6
                E ICIA 5165/CN
                E ICIA-5165/CN
                E TIOTIDINE/CN
L28           1 E3
                E ORF/CN
L29           1 E4
                E LUPITIDINE/CN
L30           1 E3
                E DONETIDNE/CN
                E DONETIDINE/CN
L31           1 E3
                E FAMOTIDINE/CN
L32           2 E3-5
                E ROXATIDINE/CN
L33           4 E3-6
                E PIFATIDINE/CN
L34           1 E3
                E LAMTIDINE/CN
L35           1 E3
                E BL/CN
                E BL-6548/CN
                E BMY/CN
L36           1 E5
```

```
                E ZALTIDINE/CN
L37           1 E3
                E NIZATIDINE/CN
L38           1 E3
                E BMY/CN
L39           1 E6
                E BL/CN
L40           1 E16-17
                E ICI/CN
L41           1 E22
                E ICIA/CN
                E RAMIXOTIDINE/CN
L42           1 E3
                E WY/CN
                E WY-45727/CN
L43           1 E3
                E SR-58042/CN
                E SR 58042/CN
                E BMY/CN
L44           3 E18-20
                E LOXITIDINE/CN
                E LOXTIDINE/CN
L45           1 E3
                E DA/CN
                E BISFENTIDINE/CN
L46           1 E3
                E SUFOTIDINE/CN
L47           1 E3
                E EBROTIDINE/CN
L48           1 E3
                E HE/CN
                E D-16637/CN
                E D 16637/CN
                E FRG/CN
L49           1 E5
L50           1 E4
                E IMPROMIDINE/CN
L51           1 E3
                E L-643728/CN
                E HB/CN
L52          35 L25-51
                SEL DCSE
                EDIT /DCSE /DCRE
L53         450 E1-35/DCRE
                SEL SDCN L52
                EDIT /SDCN /DCN
L54         798 E36-75
L55          41 L14 AND L53-54
L56          39 L55 AND ((M782 OR P86?)/M0,M1,M2,M3,M4,M5,M6 OR (B12-C09 OR C12
L57          12 L56 NOT (PY>2000 OR AY>2000 OR PRY>2000)
                SEL AN 1-3 5-6 7-8 11
L58           8 E76-83 AND L57
L59          27 L56 NOT L57
L60           5 L59 AND L1-7
L61          13 L58,L60

=>
```